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ABSTRACT
Previous publications from this laboratory demonstrated that administration of leukemia
inhibitory factor (LIF) (125 µg/kg) to young, male Sprague-Dawley rats at 6, 24, and 48 h after
middle cerebral artery occlusion (MCAO) reduced infract volume, improved sensimotor skills, and
alleviated damage to white matter at 72 h after the injury. In vitro studies using cultured
oligodendrocytes (OLs) showed that LIF (200 ng/ml) also protects against 24 h of oxygen-glucose
deprivation through activation of Akt signaling and upregulation of the antioxidant enzymes
peroxiredoxin IV and metallothionein III. Other groups have demonstrated that LIF reduces
neurodegeneration in animal models of disease, but the neuroprotective mechanisms of LIF
during permanent ischemia have not yet been examined. The overall hypothesis to be tested in
this project is whether LIF exerts similar protective mechanisms against neurons during ischemia
through increased antioxidant enzyme expression in neurons.
In the first set of experiments, superoxide dismutase (SOD) activity was significantly
increased in the ipsilateral hemisphere of LIF-treated rats compared to rats that received PBS
treatment at 72 h after MCAO. Western blot and immunohistochemical analysis revealed that
SOD3 was upregulated in brain tissue and induced specifically in cortical neurons tissue at this
time point. Neurons that expressed high levels of SOD3 at 72 h after MCAO also showed high
levels of phosphorylated Akt (Ser473). LIF (200 ng/ml) reduced necrotic and apoptotic cell death
against 24 h of OGD as measured by lactate dehydrogenase (LDH) release and caspase-3
activation. Quantitative real-time PCR analysis showed that LIF treatment upregulated SOD3
gene expression in vitro during OGD. Treatment with 10 µM Akt Inhibitor IV and transfection with
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SOD3 siRNA counteracted the neuroprotective effects of LIF in vitro, showing that upregulation
of SOD3 and activation of Akt signaling are necessary for LIF-mediated neuroprotection.
Several transcription factors that regulated Akt-inducible genes were previously identified
by this lab, including myeloid zinc finger-1 (MZF-1) and specificity protein-1 (Sp1). The goal of the
second set of experiments was to determine whether LIF exerted protective actions through MZF1 and Sp1. According to analysis with Genomatix, MZF-1 and Sp1 have multiple binding sites in
the promoter for the rat SOD3 gene. Western blot analysis showed that there was a trend towards
increased MZF-1 protein expression in the brains of LIF-treated rats that approached significance.
Immunohistochemical analysis and quantitative real-time PCR showed a significant in vitro
upregulation in MZF-1 expression among LIF-treated neurons compared to PBS-treated neurons.
Sp1 gene expression was not changed by LIF treatment, but there was a trend towards increased
protein expression. In addition, there was a significant correlation between Sp1 and MZF-1 among
brain samples from LIF-treated rats but not PBS-treated or sham rats at 72 h after MCAO.
Immunohistochemical analysis revealed that Sp1 and MZF-1 co-localized with neuronal nuclei
and SOD3 at 72 h after MCAO. Neurons that were transfected with MZF-1 or Sp1 siRNA following
isolation did not show a significant decrease in LDH release after 24 h OGD that was observed
among neurons transfected with scrambled siRNA. These data demonstrate that Sp1 and MZF1 are involved with the neuroprotective signaling of LIF under ischemia.
This laboratory has demonstrated that LIF activates transcription of protective genes and
increases the activity of transcription factors through modulation of intracellular signaling.
However, the upstream signaling mechanisms of LIF during ischemia had not previously been
investigated. Previous investigators found that the LIF-specific subunit of the heterodimeric LIF
receptor (LIFR) is induced by CNS injury. Western blot analysis was used to determine whether
LIFR was induced in the brain and the spleen, which plays a role in the peripheral immune
response, after MCAO. According to these results, LIF treatment significantly upregulates LIF in
xii

the brain compared to PBS treatment or sham injury at 72 h after MCAO. Genomatix analysis of
the LIFR promoter region revealed a binding site for Sp1, which is one of the transcription factors
responsible for neuroprotection by LIF. At this same time point, splenic LIFR expression is
significantly reduced after MCAO compared to sham injury. LIF treatment did not significantly
increase LIFR expression, but did significantly increase spleen size compared to PBS treatment
at 72 h after MCAO. Although there was a trend towards increased LIFR expression in the spleen
from 24 h to 72 h after MCAO, this increase was not statistically significant. However, there was
a significant positive correlation between spleen weight and LIFR expression among rats
euthanized 24-72 h after MCAO/sham injury. In addition, there was a significant negative
correlation between LIFR expression in the brain and the spleen weight, thus showing that LIFR
is upregulated following the splenic response.
According to findings from other groups, JAK1 has been shown to associate with the
heterodimeric LIF receptor (LIFR/gp130) and directly activate PI3K/Akt signaling. To test whether
JAK1 contributes neuroprotection during ischemia, cultured neurons were treated with several
concentrations (2.5-50 nM) of GLPG0634, a JAK1-specific inhibitor prior to 24 h of OGD. With the
exception of the 2.5 nM concentration, all concentrations of GLPG0634 significantly decreased
LDH release compared to DMSO treatment, with the 5 nM concentration having the most potent
effect on reducing cytotoxicity. However, the 5 nM concentration had no significant did not
significantly reduce LDH release compared to DMSO treatment under 24 h of normoxic
conditions. These results indicate that JAK1 activity is primarily detrimental to neurons during
ischemia. Although it is possible that LIF signaling activates JAK1, it is unlikely that JAK1 is
responsible for LIF-mediated neuroprotection during ischemia.
The results of these experiments allowed us to determine several molecular mechanisms
for LIF-mediated neuroprotection. LIF, which binds to its heterodimeric receptor, activates Akt
signaling during ischemia. The transcription factors Sp1 and MZF-1, which are located
xiii

downstream of Akt, bind to the promoter of the SOD3 gene. In addition, Sp1 also regulates the
LIFR gene. SOD3 upregulation increases total SOD activity, which decreases apoptotic and
necrotic cell death during apoptosis. Due to its ability to promote antioxidant expression and
survival signaling in multiple neural cell types, LIF shows promise as a novel treatment for
permanent focal cerebral ischemia.
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CHAPTER ONE
INTRODUCTION
Stroke Overview
Stroke as a Worldwide Healthcare Problem
A cerebrovascular accident, commonly known as a stroke, occurs when the blood supply
of the brain becomes disrupted due to a blocked or ruptured vessel. Stroke contributes to the
fifth leading cause of death in the United States overall and among individuals age 15-59
worldwide. Among individuals older than 60 years of age, stroke is the second leading cause of
death worldwide. Although many stroke cases are not fatal, resulting brain damage may lead to
permanent disabilities in motor skills and cognitive function (2015a). In addition to the mortalities
and morbidities resulting from stroke, treatment of stroke patients imposes a significant financial
burden on the U.S. healthcare system. In 2008, $65 billion of direct and indirect healthcare costs
may be attributed to stroke-related injuries (Demaerschalk, Hwang et al. 2010). Notable
advances have occurred in regards to the prevention and treatment of strokes over the past two
decades, which contributed to lower age-standardized stroke mortality. Nonetheless, the rapid
aging of the U.S. population will almost certainly lead to a higher incidence of stroke in the near
future (Feigin, Forouzanfar et al. 2014).
Risk Factors for Stroke
Factors that render patients more susceptible to stroke may be divided into two
categories: factors that may be controlled by lifestyle choices and factors that are out of the
1

patient’s control. Age is arguably the most important contributing factor towards stroke risk, since
the risk of stroke doubles for individuals every decade past the age of 55. Certain racial groups
such as African-Americans are more prone to strokes due to high prevalence of hypertension
among these individuals. In addition, women are more susceptible to stroke-related mortality
compared to men. Although these factors cannot be controlled by patients, lifestyle choices such
as smoking, alcoholism, inactivity, and poor diet may lead to hypertension, obesity, diabetes,
and other cardiovascular complications. Individuals with these heath conditions have a much
greater risk of having a stroke compared to those who maintain healthier lifestyle choices.
Types of Stroke
Ischemic strokes comprise 85% of all stroke cases. These strokes occur when a cerebral
blood vessel becomes occluded by an on-site clot (thrombotic) or an embolus that forms
elsewhere in the body (embolic). Hemorrhagic strokes make up the other 15% of stroke cases
and occur when a blood vessel ruptures due to weak spot (aneurysm) or other trauma. In 10%
of all stroke cases, the ruptured vessel is located within the brain. This event triggers an
intracranial hemorrhage (ICH). When the ruptured vessel is located between the brain and the
meninges, a subarachnoid hemorrhage (SAH) occurs. SAH events comprise 3% of all stroke
cases. In the instance that an ischemic stroke is too short lived for significant brain damage to
occur, the stroke is classified as a transient ischemic attack (TIA) or mini-stroke. Approximately
33% of individuals who have experienced a TIA will have a major ischemic stroke within the
year(Association 2015a, Association 2015b). This project will focus on the pathogenesis and
treatment of ischemic stroke.
Animal Models of Ischemic Stroke
Several in vivo models may be used to recapitulate the effects of cerebral ischemia. Due
to their relatively low cost and variability between subjects, rodent models using the house mouse
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and Norway rat are widely used in mammalian models of ischemic stroke. However, higher
mammals with gyrencephalic brains, which include the miniature pig, sheep, and several primate
species, are also used in models of stroke (Bacigaluppi, Comi et al. 2010). For the purpose of
this introduction, the focus will remain on rodent models of ischemic stroke.
In models of global ischemia, which often occurs following cardiac arrest, both
hemispheres of the brain become ischemic. Global ischemia may be induced using ventricular
fibrillation, bilateral occlusion of the common carotid arteries, or an inflatable neck cuff. Focal
cerebral ischemia (FCI) reduces perfusion of one hemisphere via occlusion of a single vessel. In
most cases, the blocked vessel in question is the middle cerebral artery, which becomes blocked
in the majority of human stroke cases (Mohr, Lazar et al. 1992, Traystman 2003). This laboratory
utilizes the proximal middle cerebral artery occlusion (MCAO) model, where a 40 mm filament is
advanced to the origin of the MCA via the external carotid artery (Koizumi, Nakazawa et al. 1985,
Longa, Weinstein et al. 1989). Other models involving blockage of the MCA include the distal
MCAO procedure, where the portion of the MCA near the rhinal fissure is occluded in order to
avoid blockage of collateral vessels (Robinson and Coyle 1980, Kuraoka, Furuta et al. 2009).
Electrocoagulation and photothrombosis are used to induce clotting on site within the MCA
(Kobatake, Sako et al. 1984, Yao, Ibayashi et al. 1996). Finally, the injection of clot fragments
into the common carotid artery may also be used to block the origin of the MCA. However, this
model is disadvantageous due to the high variability in the infarct size/location following clot
injection (Kaneko, Nakamura et al. 1985, Traystman 2003).
Current Treatments for Ischemic Stroke
Thrombolytic Therapy
In 1996, tissue-type plasminogen activator (tPA) was approved by the FDA (Zivin 2009).
Currently, it remains the only FDA-approved treatment for ischemic stroke patients. While
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intravenous tPA therapy may be effective at dissolving clots if administered within 3-4.5 hours
following the onset of stroke, many patients are not able to receive tPA within this time window
(Hacke, Kaste et al. 2008). In other instances, patients have preexisting conditions that are
contraindicated with tPA therapy such as advanced age (≥ 80 years), diabetes mellitus,
hypertension, or are recipients of anticoagulant/antiplatelet drugs (Frank, Grotta et al. 2013).
Thrombolytic therapy also carries the risk of triggering an ICH by increasing levels of matrix
metalloproteinases (MMPs) 2 and 9 and subsequently weakening the blood-brain barrier (BBB)
(The NINDS t-PA Stroke Study Group 1997, Foerch, Rosidi et al. 2013).
Cellular Treatment
Although tPA is the only FDA-approved drug for the treatment of ischemic stroke, cellular
therapies have shown promise in preclinical models as well as clinical trials. Postmitotic
immature neurons derived from human teratocarcinomas were effective at reducing brain
damage in rats following distal MCAO. These promising results led to a nonrandomized phase I
trial where the cells were administered intracranially following basal ganglia stroke. Patients
administered these cells in phase I trials showed little to no adverse effects. Moreover, these
cells increased metabolic activity in the infarct as indicated by fluorodeoxyglucose-positron
emission tomography scans. Although phase II trials revealed no significant difference in motor
improvement using the European Stroke Scale motor score, treatment was associated with
improvement as measured by the Action Research Arm Test (Rosado-de-Castro, PimentelCoelho et al. 2013).
Among preclinical rodent studies, neural stem cells (NSCs) contributed to brain repair
through several mechanisms. These cells, which are derived from neurogenesis sites in the
subventricular and subgranular zones, facilitate tissue repair by proliferating and differentiating
into neurons and glia. Preclinical studies indicate that NSCs confer neuroprotection through the
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release of neurotropic and anti-inflammatory factors as well. Cell populations from the bone
marrow, umbilical cord blood, and autologous peripheral blood have also been reported as
cerebroprotective by several groups. These cells are currently undergoing several independent
clinical trials. Although these therapies contain mesenchymal stem cells, cells isolated from
autologous peripheral and umbilical cord blood also contain a large fraction of mononuclear cells,
which consist of monocytes/macrophages, lymphocytes, and neutrophils. Similar to NSCs, these
cell populations have been shown to exert protective effects via released factors that activate
survival signaling. This laboratory determined through preclinical rodent studies that HUCB
treatment after stroke increases PI3K/Akt signaling and induces the expression of antioxidant
enzymes (Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). The cerebroprotective
potential of cellular therapies lies in their ability to turn on pro-survival signaling in neural cells
via paracrine mechanisms. However, one major obstacle to overcome in regards to cellular
therapies is standardization of treatment, since heterogeneous cell populations may vary in
efficacy.
Other Therapies
Several clinical trials examined whether commonly-prescribed therapeutics may serve as
alternative treatments for stroke.

Drugs commonly prescribed for hypertension, such as

angiotensin receptor blockers, diuretics, and calcium channel blockers have shown to be
cerebroprotective in animal models of ischemic and hemorrhagic stroke(Maniskas, Roberts et
al. 2015, Wijkman 2015). These classes of drugs, which stimulate production of angiotensin II,
may promote the recruitment of collateral vessels to the ischemic core. Although angiotensin II
confers pro-hypertensive effects via systemic activation of AT1 receptors, these neuroprotective
benefits primarily occur through AT2, which is induced in the cerebral microcirculation following
ischemia (Fournier, Messerli et al. 2004). Diuretics also reduce brain damage by counteracting
cerebral edema. For instance, combination therapy with conivaptan, a vasopressin receptor
5

antgonist, and hypertonic saline reduced post-stroke inflammation as well as edema (Decker,
Collier et al. 2016). Agonists for peroxisome proliferator-activated receptors (PPARs), which are
normally used for the treatment of type 2 diabetes mellitus/metabolic syndrome, have also shown
potential in animal as well as human models of stroke.

In a rat model of transient FCI,

administration of the PPAR-γ receptor agonist pioglitazone upregulated expression of antioxidant
enzymes in the brain and improved neurological scoring compared to vehicle treatment
(Shimazu, Inoue et al. 2005). Clinical research also suggests that pioglitazone treatment may
help prevent reoccurring strokes in diabetes patients (Wilcox, Bousser et al. 2007).
Unfortunately, pre-clinical results demonstrated that pioglitazone was ineffective at providing
neuroprotection against permanent FCI.
Phases of Stroke Pathophysiology
Acute Excitotoxic Injury
Although neural cell death during stroke is commonly associated with energy failure and
low levels of oxygen, resulting brain damage occurs during two distinct phases of cellular
damage. The acute cytotoxicity phase, which occurs minutes to hours after the onset of stroke,
results in the death of cells within the ischemic core. Reduced generation of ATP due to low
glucose and oxygen levels leads to difficulties in maintaining neuronal membrane potential. As
a result, rates of neuronal depolarization and subsequent glutamatergic transmission increase
rapidly. The release of glutamate from injured cells and reduced glutamate uptake by astrocytes
causes further depolarization, activation of NMDA receptors, and influx of Na+ and Ca2+ into
neurons. Higher intracellular Ca2+ may trigger neuronal death through mitochondrial dysfunction,
calpain activation, and caspase cleavage (Rothstein, Dykes-Hoberg et al. 1996, Bano and
Nicotera 2007). This phase occurs immediately following the onset of stroke and may be targeted
by thrombolytic therapy.
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Delayed Neuroinflammation
Approximately 18 h after the onset of stroke, dying cells release compounds such as
ATP, CX3CL1, or other danger-associated molecular patterns, which activate microglia, the
resident macrophage-like immune cells in the brain (Streit, Graeber et al. 1988, Davalos,
Grutzendler et al. 2005, Marsh, Williams-Karnesky et al. 2009, Patel, Ritzel et al. 2013). Once
activated, microglia damage the BBB via the release of pro-inflammatory cytokines and MMPs
(Clark, Krekoski et al. 1997). Increased permeability of the BBB contributes to cerebral edema,
and renders cells in the parenchyma vulnerable to invading peripheral immune cells. These
immune

cells

infiltrate

the

brain

approximately

48

h

after

FCI,

and

include

monocytes/macrophages, lymphocytes, and neutrophils (Akopov, Simonian et al. 1996, Barone
and Feuerstein 1999, Vendrame, Cassady et al. 2004). Although certain populations of these
immune cells, such as anti-inflammatory macrophages/microglia, may play a crucial role in
phagocytosis and tissue repair, pro-inflammatory leukocytes perpetuate further damage in the
area surrounding the ischemic core (penumbra). In addition, peripheral B and T lymphocytes that
are exposed to central nervous system (CNS)-specific antigens may contribute towards the poststroke adaptive immune response by antibody secretion or direct cytotoxicity (Hurn,
Subramanian et al. 2007, Iadecola and Anrather 2011). This secondary phase continues until
approximately 96 h after the onset of stroke, when the infarct reaches its maximum volume
(Leonardo, Hall et al. 2010, Leonardo, Seifert et al. 2012).
Role of the Spleen
Of the peripheral immune cell populations that infiltrate the brain after stroke, a
substantial portion of them originate in the spleen. After stroke, elevated levels of norepinephrine
and epinephrine mediate splenic contraction through the activation of α and β-adrenoreceptors
in the white pulp, where splenic leukocytes reside (Myers, Norris et al. 1981, Ajmo Jr, Collier et
al. 2009). These leukocyte are released into the peripheral circulation, although the secretion of
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pro-inflammatory mediators causes these cells to migrate towards the injured hemisphere and
amplify the inflammatory response in the brain. Previous studies revealed inverse relationships
between post-stroke spleen weights and infract volumes in addition to spleen weights and splenic
CD8+ cytotoxic T-cell count. These findings show that greater splenic atrophy is the result of
more infiltrating immune cells, which mediate delayed neurodegeneration (Vendrame, Gemma
et al. 2005, Seifert, Hall et al. 2012). Although microglia are directly stimulated by dying cells
within the ischemic core, some studies demonstrate that peripheral immune cells, specifically
migrating splenocytes, may be crucial for full microglial activation (Chopp, Zhang et al. 1994,
Ajmo Jr., Vernon et al. 2008). Rats that underwent splenectomy 2 weeks prior to permanent
MCAO had significantly smaller infarct volumes than those that received a sham splenectomy
procedure (Ajmo Jr., Vernon et al. 2008). Published works from this laboratory demonstrate that
administration of interferon gamma (IFNγ), a pro-inflammatory cytokine produced by activated,
T lymphocytes, and natural killer (NK) cells, counteracted the protective effect of the splenectomy
(Schoenborn and Wilson 2007, Ajmo, Vernon et al. 2008). IFNγ signaling is implicated in the
development of pro-inflammatory macrophages/microglia. These data suggest that IFNγ triggers
the first step in the delayed post-stroke inflammatory response (Mosser and Edwards 2008,
Seifert, Collier et al. 2014).
Oxidative Stress
Production of Reactive Oxygen Species
Oxidative stress is characterized by the excess production of reactive oxygen species
(ROS), which may cause irreversible damage to cellular components. Although neural cell
damage during stroke is partially triggered by hypoxia, oxidative stress plays an instrumental role
during both phases of stroke pathophysiology. The increase in intracellular Ca2+ triggered by
glutamatergic activity activates calmodulin, which is responsible for neuronal nitric oxide (nNOS)
activity. Although nitric oxide is not directly neurotoxic, it may react with superoxide anions to
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form peroxynitrite, an extremely toxic reactive nitrogen species (Dawson, Dawson et al. 1991,
Dawson, Dawson et al. 1993). Protein Kinase C, which may be activated by Ca2+ and
diacylglycerol, increases activity of NAPDH oxidase, which generates additional ROS (Noh and
Koh 2000). During the secondary wave of neuroinflammation, ROS are produced by activated
microglia/peripheral immune cells. Activated microglia and peripheral macrophages generate
nitric oxide via inducible nitric oxide synthase (iNOS) (Merrill, Ignarro et al. 1993). Invading
neutrophils contribute to oxidative damage in the brain via myeloperoxidase, an enzyme
responsible for producing hypochloric acid, a strong oxidant (Beray-Berthat, Croci et al. 2003).
Generation of ROS may cause cellular necrosis by damaging mitochondria and activating proapoptotic signaling. Astrocytes facilitate endogenous protection of vulnerable cells, mainly
neurons and white matter-forming oligodendrocytes, by increasing activity of antioxidant
enzymes. Since oxidative stress is a key factor behind neural cell death at both time points,
decreasing ROS remains a popular alternative for treating ischemic stroke (Terasaki, Liu et al.
2014).
Failure of Exogenous Antioxidants
Despite the role of oxidative stress in neural cell damage during stroke, the performance
of exogenous antioxidants in clinical trials has been inconsistent. Some pro-antioxidant drugs
have yielded positive results in clinical trials. Ebselen, a glutathione peroxidase (GPx) mimetic
that improved outcomes after transient FCI in rodents, was used in a double blind clinical trial for
acute ischemic stroke patients. According to the results of the study, patients that received oral
ebselen within 24 of stroke onset showed improvement on the Glasgow Outcome Scale at 1
month after injury compare to patients who received the placebo. Unfortunately, there was no
significant improvement at 3 months post-stroke (Dawson, Masayasu et al. 1995, Yamaguchi,
Sano et al. 1998).
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Unfortunately, clinical trials for “free radical scavengers” have yielded more negative
results compared to successful treatments. Arguably the most notable failed trial was for α-(2, disulfophenyl)-N-tertbutylnitrone, also known as NXY-059. NXY-059 is a nitrone compound that
prevents the formation of peroxynitrite by mimicking NO. This drug performed extremely well in
rodent and primate models of FCI, and produced significant improvements on the Rankin scale
compared to placebo during its initial phase III clinical trial (SAINT I). However, NXY-059
produced no significant improvement compared to placebo in an expanded phase III trial (SAINT
II).
Several reasons were given as to why NXY-059 failed in the expanded study. For
instance, the drug used in the SAINT II trial may have been older than the lot used in the SAINT
I trial. As a result, this older lot may have undergone oxidation prior to administration, rendering
the drug less effective. Secondly, NXY-059 induces vasodilation of cerebral vessels, but does
not directly promote survival of neural cells. Pharmacokinetic issues, such as the short half-life
of the drug and its inability to easily cross the BBB may have also contributed to its lack of efficacy
(Strid, Borga et al. 2002, Lees, Zivin et al. 2006, Shuaib, Lees et al. 2007). In order to confer
longer lasting neuroprotection during ischemic stroke, researchers have begun focusing on
therapeutics that enhance the activity the brain’s endogenous antioxidant enzymes.
Endogenous Antioxidant Protection
Glutathione Metabolism
Under physiological and pathophysiological conditions, several enzymes are responsible
for regulating redox balance in neurons. Some of these enzymes product neurons from oxidative
stress by maintaining adequate levels of the antioxidant glutathione (GSH). GSH, an oligopeptide
containing a cysteine residue, acts as a nucleophile by donating electrons to break the disulfide
bonds of oxidized proteins. Once reduced, these proteins are unable to react with other cellular
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components and cause further damage. Oxidized glutathione molecules will form disulfide bonds
with each other until they are converted to reduced GSH by glutathione reductase (Kidd 1997,
Pompella, Visvikis et al. 2003). GSH may also reduce the accumulation of pro-oxidant xenobiotic
agents via the glutathione-S-transferase-dependent conjugation (Friling, Bensimon et al. 1990).
Although GSH is low in neurons, astrocytes may protect neurons by synthesizing and secreting
high levels of GSH in vitro. In addition, neuronal glutathione synthesis is largely dependent upon
the release of a cysteine-glycine dipeptide from astrocytes (Raps, Lai et al. 1989, Dringen,
Pfeiffer et al. 1999).
In addition to its endogenous antioxidant capabilities, GSH serves as a cofactor for the
GPx family of enzymes. GPx enzymes contain the amino acid selenocysteine, which contains a
selenium in the space normally occupied by sulfur. Although debate has occurred regarding the
function of selenocysteine vs cysteine, studies suggest that the higher reactivity of selenium
allows selenoproteins to scavenge peroxides more efficiently (Brigelius-Flohe 1999, Saccoccia,
Angelucci et al. 2014). Some members of the GPx family that are expressed in mammalian
tissues include classical GPx, gastrointestinal GPx, plasma GPx, and phospholipid
hydroperoxide GPx. All GPx enzymes possess the ability to catalyze the breakdown of organic
hydroperoxides, but some isoforms such as plasma GPx are able to reduce more complex
hydroperoxides. Phospholipid hydroperoxide GPx and classical GPx are highly stable in brain
tissue, and preclinical studies show that upregulation of GPx may occur in response to oxidative
damage in animal models of neurodegeneration, including Parkinson’s Disease (PD) and
Alzheimer’s Disease (AD) (Aksenov, Tucker et al. 1998, Lindenau, Noack et al. 1998, Schulz,
Lindenau et al. 2000). GPx activity is also neuroprotective in animal models of stroke. In rodent
models of transient MCAO, overexpression of GPx enzymes as well as treatment with a GPx
mimetic (ebselen) aided in protection against oxidative injury (Dawson, Masayasu et al. 1995,
Weisbrot-Lefkowitz, Reuhl et al. 1998, Ishibashi, Prokopenko et al. 2002).
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Peroxirexodins
Peroxiredoxin (Prdx) family enzymes, or “thiol-specific antioxidants,” were initially
identified due to their ability to reduce oxidized proteins in the presence of dithiothreitol, which
reduced molecular O2 to form several ROS species (Chae, Kim et al. 1993). Similar to GPx, Prdx
enzymes are able to form disulfide linkages following oxidation, and return to their active form
following reduction by an additional enzyme (thioredoxin) (Rhee, Kang et al. 2001). During each
redox cycle, Prdx enzymes catabolize the conversion of H2O2 into H2O and O2. However, a study
by Bryk et al. indicated that Prdx isoforms in bacteria have the capacity to scavenge peroxynitrite
(ONOO-) (Bryk, Griffin et al. 2000). Six Prdx isoforms are expressed in mammals; the cytosolic
isoforms Prdx1, Prdx2, and Prdx6; the mitochondrial isoform Prdx3; the secreted isoform Prdx4;
and Prdx5, which is localized in multiple organelles (Rhee, Woo et al. 2012). In brain tissue,
Prdx2-5 are expressed by neurons, while Prdx1, 4, and 6 are localized to glial cells (Goemaere
and Knoops 2012). As previously mentioned, Prdx4, the isoform expressed by multiple neural
cell types, is one of the antioxidant enzymes upregulated by HUCB cell therapy after permanent
MCAO(Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). Currently, the role of Prdx
enzymes in neural cell protection remains controversial. Studies from this laboratory as well as
other groups identify pro-survival mechanism for Prdx 2, 4, and 5 during in vivo and in vitro
ischemia. Shichita et al. demonstrated that antibodies against Prdx 1, 2, 5, and 6 decreased
infarct volume and decreased the release of IL-23 from macrophages after transient MCAO. This
paradoxical role for Prdx enzymes in stroke pathology may be explained by several factors. The
protective role for Prdx4-5 during stroke was demonstrated using rodent models of permanent
MCAO, suggesting that differences between permanent and transient FCI pathology may
determine whether Prdx enzymes contribute to neuroprotection vs. neuroinflammation. In
addition, the time point at which the anti-Prdx antibodies are administered may determine
whether or not blocking their activity is neuroprotective. The studies showing the neuroprotective
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role of Prdx2 were performed in vitro, meaning that this isoform may only be neuroprotective in
the absence of invading leukocytes (Vendrame, Gemma et al. 2005, Boulos, Meloni et al. 2007,
Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012, Shichita, Hasegawa et al. 2012, Rowe,
Collier et al. 2014).
Catalase
Catalase, a normal component of cellular peroxisomes, is responsible for converting
H2O2 into water and molecular oxygen. Catalase is ubiquitously expressed by neurons and glia
of the CNS, and is among the most efficient enzymes found in nature (Vainshtein, MelikAdamyan et al. 1981, Moreno, Mugnaini et al. 1995). A study looking at the antioxidant enzymes
in human patients with neurodegenerative diseases demonstrated that patients who had
experienced an ischemic stroke or had PD showed lower levels of catalase activity in the brain
(Rosario de la Torre, Casado et al. 1996). As a result, increasing catalase activity has been
examined as a potential therapeutic strategy for ischemic stroke. Neurons in the striatum that
overexpress catalase are less susceptible to damage following transient MCAO (Gu, Zhao et al.
2004). Two independent groups demonstrated that injecting catalase conjugated to polyethylene
glycol reduces total infarct size as well as BBB dysfunction after transient MCAO (Liu, Beckman
et al. 1989, Armstead, Mirro et al. 1992). However, both of these studies showed that conjugated
catalase is most efficacious when administered in conjunction with a polyethylene glycolconjugated form of another antioxidant, superoxide dismutase.
Superoxide Dismutase
SOD isoforms
Superoxide dismutase (SOD) family enzymes are responsible for converting superoxide
(O2-) anions to H2O2 and H2O. Mammalian cells express three isoforms of SOD: SOD1, SOD2,
and SOD3. SOD1, alternatively known as copper/zinc-dependent SOD (Cu/Zn-dependent SOD)
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is a 32 kDa homodimeric enzyme that is ubiquitously expressed and localized in the cytosol.
SOD2, or manganese-dependent SOD, is an 88 kDa homotetrameric enzyme that is localized in
the mitochondria. Similar to SOD1, SOD2 exhibits a ubiquitous pattern of expression. SOD3, or
extracellular SOD, is also dependent upon copper and zinc and contains a signaling peptide
sequence for localization to the endoplasmic reticulum and eventual secretion into the
extracellular environment. SOD3 exists as a homotetramer of 135 kDa in humans and mice, but
it is primarily dimeric in rats (Carlsson, Marklund et al. 1996, Zelko, Mariani et al. 2002). In
contrast to the ubiquitous expression of SOD1 and SOD2, levels of SOD3 expression vary
greatly between organs. Under physiological conditions, SOD3 mRNA levels are highest in the
heart, lung, and pancreas, but low in brain tissue. Fukui et al. showed that neuronal populations
have the capacity to induce SOD3 following FCI, indicating that SOD3 activity may be
neuroprotective despite its low basal expression (Fukui, Ookawara et al. 2002).
SOD enzymes as stroke targets
Since oxidative stress is a pathological hallmark of neurodegeneration, SOD dysfunction
is implicated in diseases characterized by neuronal loss. Mutations in SOD1 contribute to the
development of familial amyotrophic lateral sclerosis (ALS), and multiple studies suggest that
reduced SOD2 activity may be associated with AD and PD. However, preclinical studies
demonstrate that increased activity of all three SOD enzymes may reduce brain damage after
FCI. As previously mentioned, treatment with polyethylene glycol-conjugated catalase and SOD
effectively reduced ischemic brain damage. EUK-134, a selenium -manganese complex that acts
as a mimetic for SOD and catalase, decreased brain damage when administered 3 h after stroke,
a comparable time point to administration of tPA (Baker, Marcus et al. 1998). Since H2O2 is a
product of the reduction of O2-, combination therapy with both enzymes would allow for
scavenging of both ROS and better protection against ischemic damage.
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Targeting SOD enzyme expression has also shown considerable success in animal
models of stroke. Davis et al. showed that delivery of the SOD1 gene using herpes simplex viral
vectors protected mice against striatal damage induced by transient MCAO compared to the
vector alone (Davis, Zhao et al. 2007). Unfortunately, the neuroprotective effect of SOD1
overexpression appears to be limited to models of cerebral ischemia/reperfusion injury, since
SOD1 overexpressing mice did not show a significant decrease in infarct volume compared to
wild-type mice after permanent MCAO. The authors of the latter study suggest that the protective
effect of SOD1 overexpression is minimal due to high basal levels of SOD1 in the brain tissue of
wild-type mice (Chan, Kamii et al. 1993). Several independent groups reported that SOD2
knockout mice show greater susceptibility to oxidative stress after permanent and transient
MCAO (Mikawa, Li et al. 1995, Murakami, Kondo et al. 1998, Kim, Kondo et al. 2002). Increasing
SOD3 is also an effective strategy in protecting against oxidative damage in models of ischemic
stroke. Sheng et al. demonstrated that mice that overexpress the SOD3 gene have smaller
infarct volumes compared to wild-type mice (Sheng, Brady et al. 1999). The effectiveness of
SOD3 overexpression as neuroprotective strategy stems from its low levels of basal expression
in the brain. While SOD1 and SOD2 are highly expressed under basal conditions, SOD3 is only
induced in neurons during injury (Fukui, Ookawara et al. 2002). Therefore, the difference in
antioxidant capacity between SOD3 transgenic mice and wild-type mice might be greater than
the difference between SOD1/SOD2 transgenic mice and wild-type mice.
Transcription Factors
Upregulation of Protective Genes
During the HUCB studies from this laboratory, emphasis was not only placed on
identifying protective genes that were induced by the cells, but also transcription factors (TFs)
that might be involved in regulating expression of protective genes. Using the software program
Genomatix, this laboratory analyzed the promoter regions of eight genes induced by HUCB cell
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therapy to identify possible transcription factors implicated in oligoprotective gene upregulation.
According to Genomatix analysis, several common TFs had binding sites in the promoters of all
8 genes, while several more were found in 7 out of the 8 genes. Moreover, the pro-survival effects
of HUCB cells, in addition to expression of Prdx4, were determined to be dependent upon
PI3K/Akt activation in cultured oligodendrocytes (Rowe, Leonardo et al. 2010, Rowe, Leonardo
et al. 2012). Further investigation revealed that several of the identified TFs are activated by
PI3K/Akt signaling; these factors including myeloid zinc finger-1 (MZF-1) and specificity protein
1 (Sp1) (Pore, Liu et al. 2004, Moeenrezakhanlou, Shephard et al. 2008).
Myeloid Zinc Finger-1
Hromas et al. first identified MZF-1 as a member of the Kruppel TF family that regulates
hematopoietic development (Hromas, Collins et al. 1991). MZF-1 consists of 13 C2H2 zin fingers
that make up two separate DNA-binding domains. Each binding domain recognizes a separate
consensus sequence containing several consecutive guanine resides (Morris, Hromas et al.
1994). Similar to other zinc finger TFs, MZF-1 regulates genes containing GC-rich promoters
lacking TATA and CAAT boxes (Mudduluru, Vajkoczy et al. 2010). Currently, there are few
known regulatory mechanisms of MZF-1. Moeenrezakhanlou et al. showed that the pro-survival
PI3K/Akt signaling pathway induces MZF-1 in myeloid cells. This study showed that the
regulation of MZF-1 by Akt was controlled at the level of expression, but a recent report by Eguchi
et al. indicates that MZF-1 may also contain phosphorylation sites (Moeenrezakhanlou,
Shephard et al. 2008, Eguchi, Prince et al. 2015).
Although MZF-1 has not been extensively characterized in brain tissue, several studies
show that MZF-1 is involved with the regulation of genes that are implicated in stroke pathology.
Luo et al. showed that fibroblast growth factor-2 (FGF-2), a neuroprotective trophic factor, is
induced in astrocytes following treatment with apomorphine, a dopamine receptor agonist.
Furthermore, increased transcription of the FGF-2 gene was shown to be dependent upon MZF16

1 activity (Alzheimer and Werner 2002, Luo, Zhang et al. 2009). Cystathionine-β-synthase and
cystathionine-γ-lyase, two enzymes involved with hydrogen sulfide (H2S) synthesis, are
positively regulated by MZF-1. Although the role of H2S in mediating ischemic damage is
controversial, Wen et al. reported that H2S reduces hippocampal neuron damage and cognitive
deficits after stroke in an Akt-dependent manner (Wen, Qi et al. 2014). MZF-1 also suppresses
transcription of genes that may be detrimental during ischemia. Expression of MMP-2, a
gelatinase that mediates the breakdown of the BBB, is decreased in cervical cancer cells
following overexpression of MZF-1 (Clark, Krekoski et al. 1997, Tsai, Hwang et al. 2012). Of
particular interest to this project is the ability of MZF-1 to control expression of antioxidant
enzymes. In addition to Prdx4, MZF-1 regulates the expression of Prdx1 in lung cancer cells and
SOD3 in the same tissue under physiological conditions (Zelko and Folz 2003, Kim, Bogner et
al. 2008).
Specificity Protein 1
Sp1, alternatively known as stimulating protein 1, is a ubiquitously expressed zinc finger
transcription factor. Sp1 was first discovered as a regulator of the Simian virus 40 and AIDS
retrovirus early promoters (Dynan and Tjian 1983, Jones, Kadonaga et al. 1986). Further
characterization by other groups revealed that it contains two DNA-binding domains with
molecular weights of 105 and 95 kDa binds to a 5’-GGGGCGGGGC consensus sequence.
Genes regulated by Sp1 usually contain GC-rich promoter sequences and may or may not
contain a TATA box. Pugh and Tijan reported that Sp1 cannot function as the sole activator for
TATA-less genes in Drosophila. Emani et al. published a later study showing that in the presence
of human transcription tactor IID, Sp1 may initiate transcription of genes lacking the TATA box
(Briggs, Kadonaga et al. 1986, Pugh and Tjian 1990, Emami, Smale et al. 1998). In addition to
transcription factor IID, several other mechanisms regulate the DNA-binding activity of Sp1. Sp1
contains several post-translational modifications that facilitate its interaction with gene
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promoters. For instance, acetylation by the histone actetyltransferases p300 and p300/CREB
binding protein-associated factor enhance its interaction with the promoter of transforming
growth factor β type II receptor (Huang, Zhao et al. 2005). PI3K/Akt signaling increases the
activity of Sp1 by two independent mechanisms. Akt phosphorylates Sp1 and induces its protein
expression (Pore, Liu et al. 2004, Amodio, Di Martino et al. 2012).
Sp1 plays several known roles in controlling gene expression in brain tissue. Zawia et al.
determined that Sp1 regulates the expression of genes involved in brain development, including
myelin basic protein and proteolipid protein, and its regulatory activity may be altered by heavy
metal toxicity (Zawia, Sharan et al. 1998). Moreover, the transcriptional activity of Sp1 is
dysregulated in several neurodegenerative diseases. Some of these studies demonstrate that
Sp1 activity is primarily neuroprotective. Dunah et al. showed that the DNA-binding activity Sp1,
in addition to transcription factor IID subunit 4, is decreased by aggregated huntingtin in a mouse
model of Huntington’s disease (HD) (Dunah, Jeong et al. 2002). Hypoxia-inducible factor-1α
confers neuroprotection against prion diseases by upregulating Sp1 (Jeong and Park 2012).
However, other groups found that Sp1 transcriptional activity is upregulated in models of HD
(Qiu, Norflus et al. 2006). In addition, Citron et al. showed that Sp1 contributes to AD pathology
through regulation of amyloid precursor protein and tau (Citron, Dennis et al. 2008). In spite of
these conflicting roles in other neurodegenerative diseases, research points to a neuroprotective
role for Sp1 during cerebral ischemia. Yeh et al. showed that neurons will upregulate Sp1 in vitro
as a protective mechanism against oxygen glucose deprivation (OGD). Histone deacetylase
inhibitors, including valproic acid and trichostatin A protect neurons against in vitro oxidative
damage. This pro-antioxidant effect of Sp1 activity stems from its ability to induce transcription
of enzymes that break down ROS, including SOD3. (Ryu, Lee et al. 2003a, Ryu, Lee et al.
2003b, Lee, Kosaras et al. 2006, Marinova, Ren et al. 2009).
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Leukemia Inhibitory Factor
Discovery of LIF
Leukemia inhibitory factor (LIF) is a cytokine in the interleukin-6 (IL-6) family that was
initially identified based on its ability to induce terminal differentiation of a myeloid leukemia cell
line. Medium that had been pre-conditioned with Krebs-II ascites tumor cells was used to purify
LIF and cloning was achieved using cDNA from a mouse T lymphocyte library. Cloning studies
revealed that LIF consisted of a single polypeptide chain containing four α-helices that was
glycosylated. LIF was also shown to facilitate maturation of macrophages. Despite its inhibitory
effects on the self-renewal on leukemia cells, LIF has a crucial role in maintaining the
pluripotence of embryonic stem cells. (Gearing, Gough et al. 1987, Gough, Gearing et al. 1988,
Hilton, Nicola et al. 1988, Metcalf 2003).
LIF signaling
LIF confers its effects via activation of its heterodimeric receptor: the low-affinity LIF
receptor (LIFR) subunit and the high-affinity glycoprotein 130 (gp130) subunit, which is shared
by all IL-6 family cytokine receptors (Gearing, Thut et al. 1991). Both receptor subunits dimerize
upon LIF binding, and Janus kinases (JAKs) that associate with both receptor subunits undergo
self-phosphorylation. Three main signaling pathways may be subsequently activated:
Ras/MAPK/ERK, PI3K/Akt, and JAK/STAT signaling (Boulton, Stahl et al. 1994, Stahl, Boulton
et al. 1994, Stahl, Farruggella et al. 1995, Oh, Fujio et al. 1998). The precise consequences of
each signaling pathway differ between cell types, but one of the ways in which LIF exerts longlasting effects is through changes in gene expression. In several ES cell populations, Ras/MAPK
signaling upregulates genes involved in proliferation, JAK/STAT controls genes that regulate
self-renewal, and PI3K/Akt signaling induces pro-survival genes (Graf, Casanova et al. 2011,
Majumder, Banerjee et al. 2012)
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Clinical Trials
Although LIF has not yet been used to treat brain damage, it has been tested for the
treatment of other conditions under the trade name of Emfilermin. For instance, LIF was used in
clinical trials for the treatment of chemotherapy-induced peripheral neuropathy, infertility, and
several types of cancer, including non-small cell lung carcinoma. Unfortunately, none of these
trials yielded successful results. However, these studies reported a very low incidence of adverse
effects in response to LIF treatment, indicating that it would be a safe therapeutic option for other
diseases (Gunawardana, Basser et al. 2003, Davis, Kiers et al. 2005, Brinsden, Alam et al.
2009).
LIF in the Nervous System Development
LIF exerts pleiotropic effects on the body due to the wide distribution of its receptors, but
it exerts several important functions as a neurokine in the peripheral and central nervous
systems. According to Murphy et al., treatment of mouse neural crest cells triggered the
development of sensory neurons in vitro (Murphy, Reid et al. 1991). LIF also induces the
development of neurons from precursor cells in the spinal cord (Richards, Kilpatrick et al. 1992),
and induced neurogenesis in vitro when combined with ciliary neurotrophic factor (CTNF),
another IL-6 family neurokine (Galli, Pagano et al. 2000). However, LIF exerts anti-neurogenic
effects by inhibiting the terminal differentiation of murine olfactory receptor neurons (Moon, Yoo
et al. 2002). The reason for this inhibitory effect on neurogenesis in the olfactory bulb is explained
by its effects on embryonic self-renewal. LIF increases NSC populations and enhances selfrenewal by inhibiting differentiation, which allows NSCs to aid in neural repair during injury (Bauer
and Patterson 2006). Using a gene microarray, Wright et al. demonstrated that these antidifferentiation effects on NSC populations following LIF treatment occurred due to changes in
the expression of over 200 genes (Wright, Li et al. 2003).
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LIF regulates the development of several glial cell populations in addition to neurons. LIF
enhances proliferation of oligodendrocyte progenitor cells and increased the population of
mature oligodendrocytes in the hippocampus during cuprizone-induced demyelination
(Deverman and Patterson 2012). LIF, in conjunction with bone morphogenetic protein 2 causes
NSCs to differentiate into astrocytes (Yoshida, Satoh et al. 1993, Nakashima, Yanagisawa et al.
1999). However, the study by Koblar et al. shows that LIF knockout mice show only a partial
reduction in hippocampal astrocytes, while LIFR knockout mice show a complete deficiency
(Koblar, Turnley et al. 1998). Other IL-6 family neurokines, such as CNTF and neuropoetin, exert
similar downstream effects to LIF since they also signal through gp130 and LIFR (Ip, Nye et al.
1992) (Derouet, Rousseau et al. 2004). These studies that the presence of the low-affinity LIF
receptor is more important for the development of certain neural cell populations compared to
LIF alone (Li, Sendtner et al. 1995, Koblar, Turnley et al. 1998).
Treatment of Neurodegenerative Disease
Under pathophysiological conditions, LIF is upregulated endogenously and released by
several cells of the nervous system. Brain endothelial cells release LIF to promote the
differentiation of astrocytes, which also secrete LIF to promote neuroprotective signaling
(Banner, Moayeri et al. 1997, Mi, Haeberle et al. 2001, Moidunny, Vinet et al. 2012). Pericytes,
which help comprise the BBB, have been tested as a therapeutic for myocardial infarction based
on their ability to promote cardioprotection via secretion of LIF (Chen, Okada et al. 2013). NSC
populations upregulate LIF mRNA following stimulation with IFNγ, which is produced by T
lymphocytes and NK cells after stroke. This secretion of LIF promotes brain repair by acting on
neural cells and by triggering proliferation of other NSCs (Yilmaz, Arumugam et al. 2006, Laterza,
Merlini et al. 2013). Neurons also increase expression of LIF in response to injury. Getchell et al.
showed that olfactory receptor neurons upregulate LIF mRNA following targeted ablation, which
may promote survival in an autocrine manner (Getchell, Shah et al. 2002).
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Animal models of neurodegeneration show that LIF enhances survival of neural cells and
promote regeneration of damaged tissue. Anzari et al. revealed LIF decreased the degradation
of motor neurons in the G93A SOD1 mouse model of familial ALS and reduced white matter
damage after spinal cord injury (Azari, Galle et al. 2001, Azari, Lopes et al. 2003, Azari, Profyris
et al. 2006).Due to its pro-survival effects on oligodendrocytes, LIF has been explored as a
therapeutic for demyelinating diseases, most notably multiple sclerosis (Butzkueven, Zhang et
al. 2002, Butzkueven, Emery et al. 2006, Slaets, Dumont et al. 2008, Laterza, Merlini et al. 2013).
The ability of LIF to rescue gray and white matter from damage makes it a promising
candidate for preclinical stroke studies, in which preventing neuronal and oligodendrocyte loss
is crucial. Suzuki et al. showed that LIF activates its three main signaling pathways (MAPK,
PI3K/Akt, and JAK/STAT) to promote neuroprotection after FCI (Suzuki, Yamashita et al. 2005).
LIF treatment alone and in conjunction with fibroblast growth factor-2 increased the activity of
antioxidant enzymes, including GPx and SOD isoforms, and reduced oxidative damage when
administered after MCAO (Huang, Li et al. 2012). This laboratory performed more extensive
studies regarding the ability of LIF to protect white matter during permanent FCI in the rat. Not
only did LIF promote oligodendrocyte survival in vivo and in vitro via the Akt-dependent
upregulation of Prdx4, but LIF treatment also reduced the infarct volume and improved motor
function 72 h after MCAO (Rowe, Collier et al. 2014).
Immunomodulation by LIF
Although LIF belongs to the same family as IL-6, which is commonly associated with
inflammation, LIF primarily confers anti-inflammatory and pro-regulatory effects. Metcalfe et al.
reported that LIF signaling was associated with greater immune tolerance following
transplantation. This phenomenon may be explained by the role of LIF in suppressing the
immune response(Metcalfe, Watson et al. 2005).
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During the maturation of naïve T lymphocytes, the balance between IL-6 and LIF
determines whether the immature cells will develop into CD4+ IL-17+ helper T (Th17) or CD4+
forkhead box transcription factor P3 (FOXP3)+ regulatory T (Treg) lymphocytes. Th17 cells
require IL-6, interleukin-1 (IL-1), and transforming growth factor-β for maturation, and are
distinguished by their ability to secrete interleukin-17 (IL-17). Th17 cells are often active at sites
of inflammation in autoimmune diseases such as multiple sclerosis (MS) or rheumatoid arthritis.
In the absence of IL-6, the naïve lymphocytes will mature into CD4+ Tregs (FuruzawaCarballeda, Vargas-Rojas et al. 2007, Kimura and Kishimoto 2010). Gao et al. reported that LIF
induces the development of Tregs and inhibits Th17 maturation by increasing the expression of
FOXP3. Mature Tregs will maintain immunotolerance by releasing LIF and favoring the
development of other Treg populations. By contrast, IL-6 quenches LIF signaling by
downregulating LIFR mRNA and activating the E3 ubiquitin ligase MARCH-7, which targets LIFR
for degradation (Gao, Thompson et al. 2009). Cao et al. reported similar findings, in which LIF
not only induced Treg differentiation, but suppressed IL-6-mediated Th17 development through
upregulation of suppressor of cytokine signaling-3 (Cao, Yang et al. 2011). The ability of LIF to
suppress the immune response renders it a promising therapeutic for neuroinflammatory
diseases. Although LIF was initially explored as a treatment for MS based on its ability to promote
oligodendrocyte survival and remyelination, recent studies have focused more on its ability to
suppress autoimmunity by increasing Treg populations (Butzkueven, Zhang et al. 2002,
Butzkueven, Emery et al. 2006, Slaets, Dumont et al. 2008, Janssens, Van den Haute et al.
2015, Metcalfe, Strom et al. 2015).
Dysregulation of the balance between Th17 and Treg populations may be induced by
ischemic stroke. Th17 cells are among the populations that mediate tissue damage, and, and
several groups have reported a higher Th17/Treg ratio after stroke and TIA (Li, Wang et al. 2013,
Swardfager, Winer et al. 2013, Hu, Zheng et al. 2014). By contrast, depletion of Tregs prior to
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stroke decreased levels of the anti-inflammatory cytokine IL-10, increased the severity of brain
damage and worsened overall outcome after permanent MCAO (Liesz, Suri-Payer et al. 2009,
Liesz, Zhou et al. 2013). Other reports show that higher Treg numbers may be detrimental after
stroke, since Treg activity is associated with post-stroke immunosuppression (Offner,
Subramanian et al. 2006). However, controlled administration of LIF could be used to merely
restore the Th17/Treg balance rather than induce complete immunosuppression.
In addition to its effects on Th17 and Treg populations, LIF exerts beneficial signaling on
macrophages that could potentially decrease delayed brain damage after stroke. While activated
macrophages/microglia potentiate tissue damage via the release of pro-inflammatory mediators,
IL-6 family cytokines (LIF, IL-6, IL-11, oncostatin M) polarize macrophages/microglia towards an
anti-inflammatory phenotype. These cells are primarily phagocytic, assist in tissue repair, and
release IL-10 and TGF-β (Duluc, Delneste et al. 2007, Janssens, Slaets et al. 2015). Considering
pro-inflammatory macrophages and T lymphocytes are among the splenocyte populations that
contribute to brain damage during stroke, LIF may also reduce brain damage by attenuating
splenic response.
LIF as a Neuroprotective Stroke Therapeutic
This laboratory has previously explored the role of LIF in decreasing white matter damage
by inducing antioxidant enzymes as well as the targeting the immune response generated by the
spleen after stroke. However, the role of LIF in protecting gray matter and mediating the splenic
response has not been thoroughly explored. LIF-mediated oligoprotection and upregulation of
Prdx4 occurs primarily via Akt signaling, which increases the activity of TFs that modulate
antioxidant expression. By identifying protective signaling mechanisms induced in neurons, we
may further evaluate LIF as a stroke therapeutic. Furthermore, determining whether LIF plays a
role in the splenic response may open the door for LIF-based stroke immunotherapies. The
following set of experiments discussed in this dissertation will be used to determine whether: 1)
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LIF protects neurons during ischemia by upregulating SOD3, 2) MZF-1 and Sp1 confer
neuroprotection downstream of LIF by regulating SOD3 transcription, and 3) LIF treatment
enhances sensitivity to subsequent LIF signaling in the brain and spleen via LIFR/JAK dependent
mechanisms.
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CHAPTER 2
LEUKEMIA INHIBITORY FACTOR PROTECTS NEURONS FROM ISCHEMIC DAMAGE VIA
UPREGULATION OF SUPEROXIDE DISMUTASE 3
Note to Reader
The contents of this chapter have previously been published in Molecular Neurobiology
(Davis, Collier et al. 2016). Permission to use said material has been obtained from the publisher.
Stephanie Davis was the main author on this manuscript. Lisa A. Collier, Dr. Hilary A. Seifert, Dr.
Christopher C. Leonardo, and Dr. Craig T. Amjo Jr. assisted with experimentation and editing of
the manuscript and all are listed as co-authors on the published manuscript. This project was
overseen by Dr. Keith R. Pennypacker, who is the corresponding author on the published
manuscript.
Abstract
Leukemia inhibitory factor (LIF) has been shown to protect oligodendrocytes from
ischemia by upregulating endogenous antioxidants. The goal of this study was to determine
whether LIF protects neurons during stroke by upregulating superoxide dismutase 3 (SOD3).
Animals were administered PBS or 125 µg/kg LIF at 6, 24, and 48 h after middle cerebral artery
occlusion or sham surgery. Neuron were isolated from rat pups on embryonic day 18 and used
between 7-15 days in culture. Cells were treated with LIF and/or 10 µM Akt inhibitor IV with PBS
and 0.1% DMSO acting as vehicle controls. Neurons transfected with scrambled or SOD3 siRNA
were subjected to 24 h ischemia after PBS or LIF treatment. LIF significantly increased
superoxide dismutase activity and SOD3 expression in ipsilateral brain tissue compared to PBS.
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Following 24 h ischemia, LIF reduced cell death and increased SOD3 mRNA in vitro compared
to PBS. Adding Akt inhibitor IV with LIF counteracted the decrease in cell death. Partially
silencing expression of SOD3 using siRNA prior to LIF treatment counteracted the protective
effect of LIF alone PBS treatment. These results indicate that LIF protects neurons in vivo and
in vitro via upregulation of SOD3.
Key Words
Stroke, Neuroprotection, Superoxide Dismutase, Oxidative Stress
Introduction
Reactive oxygen species (ROS) play an instrumental role in both the acute and delayed
phases of neuronal death during focal cerebral ischemia (FCI). During the early phase of
ischemia, energy failure leads to membrane depolarization (Calabresi, Pisani et al. 1995),
calcium influx, and activation of pro-oxidant enzymes such as neuronal nitric oxide (NO)
synthase (Dawson, Dawson et al. 1991 ) and nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (Brennan, Won Suh et al. 2009). These enzymes generate ROS, such as
peroxynitrite and superoxide, which damage cellular components and trigger neuronal death
(Bonfoco, Krainc et al. 1995). A second wave of neuronal death occurs during the period of
delayed neuroinflammation, which may continue hours to days after the initial injury (Dirnagl,
Iadecola et al. 1999). Activation of microglia exacerbates oxidative damage to neurons via
inducible NO synthase activation (Merrill, Ignarro et al. 1993). Furthermore, matrix
metalloproteinases derived from activated microglia compromise blood-brain barrier (BBB)
function by disrupting tight junctions (Gasche, Copin et al. 2001, McColl, Rothwell et al. 2008
Leonardo, 2010 #94). Increased BBB permeability allows for the invasion of peripheral
lymphocytes, monocytes/macrophages, and neutrophils (Offner, Subramanian et al. 2006).
Accumulation of immune cells in the brain damages already degenerating neurons in the
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penumbra (Rosell, Ortega-Aznar et al. 2006). Since the therapeutic window for tissue
plasminogen activator, the only FDA-approved drug for ischemic stroke, ranges from 3 to 4.5
hours after stroke, it cannot target this delayed phase of neuronal death (Hacke, Kaste et al.
2008). Consequently, the need for novel stroke therapeutics that will protect vulnerable neurons
from oxidative stress remains high.
While small molecule scavengers of ROS have demonstrated limited efficacy in clinical
trials (Shuaib, Lees et al. 2007), overexpressing endogenous antioxidant enzymes may be more
effective than administering exogenous agents. These enzymes include those in the superoxide
dismutase (SOD) family, which react with excess superoxide to form hydrogen peroxide and
water. Three SOD isoforms have been identified in mammals (Scandalios 1993, Zelko, Mariani
et al. 2002) Moreover, decreased activity of SOD enzymes yields deleterious effects on nervous
system function. The G93A mutation in SOD1, a ubiquitously expressed cytoplasmic enzyme, is
associated with familial amyotrophic lateral sclerosis (ALS) (Wiedau-Pazos, Goto et al. 1996,
Yim, Kang et al. 1996, Boillée, Yamanaka et al. 2006). Dysfunction of SOD2, which regulates
ROS production in the mitochondria (Melov, Coskun et al. 1999), is implicated in the
development of conditions such as AD (Wiener, Perry et al. 2007, Massaad, Washington et al.
2009, Belluzzi, Bisaglia et al. 2012) and PD (Belluzzi, Bisaglia et al. 2012). SOD3, the
extracellular isoform with the lowest expression in neural cells (Folz and Crapo 1994), opposes
the negative effects of hypertension in the brain by increasing NO bioavailability and regulating
cerebral blood flow (Demchenko, Oury et al. 2002).
Several murine studies have implicated the neuroprotective role of SOD enzymes
following FCI. Delivery of the SOD1 gene via herpes simplex virus protects mice against cerebral
ischemia/reperfusion injury (Davis, Zhao et al. 2007). SOD2 homozygous knockout mice had
greater infarct volumes after transient FCI compared to their wild-type counterparts (Mikawa, Li
et al. 1995). Conversely, mice overexpressing SOD3 showed resistance to neural cell damage
42

following transient FCI (Sheng, Brady et al. 1999). Nonetheless, information regarding the role
of SOD3 in protecting neurons remains limited.
Few studies focus on exogenous agents that upregulate expression of these enzymes.
Previous data from this lab demonstrates the therapeutic potential of upregulating endogenous
antioxidant enzymes as a protective strategy against stroke. Specifically, the Akt-dependent
upregulation of the antioxidant enzyme peroxiredoxin IV (Prdx4) contributes to human umbilical
cord blood (HUCB) cell-mediated protection of oligodendrocytes (Rowe, Leonardo et al. 2010,
Rowe, Leonardo et al. 2012). This lab has chosen to focus on released factors such as leukemia
inhibitory factor (LIF), which provide neural cell protection while avoiding cellular treatment
(Neuhoff, Moers et al. 2007, Rowe, Leonardo et al. 2010).
Leukemia inhibitory factor (LIF), an anti-inflammatory cytokine in the interleukin-6 family,
(Metcalfe, Watson et al. 2005) binds to a heterodimeric receptor consisting of the LIF receptor
(LIFR) and glycoprotein 130 (gp130) subunits. Upon binding, several downstream signaling
pathways are activated including the MAPK (Boulton, Stahl et al. 1994), PI3K/Akt (Oh, Fujio et
al. 1998), and JAK/STAT pathway (Stahl, Boulton et al. 1994, Stahl, Farruggella et al. 1995).
These signaling cascades, especially the PI3K/Akt pathway, play an instrumental role in the prosurvival and neurotrophic effects of LIF (Alonzi, Middleton et al. 2001).
LIF has shown promising results as a therapeutic in several animal models of
neurodegenerative disease. Administration of LIF reduces demyelination in the experimental
autoimmune encephalomyelitis model of multiple sclerosis (Butzkueven, Zhang et al. 2002) and
a murine model of spinal cord injury (Azari, Profyris et al. 2006). In addition, LIF reduced
degeneration of motor neurons in the SOD1 G93A murine model of familial ALS (Azari, Galle et
al. 2001). Recently, we showed that LIF decreases infarct volume, improves functional recovery,
and upregulates Prdx4 in oligodendrocytes after ischemia (Rowe, Collier et al. 2014). Although
LIF is released by several cell types during brain injury (Banner, Moayeri et al. 1997, Chen,
43

Okada et al. 2013, Laterza, Merlini et al. 2013), its potential as a stroke therapeutic has not yet
been determined.
The ability of LIF to activate protective pathways and reduce neural cell damage in
several animal models of disease makes it a prime candidate for targeting delayed neuronal
death after stroke. The goal of this study is to identify the molecular mechanisms by which LIF
exerts neuroprotection after permanent FCI. This lab tested the hypothesis that LIF increases
neuronal survival after stroke by upregulating SOD enzyme expression and activity.
Materials and Methods
Animal care
All animal procedures were conducted in agreement with the NIH Guide for the Care and
Use of Laboratory Animals. Experimental protocols were approved by the Institutional Animal
Care and Use Committee at the University of South Florida. Power analysis was conducted prior
to experiments to determine the minimum number of animals required to detect significant
effects. Sprague–Dawley rats were purchased from Harlan Labs (Indianapolis, IN, USA),
maintained on a 12 h light–dark cycle (07:00–19:00 h) in a climate-controlled room, and allowed
access to food and water ad libitum. Neurons for in vitro experiments were taken from embryonic
day 18 (E18) rat pups obtained from timed pregnant dams. Young, male rats weighing 300 to
350 g were used for in vivo experiments.

Permanent Middle Cerebral Artery Occlusion (MCAO) and Administration of LIF
Induction of FCI was achieved using the permanent MCAO model as previously
described (Ajmo, Vernon et al. 2006). Briefly, an incision was made near the sternum and blunt
dissection was used to expose the common carotid artery. After ligating and cutting the external
carotid artery, a 40 mm monofilament was introduced and fed through the internal carotid artery.
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The monofilament was advanced to the base of the middle cerebral artery. The monofilament
was secured and the wound was closed using polypropylene sutures. Laser Doppler (Moore Lab
Instruments, Farmington, CT) was used to confirm the reduction in cerebral blood flow. Animals
experiencing less than a 60% reduction in CBF were excluded from analysis. For the sham
MCAO procedure, the common carotid artery was exposed without subsequent occlusion of the
middle cerebral artery. Animals were administered recombinant human LIF (ProSpec, Ness
Ziona, Israel) (125 μg/kg) or vehicle control (PBS pH 7.4) intravenously at 6, 24, and 48 h postMCAO. Rats were euthanized 24, 48, and 72 h post-MCAO for immunohistochemistry or
biochemical analysis. The number of subjects in each treatment group were as follows 24 h PBS:
n =3; 24 h LIF: n =5; 48 h PBS: n =4; 48 h LIF: n =4; 72 h PBS: n =12; 72 h LIF: n =10.
Histochemical Analysis
Tissue sections were prepared for histochemical analysis as previously described (Ajmo
Jr., Vernon et al. 2008). Following euthanization, animals were perfused transcardially with
normal saline followed by 4% paraformaldehyde in PBS (pH 7.4). Brains were removed and
incubated in 4% paraformaldehyde followed by 20% and 30% sucrose solutions. Brains were cut
into 30 µm sections including bregma -1.7 mm through +3.3 mm. 3, 3-diaminobenzidine (DAB)
immunohistochemisty was performed as previously described (Hall, Guyer et al. 2009). This
procedure was also performed as previously described (Rowe, Leonardo et al. 2010) on 18 mm
glass coverslips containing primary cortical rat neurons. The following antibodies were used for
immunological detection: mouse α-SOD3 (1:250; Novus Biologicals, Littleton, CO), rabbit αphospho-Akt (Ser473) (1:50; Cell Signaling, Danvers, MA) (Rowe, Leonardo et al. 2012) and
rabbit α-active caspase-3 (1:1000; Sigma-Aldrich, St. Louis, MO) (Rowe, Leonardo et al. 2012).
Biotinylated secondary antibodies (1:300; Vector Laboratories, Burlingame, CA) were used in
conjunction with their complimentary primary counterparts.
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Fluorescent immunohistochemistry was performed on brain tissue sections as previously
described (Rowe et al., 2010) using rabbit α-microtubule-associated protein 2 (MAP2) (1:200;
EMD Millipore, Billerica, MA) and mouse α-SOD3 (1:250; Novus Biologicals) (Wang, Harrell et
al. 2014) antibodies. Tissue sections were also double-labeled with mouse α-SOD3 (1:250;
Novus Biologicals) and rabbit anti-phospho-Akt (Ser473) (1:50; Cell Signaling) or rabbit-α-LIFR
(1:200; Santa Cruz Biotechnology, Dallas, TX) (Butzkueven, Zhang et al. 2002) and rabbit αMAP2 (1:200; EMD Millipore) (Justice, Yuan et al. 2008) antibodies. AlexaFluor® 488 and 594
secondary antibodies (1:1000; Life Technologies, Carlsbad, CA) were used for fluorescent
visualization and slides were mounted using VECTASHIELD® medium containing 4', 6diamidino-2-phenylindole (DAPI) (Vector Labs). Images were captured using a Zeiss AxioCam
color camera attached to a Zeiss AxioSkop2 microscope (Dublin, CA) interfaced with OpenLab
imaging software (Boston, MA).
Western Blot Analysis
Brain tissue was homogenized in whole cell lysis buffer and protein concentrations were
measured using a Bradford Assay (Bio-Rad, Hercules, CA). Samples were prepared and run on
SDS-PAGE gels (10% for SOD3, 12% for SOD2 and 15% for SOD1). Nitrocellulose membranes
were blocked in 5% nonfat milk in TBS + 0.1% Tween (TBST) for 1h at 25˚C and probed with
the following primary antibodies overnight at 4˚C: mouse α-SOD3 (1:500; Novus Biologicals)
(Wang, Harrell et al. 2014), rabbit α-SOD1 (1:500; Abcam, San Francisco, CA) (Marengo, De
Ciusis et al. 2010) or rabbit α-SOD2 (1:500; Novus Biologicals) (Chen, Lin et al. 2014).
Membranes were then probed with AlexaFluor® 488 goat α-rabbit IgG (1:250) or AlexaFluor®
488 goat α-mouse IgG1 (1:250) for 1h at 25˚C and visualized using a Typhoon 9410 Imager (GE
Healthcare Life Sciences, Marlborough, MA). Membranes were also probed with mouse α-βactin (1:5000; Novus Biologicals) (Lee, Kan et al. 2012) antibodies. All protein bands of interest
were normalized to β-actin bands to act as a loading control.
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SOD Inhibition Assay
Prior to assay, brain tissue samples were diluted in an equal volume of dilution buffer to
lower detergent concentrations. Percent inhibition of SOD activity was measured according to
the manufacturer’s protocol (K-Assay, Seattle, WA). Absorbance was measured at 450 nm using
a µQuant microplate spectrophotometer (Biotek, Winooski, VT) and KC Junior software (BioTek).
The following equation was used to calculate % inhibition:
[(A Blank 1 – A Blank3) - (A Sample-A Blank 2)] / (A Blank 1- A Blank 3) * 100%
Average % Inhibition rates for each set of sample dilutions were graphed using the nonlinear
regression function. The slope of the linear portion of each standard curve was used to calculate
the IC50 for each sample. The IC50 and protein concentrations of samples were used to calculate
units of SOD activity per mg protein lysate (U/mg).
Cortical Neuronal Cultures
Rat primary cortical neurons were isolated as previously described (Katnik, Guerrero et
al. 2006). Cells were counted using the Trypan Blue exclusion method and seeded at a density
of 800,000 cells/ well into 12 well plates coated with 0.1 mg/ml poly-L-lysine solution. Neurobasal
complete media containing B-27 supplement and 1.25 mM glutamine (Life Technologies) was
changed 24 h after seeding and subsequent media changes occurred on a weekly basis.
Neurons were used between 7 and 15 days in vitro.
In vitro Ischemia
Oxygen glucose deprivation (OGD) was performed as previously described to induce in vitro
ischemia (Hall, Guyer et al. 2009). Cells were given a fresh media change: 1 ml DMEM with 4.5
g/L D-glucose and sodium pyruvate per well for control cells and 1 ml DMEM without D-glucose
or sodium pyruvate for cells subjected to OGD. Neurons were treated with either 50 ng/ml, 200
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ng/ml, or 1000 ng/ml LIF. Sterile filtered PBS was used as a vehicle control for LIF. In another
experiment, neurons were treated with PBS or 200 ng/ml LIF in the presence or absence of 10
μM Insolution™ Akt Inhibitor IV (EMD Millipore). This inhibitor blocks the ATP binding site of a
kinase located upstream of Akt and downsteam of PI3K. DMSO (0.1%) was used as vehicle
control for Akt Inhibitor IV. Following treatment with LIF and Akt Inhibitor IV, neurons were placed
in an airtight chamber. This chamber was flushed with a gas mixture containing 94% N2, 5%
CO2, and 1% O2 (Airgas, Tampa, FL) for 15 min prior to sealing the chamber for 24 h. Following
the 24 h incubation, cells were removed from the chamber and supernatants were collected to
measure the release of lactate dehydrogenase (LDH). Cells were washed twice with PBS,
pelleted via centrifugation, and snap-frozen. Pellets were stored at -80°C for further biochemical
analyses.
LDH Assay
Neuronal death was quantified by measuring the release of LDH as previously described
(Hall, Guyer et al. 2009) using a colorimetric assay kit (Takara Biosciences, Madison, WI). Cell
supernatant samples were diluted 1:4 in fresh medium prior to assay to avoid obtaining
absorbance readings beyond the linear threshold. Absorbance was read at 490 nm using a
µQuant microplate spectrophotometer (BioTek) and KC Junior software (BioTek). To quantify
approximate levels of neuronal death, a standard curve was created as previously described
(Hall, Guyer et al. 2009) by lysing known quantities of neurons with 2% Triton-X-100 and
measuring LDH release .
Gene Silencing
Silencing expression of SOD3 in cortical neurons was achieved via transfection with
siRNA. This procedure was performed according to manufacturer’s protocol using a
Nucleofector™ 2b Device and the Amaxa™ Basic Nucleofector™ Kit for primary mammalian
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neurons (Lonza, Allendale, NJ). Scrambled (Control-A) and siRNA sequences directed against
the rat SOD3 gene were purchased from Santa Cruz Biotechnology. Freshly isolated cortical
neurons were transfected with either scrambled or SOD3 siRNA using protocol G-013. Cells
were removed from cuvettes and seeded into 12 well plates containing pre-equilibrated DMEM
complete medium. Media was changed to Neurobasal Complete 24 h after seeding. Suppression
of SOD3 expression was confirmed using quantitative reverse transcriptase PCR (qRT- PCR).
Two-Step qRT- PCR
Two-step qRT- PCR was performed as previously described with minor modifications
(Rowe, Leonardo et al. 2010). AffinityScript® Master Mixes for reverse-transcriptase and qPCR
reactions were obtained from Agilent Technologies (Santa Clara, CA). Synthesis of cDNA was
performed per manufacturer’s instructions in a Mastercycler Gradient thermal cycler (Eppendorf,
Hauppauge, NY). Reaction components were at 25˚C for 5 min to allow primers to anneal, 42˚C
for 30 min to allow cDNA synthesis, and 95˚C for 5 min to quench the reaction. Concentration
and quality of newly synthesized cDNA was determined using a NanoDrop ND-1000
spectrophotometer (Thermo-Fisher Scientific, Waltham, MA). Primer sequences for rat SOD3
and GAPDH genes were obtained from Qiagen (Valencia, CA). The qPCR reaction was
performed according to manufacturer’s instructions using the Chromo4 DNA Engine thermal
cycler and Opticon™ 3.1 Software (Bio-Rad) with the following steps: 15 min at 95˚C to heat the
reaction mixture, 30 s at 95 ˚C to denature strands, 30 s at 55˚C to allow primers to anneal, and
30 s at 72˚C for strand elongation. This denaturing-annealing-elongation cycle was repeated 40
times. Following the qPCR reaction, melt temperature curve analysis was performed to detect
the presence of primer-dimers in the reaction mixture. Cycle threshold values were determined
by setting the threshold to a value where all samples were in the amplification phase.
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Data Analysis
All DAB immunohistochemical images were uniformly sharpened and converted to black
and white using Jasc Paint Shop Pro 9 (Eden Prairie, MN). Optical density measurements for
western blot bands and histochemical staining was performed using ImageJ 1.49 (NIH,
Bethesda, MD) and. All statistical tests were performed using Graphpad Prism 4.0 (La Jolla, CA)
software and all data are expressed as the mean ± SEM. A Pearson-D’Agostino test was used
to determine normality among data sets. Unless stated otherwise, experiments were analyzed
via a one-way ANOVA followed by Fisher’s Protected Least Significant Difference post hoc test.
Data with significantly different variances between treatment groups or a non-Gaussian
distribution was analyzed via a Kruskal-Wallis H test. Mann-Whitney U Tests were used to
determine significance between pairs and a Bonferroni correction was applied to the p value
based on the number of individual comparisons made. Statistical significance was determined
using an alpha value set at p = 0.05. All p values reported are one-tailed.
Results
LIF increases total SOD activity and SOD3 expression 72 h post-MCAO
Total SOD activity was measured in brain lysates from rats euthanized 24, 48, or 72 h
after MCAO or sham surgery. Mean SOD activities were normalized to the mean activity in
samples from 72 h sham-operated rats. Ipsilateral tissue samples from all MCAO rats
demonstrated a time-dependent increase in SOD activity from 24 to 72 h, while activities in
contralateral samples remained stable throughout this period. SOD activities were significantly
altered among treatment groups at 72 h post-MCAO (H (3) =13.29; p = 0.004). SOD activity was
significantly higher in LIF-treated ipsilateral tissue compared to PBS-treated ipsilateral tissue (U
= 1.00; p = 0.0237). In addition, there was a trend towards increased SOD activity in the PBS
and LIF ipsilateral samples compared to their contralateral counterparts (Fig. 2.1a).
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Western blotting was used to determine protein expression of SOD1, SOD2, and SOD3
in brain tissue from rats euthanized 72 h post-MCAO. At 72h post-MCAO, SOD1 was only
significantly induced in contralateral tissue from LIF treated rats (p = 0.0051, F4,10 = 7.321).
Contralateral SOD1 expression from LIF-treated rats was significantly higher than that of
ipsilateral tissue from PBS-injected rats (p = 0.0026) and ipsilateral tissue from the same
treatment group (p = 0.0004; Fig. 2.1b). There were no significant differences in SOD2
expression between tissue samples at this time point (H (4) = 8.400; p = 0.0780), but there was
trend toward decreased SOD2 expression in ipsilateral tissue from LIF-treated rats compared to
other samples (Fig. 2.1c). SOD3 expression was significantly higher in ipsilateral tissue from LIFtreated rats (p = 0.0021, F4,10 = 9.271) compared to ipsilateral tissue from PBS-treated rats (p =
0.0111) and sham-treated rats (p = 0.008; Fig. 2.1d). SOD3 expression remained relatively
constant between the sham and contralateral samples.
Immunohistochemistry was used to visualize SOD3 expression within the intact cortical
tissue. Representative images show several SOD3-positive cells in the ipsilateral cortex of PBStreated rats. However, these SOD3-positive cells appeared dysmorphic (black arrows) and many
cells were surrounded by noticeable tissue lesions. By contrast, stained ipsilateral tissue from
LIF-treated rats revealed SOD3-positive cells that retained a common triangular morphology
compared to those found in PBS-treated rats. These cells were arranged in an orderly fashion
and less tissue damage was observed in the LIF-treated rat brains. Contralateral cortical staining
from both treatment groups did not reveal noticeable SOD3 staining (Fig. 2.2a). Quantitative
analysis of cortical staining revealed induction of SOD3 in the ipsilateral cortex following LIF
treatment (p < 0.0001, F3,15 = 24.38). Among PBS-treated rats, elevated levels of SOD3 were
observed in the ipsilateral cortex compared to the contralateral cortex (p = 0.0111). However,
LIF treatment yielded significantly higher SOD3 expression in the ipsilateral cortex compared to
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PBS treatment (p = 0.0048). Levels of SOD3 staining were normalized to sham tissue to account
for baseline SOD3 expression in the ipsilateral cortex (Fig. 2.2b).
SOD3 is induced in cortical neurons following LIF treatment
To determine whether LIF exerts positive neurotrophic effects on cortical neurons, brain
tissue sections and cultured neurons were labeled with antibodies against LIFR and MAP2.
Staining revealed localization of LIFR in neurons of the cerebral cortex (Fig. 2.3a). Cultured
cortical neurons also expressed basal LIFR levels under physiological in vitro conditions (Fig.
2.3b). Tissue sections from LIF-treated animals that were euthanized 24 h and 72 h post-MCAO
were double-labeled with SOD3 and MAP2 antibodies. MAP2-positive neurons were observed
at 24 and 72 h after MCAO (Figs. 2.3c, 2.3d). Likewise, SOD3-positive cells were also visualized
at these time points (Figs. 2.3e, 2.3f). DAPI was used to indicate the presence of cell nuclei at
both time points (Figs. 2.3g, 2.3h). Co-localization of SOD3 and MAP2 was observed at 24 h and
72 h after MCAO, indicating the presence of SOD3-positive neurons at both time points (Figs.
2.3i, 2.3j).
To determine whether this increase in neuronal SOD3 occurred in conjunction with Akt
activation, tissue sections from LIF-treated rats euthanized at 24 h and 72 h after MCAO were
double-labeled with antibodies against SOD3 and Akt phosphorylated on residue Ser473
(phospho-Akt). Several cells stained positive for phospho-Akt at 24 h and 72 h post-MCAO (Figs.
2.4a, 2.4b). Likewise, SOD3 positive cells were also visualized at both time points (Figs. 2.4c,
2.4d). Cell nuclei were labeled using DAPI at 24 and 72 h post-MCAO (Figs. 2.4e, 2.4f) Cells
staining positive for phospho-Akt and SOD3 were observed at 24 h and 72 h post-MCAO (Figs.
2.4g, 2.4h).
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LIF protects neurons from in vitro ischemic damage
This laboratory previously demonstrated that 200 ng/ml LIF protects oligodendrocytes
during OGD(Rowe, Collier et al. 2014). A similar concentration response experiment was
performed to determine whether this concentration of LIF confers neuroprotection against in vitro
ischemia. Subjecting neurons to 24 h OGD and treating with LIF yielded a significant change in
LDH release (H (7) =25.74; p = 0.0006) Treating cells with 200 ng/ml LIF significantly decreased
LDH release compared to PBS-treated neurons that were subjected to the same 24 h OGD
exposure (U = 7.000; p = 0.0256; Fig. 2.5a). To confirm the results of the LDH assay, neuronal
cultures were subjected to the same conditions and treatments but were subsequently labeled
with antibodies generated against activated caspase-3. Representative images show levels of
active caspase-3 in neurons following 24 h normoxia, 24 h OGD + PBS, or 24 h OGD + 200
ng/ml LIF (Fig. 2.5b). Immunohistochemical analysis revealed significant changes in caspase-3
activation triggered by OGD exposure and LIF treatment (p = 0.0003, F2,9 = 23.57). Caspase-3
immunoreactivity was significantly higher after 24 h OGD + PBS compared to 24 h normoxia (p
= 0.0003) while LIF treatment reduced caspase-3 activation during OGD compared to PBS
treatment (p = 0.0128; Fig. 2.5c).
Neuroprotective Effects of LIF are dependent upon Akt activity
To determine whether the protective effects of LIF are dependent upon Akt activity,
neurons were treated with PBS + 0.1% DMSO, 200 ng/ml LIF + 0.1% DMSO, PBS + 10 μM Akt
Inhibitor IV, or 200 ng/ml LIF + 10 μM Akt Inhibitor IV prior to OGD. LIF and Akt IV treatment
both exerted significant effects on LDH release following 4 h OGD (H (3) = 17.55; p = 0.0005).
Treatment with 200 ng LIF significantly reduced LDH release compared to PBS (U = 15.00; p =
0.0012). Co-incubating cells with 10 μM Akt Inhibitor IV and LIF yielded significantly higher levels
of LDH compared to neurons treated with LIF alone (U = 19.00; p = 0.0024; Fig. 2.6a). To
determine whether this decrease in neuronal death correlated with higher expression of SOD3
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in vitro, representative coverslips subjected to 24 h normoxia or 24 h OGD with DMSO + PBS,
DMSO + LIF, Akt Inhibitor IV + PBS, or Akt Inhibitor IV + LIF treatment were stained with
antibodies directed against phospho-Akt or SOD3. Neurons incubated under normoxia revealed
low basal levels of phospho-Akt and SOD3 (Figs. 2.6b, 2.6c). Cells treated with DMSO + PBS
followed by 24 h OGD yielded higher levels of phospho-Akt and SOD3 compared to normoxic
cells. (Figs. 2.6d, 2.6e). However, neurons that were treated with DMSO + LIF prior to OGD
showed high levels of phospho-Akt and SOD3 while returning to the healthy morphology seen in
normoxic cells (Figs. 2.6f, 2.6g). Treatment with Akt Inhibitor IV + PBS prior to OGD decreased
phospho-Akt compared to the neurons treated with DMSO + PBS (Fig. 2.6h), but SOD3 levels
did not change (Fig. 2.6i). Co-incubation with LIF and Akt Inhibitor IV lowered phospho-Akt and
SOD3 staining compared to neurons treated with DMSO + LIF (Figs. 2.6j, 2.6k).
Neuroprotection against OGD by LIF is dependent upon increased SOD3
Expression
Transfection with siRNA and treatment with LIF prior to 24 h OGD significantly altered
levels of SOD3 mRNA in primary cortical neurons (p < 0.0001, F3,17 = 17.51). LIF significantly
increased SOD3 mRNA compared to PBS treatment in cells transfected with scrambled siRNA
(p = 0.0023). Transfection with SOD3 siRNA significantly downregulated expression of SOD3
compared to scrambled siRNA (p = 0.0165). Transfection with SOD3 siRNA prior to LIF treatment
significantly decreased SOD3 expression compared to scrambled siRNA+ PBS cells (p = 0.0212)
and siRNA + LIF cells (p = 0.0005; Fig. 2.7a). LIF and siRNA treatment yielded an overall trend
towards altered LDH release following 24 h OGD (p = 0.1701, F3,8 = 2.165). However, LIF
treatment significantly reduced LDH release among neurons transfected with scrambled siRNA
(p < 0.05; Bonferroni method; Fig. 2.7b). Representative images show levels of active caspase3 among treatment groups (Fig. 2.7c). Treatment with LIF and SOD3 siRNA significantly altered
caspase-3 activation following OGD (p = 0.0002, F3,13 = 14.50).
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LIF significantly reduced

caspase-3 activation following OGD compared to PBS treatment among scrambled siRNAtransfected cells (p = 0.0104). SOD3 siRNA + PBS treatment prior to OGD significantly increased
activation of caspase-3 compared to scrambled siRNA + PBS treatment (p = 0.0003). LIF
significantly lowered caspase-3 activation compared to PBS among SOD3 siRNA-transfected
cells (p = 0.0214). However, SOD3 knockdown prevented LIF from reducing caspase-3
activation compared to scrambled siRNA + PBS cells (Fig. 2.7d).
Discussion
SOD3, unlike SOD1 and SOD2, is not highly expressed by neural cells under normal
physiological conditions (Folz and Crapo 1994, Chan 2001). Nonetheless, several distinct
neuronal populations will upregulate SOD3 following FCI, including cortical and striatal neurons
(Fukui, Ookawara et al. 2002). These data demonstrate that LIF treatment further increases
SOD3 in neurons following ischemic injury. At 72 h post-MCAO, antibodies against SOD3
detected three Western blot bands corresponding to the monomer (40 kDa), dimer (80 kDa), and
tetramer (140 kDa) of SOD3. Wild-type SOD3 is expressed as a dimer in rats, compared to the
tetrameric human and murine isoforms, a single point mutation of the Asp residue at position 24
may yield a tetrameric SOD3 isoform (Carlsson, Marklund et al. 1996). This mutant isoform may
correspond to the smaller, high molecular weight band at 140 kDa. These findings were further
confirmed by measuring SOD3 immunoreactivity in the cerebral cortex. Immunohistochemical
analysis revealed higher levels of SOD3 in the ipsilateral tissue of sham rats compared to the
ipsilateral cortex of PBS-treated rats. The higher level of staining is most likely due to the higher
number of viable neural cells in the cortex after sham operation compared to MCAO. Cells
expressing SOD3 after LIF treatment had a morphology resembling pyramidal neurons, and
double-labeling tissue with MAP2 and SOD3 antibodies confirmed neuronal localization of
SOD3.
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Western blotting and histochemical analysis revealed that SOD3 was upregulated in the
ipsilateral, but not contralateral hemisphere at 72 h post-MCAO. The absence of LIF-mediated
cellular protection under normoxia reflects previous findings with cultured oligodendrocytes
(Rowe, Collier et al. 2014). Decreased LDH release from cultured oligodendrocytes following LIF
treatment was not observed under normoxia, but LIF significantly reduced LDH release during
OGD (Rowe, Collier et al. 2014). Although LIF is transported into the brain via an ATP-dependent
carrier (Pan, Kastin et al. 2000), Pan et al. demonstrated that LIF transport increases following
neuronal injury (Pan, Cain et al. 2006). Breakdown of the BBB following permanent FCI (Kastrup,
Engelhorn et al. 1999) could allow LIF to reach the ipsilateral hemisphere via paracellular
transport. In addition, negative feedback mechanisms that regulate PI3K/Akt signaling under
physiological conditions are compromised under FCI (Omori, Jin et al. 2002). Finally, minimal
levels of cellular death under normoxia may account for the lack of significant LIF-mediated
neuroprotection under normoxic conditions. Despite the overall increase in SOD activity, neither
SOD1 nor SOD2 expression was significantly altered from the ipsilateral tissue of PBS-treated
rats. The trend towards decreased SOD2 expression in the ipsilateral hemisphere of LIF-treated
rats is most likely due to increased activation of Akt. Previous findings show that Akt may
downregulate SOD2 expression via inactivation of the transcription factor FoxO3 (Li, Chiu et al.
2006, Laatikainen, Incoronato et al. 2011, Du, Yu et al. 2013). Significantly higher levels of SOD1
at 72 h post-MCAO were observed after LIF treatment, but only in contralateral tissue. This
finding reflects studies where LIF treatment ameliorates the ALS-like symptoms seen in G93A
mice (Azari, Galle et al. 2001, Azari, Profyris et al. 2006). Although western blotting did not show
increased SOD1 in the ipsilateral tissue of LIF-treated rats, ischemic conditions may cause SOD1
to aggregate. These insoluble aggregates would not be detected in the portion of lysates used
for western blot analysis (Chen, Guan et al. 2012).
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The answer to the difference between the efficacies of LIF under normoxia vs ischemia
may lie in the regulation of LIFR/gp130. Immunohistochemical detection of LIFR in neurons
incubated under normoxia showed that LIF could hypothetically trigger protective signaling in the
absence of ischemia.

Moreover, oligodendrocytes express LIFR under basal conditions

(Butzkueven, Zhang et al. 2002). Future studies may be needed to further explain how LIF signal
transduction is regulated in neurons. Several groups reported that the termination of LIF signaling
is facilitated via the phosphorylation of both receptor subunits (Gibson, Schiemann et al. 2000,
Radtke, Wüller et al. 2010). Our immunohistochemical staining reveals high levels of nuclear
LIFR in the absence of LIF signaling. Nuclear LIFR was previously seen under physiological
conditions in several cell types, including neurons of the dorsal root ganglion. However, injury to
the dorsal root ganglion caused LIFR to translocate from the nucleus to the cytoplasm (1999,
Gardiner, Cafferty et al. 2002). Endocytosis of LIFR and gp130 have been previously reported
by multiple independent groups (Gerhartz, Dittrich et al. 1994, Thiel, Behrmann et al. 1999,
Blanchard, Duplomb et al. 2000). While the internalization of LIFR may precede its degradation,
it is also possible that the majority of LIFR remains in the nucleus until stimulation with LIF
promotes its trafficking to the cell membrane.
The increase in SOD3 mRNA and decrease in LDH release/caspase-3 activation
following LIF treatment indicates that upregulation of SOD3 is responsible for LIF’s protective
effects protection against OGD. Furthermore, LIF-treated neurons that were previously
transfected with SOD3 siRNA showed no significant difference in LDH release and caspase-3
activation compared to PBS-treated neurons transfected with scrambled siRNA. These results
indicate that LIF primarily protects neurons against ischemic oxidative damage via SOD3
upregulation. LIF and siRNA treatment yielded a significant overall change among treatment
groups when caspase-3 activation was measured, but not LDH. This discrepancy between these
results could be due to several factors. LDH release corresponds to the rate of necrosis (Chan,
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Moriwaki et al. 2013) while caspase-3 cleavage corresponds to apoptosis. Previous research
indicates that neurons undergo both processes during FCI (Choi 1996, Broughton, Reutens et
al. 2009). Caspase-3 activation may be detected prior to LDH release, indicating that staining
will identify cells with intact membranes that are beginning to undergo programmed death
(Shioiri, Muroi et al. 2009). Moreover, the larger increase in caspase-3 activation may be due to
the inhibitory effect of SOD3 and active Akt on caspase-3-mediated apoptosis (Gao, Ordas et al.
2008, Laatikainen, Incoronato et al. 2011).
Previous data from this lab indicated that injection of LIF improved several outcomes
including infarct size, white matter damage, and functional motor skills at 72 h after permanent
FCI. In vitro experiments using cultured oligodendrocytes and Prdx4 antibodies confirmed that
the ability of LIF to reduce oxidative damage to white matter during stroke is primarily dependent
upon its upregulation of Prdx4 through PI3K/Akt signaling (Rowe, Collier et al. 2014). Prdx4, not
unlike SOD3, may be secreted into the extracellular environment to scavenge ROS (OkadoMatsumoto, Matsumoto et al. 2000, Sasagawa, Matsuki et al. 2001). By neutralizing extracellular
ROS, enzymes such as SOD3 and Prdx4 may protect other cells in the parenchyma by
preventing further intracellular damage. LIF-mediated upregulation of SOD3 and Prdx4 in the
brain may help regulate redox balance after FCI. Since hydrogen peroxide and water are
products of SOD-catalyzed reactions, higher SOD3 expression could potentially lead to excess
peroxidation of cellular components. Peroxiredoxin family enzymes catalyze the breakdown of
hydrogen peroxide to water and oxygen (Kang, Chae et al. 1998, Rhee, Kang et al. 2001,
Lehtonen, Svensk et al. 2004). Therefore, increased Prxd4 expression following LIF treatment
would prevent the buildup of hydrogen peroxide generated from excess SOD activity.
Although results from in vitro experiments indicate that the neuroprotective effects of LIF
are attenuated following siRNA-mediated knockdown of SOD3, this does not necessarily mean
that SOD3 upregulation is the only mechanism of in vivo neuroprotection. Unfortunately, there
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are no selective SOD3 inhibitors that could be administered following MCAO. Due to the lack of
tissue-specific knockout rats available, obtaining a neuron-specific SOD3 knockout rat strain for
these experiments would be difficult. To demonstrate that induction of Prdx4 was necessary for
in vitro oligoprotection, this laboratory used neutralizing antibodies to block Prdx4 activity prior
to OGD (Rowe, Collier et al. 2014). It is likely that the improvement in sensimotor skills and
smaller infarct volume after LIF treatment may be attributed to protective mechanisms other than
Prdx4 induction. This lab has shown that LIF confers protection in multiple neural cell types
during ischemia. Moreover, systemic LIF administration may result in additional protection that
is independent of its effects on cell survival. For instance, LIF plays a crucial role in the
development of regulatory T lymphocytes and anti-inflammatory macrophages/microglia
(Metcalfe 2011, Janssens, Slaets et al. 2015). As a result, LIF may reduce neurodegeneration
triggered by the release of inflammatory splenocytes after stroke. Further investigation will be
necessary to determine whether its primary neuroprotective mechanism in vivo is dependent
upon SOD3.
This laboratory previously measured infarct volume after LIF treatment using Fluoro-Jade
staining due to its ability to specifically label dying neurons (Schmued, Albertson et al. 1997,
Rowe, Collier et al. 2014). Although a lower number of viable neurons in the infarct and penumbra
could contribute to a significant reduction in the total area of Fluoro-Jade-positive tissue, the
improvement in motor skills among LIF-treated rats indicated that LIF reduced neuronal
degradation in addition to protecting oligodendrocytes in vivo (Gardiner, Cafferty et al. 2002).
Previous studies indicate that LIF mRNA levels are approximately thirty times higher in
astrocytes 6 h after cortical brain injury compared to pre-injury levels. Microglia were also found
to have elevated levels of LIF mRNA at this same time point (Banner, Moayeri et al. 1997). This
upregulation of LIF transcript following injury to the gray matter indicates that LIF may serve as
an endogenous protective factor against neuronal injury. However, the magnitude of damage
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observed after our model permanent FCI indicates that endogenous LIF release is not sufficient
to rescue neurons in the penumbra. These data indicate that damage may be reduced via
exogenous supplementation of LIF following injury.
Further studies will be needed to determine the mechanism of LIF-mediated upregulation of
SOD3 in neurons. Our group and others have demonstrated that LIF controls the expression of
protective genes at the transcriptional level (Rowe, Collier et al. 2014, Umoh, Walker et al. 2014).
Therefore, LIF may be activating transcription factors downstream of Akt. The reduced infarct
size and improved motor skills observed after LIF treatment in previous studies suggest that it
may exert pro-survival effects independent of antioxidant enzymes (Rowe, Collier et al. 2014).
Nevertheless, the ability to induce protective antioxidant enzymes makes LIF a promising
treatment that will protect neural cells against immediate and delayed damage following ischemic
stroke.
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Figure 2.1. LIF increases SOD activity and SOD3 Expression. (a) Total SOD activity was
measured in brain lysates from PBS and LIF-treated rats euthanized 24, 48, or 72 h post-MCAO.
LIF ipsilateral samples had significantly higher SOD activity compared to PBS-treated ipsilateral
samples at 72 h post-MCAO (*p<0.05). Mean activities were normalized to SOD activity in brains
from sham rats. n ≥ 5 samples per group. (b) At 72 h after MCAO, SOD1 expression was
significantly increased in contralateral tissue of LIF-treated rats, compared to ipsilateral tissue
from PBS-treated rat (*p<0.01) and ipsilateral tissue from the same treatment group (#p<0.001).
SOD1 bands were observed at approximately 18 kDa. (c) There was a trend towards decreased
SOD2 expression in the ipsilateral samples from the LIF group; however, this decrease was not
significant. SOD2 bands were observed at approximately 25 kDa. (d) Ipsilateral samples from
LIF-treated rats showed a corresponding increase in SOD3 expression compared to PBS
(*p<0.05) and sham (#p<0.01) ipsilateral samples. Three bands corresponding to SOD3 were
observed in all samples at approximately 50, 80, and 130 kDa. n = 3 samples per group. Ips:
ipsilateral; Contra: contralateral.

68

Figure 2.2. LIF upregulates SOD3 in the Ipsilateral Cortex. (a) Representative images of
cortical tissue from PBS rats show higher levels of SOD3 staining compared to contralateral
tissue from the same group. However, these cells appeared dysmorphic and unhealthy. LIF
treatment increased SOD3 expression in the ipsilateral cerebral cortex while visibly reducing
damage to SOD3-positive cells and surrounding tissue. (b) After normalizing to sham SOD3
levels, immunohistochemical quantification revealed significantly higher levels of staining in
ipsilateral tissue compared to contralateral tissue in PBS-treated rats (*p<0.05). LIF treatment
further raised SOD3 in the ipsilateral tissue compared to PBS (#p<0.01). n = 5 per treatment
group. Scale bars = 50 μm. Ips: ipsilateral; Contra: contralateral.
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Figure 2.3. Cortical Neurons Express SOD3 after LIF Treatment. (a) Co-labeling tissue with
MAP2 (green) and LIFR (red) antibodies revealed localization of LIFR in the neuronal somata.
LIFR was concentrated primarily in the cytoplasm and perinuclear region. (b) Cultures of cortical
neurons also showed LIFR staining in the cell bodies. Following LIF treatment, neurons stained
positive for MAP2 at (c) 24 h and (d) 72 h post-MCAO. SOD3 immunoreactivity was observed in
the brains of LIF-treated rats at (e) 24 and (f) 72 h after MCAO (g, h). DAPI was used to stain for
cell nuclei. (i, j) Co-localization with the neuronal marker MAP2 indicates that SOD3 is expressed
by neurons in vivo following LIF treatment. Scale bars = 20 µm.
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Figure 2.4. SOD3 co-localizes with Phospho-Akt (Ser473). Levels of phospho-Akt (Ser473)
increased from (a) 24 h to (b) 72 h after MCAO, which corresponded with increased SOD3
staining over this same time period (c, d). DAPI was used to stain for cell nuclei (e, f). The number
of cells staining positive for phospho-Akt (Ser473) and SOD3 increased from (g) 24 h to (h) 72 h
post-MCAO. Arrows indicate representative cells. Scale bars = 20 μm. P-Akt: phospho-Akt
(Ser473).
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Figure 2.5. LIF treatment protects neurons in vitro against OGD. (a) Following 24 h OGD,
200 ng/ml LIF significantly reduced cell death compared to PBS treatment (#p<0.05). n ≥ 3 per
treatment group. (b) Images show neurons stained with α-active caspase-3 antibodies after 24
h normoxia, 24 h OGD + PBS and 24 h OGD + 200 ng/ml LIF. Arrows identify representative
cells. (c) Neurons treated with PBS prior to OGD had significantly higher levels of active caspase3 (*p<0.001) compared to the 24 h normoxia group. LIF treatment prior to 24 h OGD decreased
caspase-3 activation compared to PBS (#p<0.05). Arrows identify representative cells. n = 4 per
treatment group. Scale bar = 50 µm. Norm = 24 h Normoxia.
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Figure 2.6. In vitro neuroprotection by LIF is dependent upon Akt activity. (a) LIF treatment
significantly lowered neuronal death during OGD compared to PBS (*p<0.001). Akt IV reverses
the neuroprotective effect of LIF treatment alone (#p<0.01) n = 12 per treatment group.
Representative images show (b) p-Akt and (c) SOD3 immunoreactivity in neurons under
normoxia. DMSO + PBS treatment before 24 h OGD increased (d) p-Akt and (e) SOD3 levels
compared to 24 h normoxia. (f) Phospho-Akt (Ser473) and (g) SOD3 levels were highest in cells
treated with DMSO + LIF before OGD. Addition of Akt IV + PBS prior to OGD caused (h) a
minimal decrease in phospho-Akt (Ser473) and (i) no change to SOD3 levels compared to the
DMSO + PBS group. Co-incubation with Akt Inhibitor IV + LIF prior to OGD prevented the LIFinduced increase in (j) phospho-Akt (Ser473) and (k) SOD3 expression. Arrows identify
representative cells. P-Akt = phospho-Akt (Ser473); Akt IV = Akt Inhibitor IV. Scale bar = 25 µm.
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Figure 2.7. LIF Increases Cell Survival by Upregulating SOD3. (a) LIF treatment prior to 24
h OGD increased SOD3 mRNA among neurons transfected with scrambled siRNA (*p<0.01).
SOD3 siRNA treatment + PBS prior to OGD significantly decreased SOD3 mRNA compared to
scrambled siRNA + PBS (#p<0.05). SOD3 siRNA + LIF reduced SOD3 mRNA compared to
scrambled siRNA + LIF (^p<0.001) and scrambled siRNA + PBS. n ≥ 4 per treatment group. (b)
LDH release was significantly lower in scrambled siRNA-transfected cells treated with LIF
compared to their PBS-treated counterparts (*p<0.05) while LIF treatment did not reduce LDH
release in SOD3 siRNA-transfected cells compared to SOD3 siRNA + PBS cells. n =3 per
treatment group. (c) Representative cells show levels of active caspase-3 among treatment
groups. (d) Active caspase-3 immunoreactivity was significantly reduced by LIF treatment in
neurons transfected with scrambled siRNA compared to Scr + PBS cells (*p<0.05). Transfection
with SOD3 siRNA + PBS treatment significantly increased caspase-3 activation compared to Scr
+ PBS treatment (#p<0.001). SOD3 siRNA + LIF cells had significantly lower levels of active
caspase-3 compared to SOD3 siRNA + PBS cells (^p<0.05), but not Scr + PBS cells. n ≥ 3 per
treatment group. Scr = scrambled siRNA. Scale bar = 50 µm.
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CHAPTER 3:
NEUROPROTECTIVE ACTIONS OF LEUKEMIA INHIBITORY FACTOR ARE DEPENDENT
UPON MYELOID ZINC FINGER-1 AND SPECIFICITY PROTEIN 1
Note to Reader
Some of the data showing SOD3 mRNA expression was previously published by Davis
et al. (Davis, Collier et al. 2016) as well as in Chapter 2 of this discussion. Stephanie Davis was
the main author on this section of the manuscript. However, assistance with experimentation and
editing was provided by Lisa A. Collier, Jawad A. Fazal, Dr. Christopher C. Leonardo, and Dr.
Craig T. Ajmo Jr. This project was overseen by Dr. Keith R. Pennypacker.
Abstract
This lab previously demonstrated that leukemia inhibitory factor (LIF) protects neurons
and oligodendrocytes (OLs) during stroke via the upregulation of antioxidant enzymes. The
hypothesis of this study was to determine whether LIF exerts its neuroprotective effects through
activation of the transcription factors myeloid zinc finger-1 (MZF-1) and specificity protein 1
(Sp1). The promoter region of the rat superoxide dismutase 3 (SOD3) gene was examined for
MZF-1 and Sp1 binding sites using Genomatix software. Stroke was induced via middle cerebral
artery occlusion and animals were administered PBS or 125 µg/kg LIF at 6, 24, and 48 h after
the injury. Cortical neurons isolated from E18 embryonic rat pups were transfected with
scrambled, MZF-1, or Sp1 siRNA were subjected to 24 h ischemia after PBS or LIF treatment.
Genomatix identified four MZF-1 sites and two Sp1 sites in the SOD3 promoter. There was a
trend towards MZF-1 upregulation in brain the brains of LIF-treated rats compared to PBS-
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treated rats at 72 h post-MCAO and significantly higher levels of MZF-1 mRNA after LIF
treatment in primary cortical neurons. Moreover, neurons that expressed higher levels of MZF-1
after LIF treatment had upregulated SOD3 as well. There was trend towards higher Sp1
expression after LIF treatment in brain tissue and no change in Sp1 mRNA among primary
neurons. However, there was a significant correlation between MZF-1 and Sp1 levels in the
brains of LIF-treated rats and nuclear localization of Sp1 and MZF-1 in neuronal tissue. At 72 h
after MCAO. At this time point, co-localization of SOD3 and MZF-1/Sp1 was observed in the
cerebral cortex of LIF-treated rats. Finally, knockdown of Sp1 and MZF-1 using siRNA
counteracted the neuroprotective effects of LIF in vitro. These data demonstrate that LIFmediated neuroprotection is dependent upon Sp1 and MZF-1, and LIF increases MZF-1 gene
expression.
Introduction
According to the National Center for Health Statistics, ischemic stroke remains the fifth
leading cause of death in the United States as well as a major cause of adult disability (Talwalkar,
Uddin et al. 2015). Treatment with thrombolytic agents, such as tissue plasminogen activator,
may be effective in curbing neurological damage during the early phases of stroke pathology
(Hacke, Kaste et al. 2008). Cellular damage in the first few hours following focal cerebral
ischemia (FCI) may be attributed to increased transmission of glutamate and the Ca2+dependent activation of apoptotic signaling and pro-oxidant enzymes (Dawson, Dawson et al.
1991, Brennan, Won Suh et al. 2009).
Although thrombolytic therapy may decrease excitotoxicity during this period, it is
ineffective at treating the symptoms of delayed neuroinflammation, which occurs hours to days
after the onset of stroke (Dirnagl, Iadecola et al. 1999). During this period, the survival of cells
within the penumbra, the area surrounding the ischemic core, is compromised by several factors.
Dying cells in the ischemic core release factors such as high-mobility group box 1 (HMGB1)
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(Faraco, Fossati et al. 2007) and ATP(Davalos, Grutzendler et al. 2005), which contribute to the
activation of microglia. Activated microglia release pro-inflammatory cytokines and matrix
metalloproteinases that increase blood-brain barrier permeability (Gasche, Copin et al. 2001,
McColl, Rothwell et al. 2008, Leonardo, Hall et al. 2010, Taylor and Sansing 2013). Peripheral
leukocyte populations infiltrate the parenchyma and further damage cells in the parenchyma by
releasing reactive oxygen species (ROS) and other inflammatory mediators (Offner,
Subramanian et al. 2006).
In order to maximize cell survival during this phase of stroke pathophysiology, several
groups have focused on therapies that upregulate protective genes in neural cells. For instance,
this laboratory demonstrated that human umbilical cord blood (HUCB) cells upregulate genes
involved with survival signaling after focal cerebral ischemia. These protective genes that are
induced by HUCBs, increase the survival of oligodendrocytes (OLs). Among these genes
induced by HUCB treatment were the antioxidant enzymes metallothionein III (Mt3) and
peroxiredoxin IV (Prdx4) (Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). Prdx4 gene
expression was also elevated in OLs after treatment with leukemia inhibitory factor, an antiinflammatory cytokine that confers cellular protection in an Akt-dependent manner (Rowe, Collier
et al. 2014). Furthermore, this laboratory identified common transcription factors (TFs) with
putative binding sites in the promoter regions the genes induced by HUCB cells, including of Mt3
and Prdx4. Among these TFs were myeloid zinc finger-1 (MZF-1) and specificity protein 1 (Sp1)
(Rowe, Leonardo et al. 2010).
MZF-1 belongs to the Kruppel family of TFs and is highly expressed by cells of myeloid
origin (Hromas, Collins et al. 1991). Although previously implicated in hematopoietic
development, MZF-1 modulates expression of several genes that play a role in stroke
pathogenesis/recovery (Morris, Davis et al. 1995, Hromas, Davis et al. 1996). Apomorphine
stimulates upregulation of fibroblast growth factor-2, a neuroprotective factor, in astrocytes
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through MZF-1 activity (Luo, Zhang et al. 2009). MZF-1 binding sites were identified in the
promoter region for peroxiredoxin I, a member of the peroxiredoxin family that is highly expressed
by OLs (Mizusawa, Ishii et al. 2000, Kim, Bogner et al. 2008). In addition, levels of MMP-2, a
gelatinase released by activated microglia during stroke, were significantly decreased by
overexpressing MZF-1 in the SiHa cervical cancer line(Tsai, Hwang et al. 2012). Studies indicate
that the activity of MZF-1 is regulated via its protein expression. For instance, calcitriol regulates
CD11b and CD14 expression in mononuclear cells by upregulating MZF-1 protein levels in a
PI3K-dependent manner (Moeenrezakhanlou, Shephard et al. 2008). Granulocyte/macrophage
colony stimulating factor (GM-CSF), a cytokine implicated in leukocyte maturation, increases
neuronal survival through PI3K/Akt activation (Takahashi, Hayashi et al. 2006, Schabitz, Kruger
et al. 2007). In addition, GM-CSF has also been shown to increase levels of MZF-1(Hui, Guo et
al. 1995).
Specificity protein 1, a ubiquitously expressed zinc finger protein, has also been shown
to confer protection against ischemic and oxidative damage by several independent groups.
Upregulation of Sp1 and Sp3 was observed in primary cortical neurons subjected to in vitro
glutathione depletion (Ryu, Lee et al. 2003). During myocardial and hepatic ischemia, Sp1
enhances the response to cellular injury by increasing the gene expression of ectonucleosidetriphosphate-diphosphohydrolase-1, the enzyme that converts ATP to adenosine (Eltzschig,
Köhler et al. 2009, Hart, Gorzolla et al. 2010). This enzyme is also implicated in restoring cerebral
perfusion during ischemic stroke; animals that were administered the soluble form of this enzyme
3 h after transient stroke demonstrated a significant reduction in infarct volume (Belayev,
Khoutorova et al. 2003). Yeh et al. determined that Sp1 activity is triggered by increased levels
of hydrogen peroxide during stroke. Moreover, administration of the Sp1-specific inhibitors
mythramycin A or WP631 following middle cerebral artery occlusion (MCAO) exacerbated
ischemic injury compared to MCAO alone(Yeh, Yang et al. 2011).
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MZF-1 and Sp1 share a common role in the regulation of superoxide dismutase (SOD)
3, a secreted antioxidant enzyme (Zelko and Folz 2003, Zelko and Folz 2004). Although basal
expression of SOD3 remains highest in vascular smooth muscle, blood, and lung tissue, cortical
neurons increase the gene expression of SOD3 as an endogenous defense mechanism against
ischemia. This laboratory previously discovered an essential role for the upregulation of SOD3
in leukemia inhibitory factor (LIF)-mediated neuroprotection after MCAO (Davis, Collier et al.
2016). Although quantitative PCR data from this study indicated that LIF increases expression
of SOD3 at the transcriptional level, the specific TFs that regulate its expression downstream of
LIF signaling are currently unknown. Considering the roles of MZF-1 and Sp1 in HUCB-mediated
oligoprotection and regulation of SOD3 in other tissues, they may be responsible for inducing
SOD3 in neurons after LIF treatment. This study will test the hypothesis that MZF-1 and Sp1 are
essential for the LIF-mediated neuroprotection, which leads to the elevated expression for
antioxidant enzymes.
Materials and Methods
Animal Care
Animal procedures were performed according to the NIH Guide for the Care and Use of
Laboratory Animals and pre-approved by the Institutional Animal Care and Use Committee at
the University of South Florida. The minimum number of animals needed for each study was
determined using power analysis. All procedures were performed on Sprague–Dawley rats were
purchased from Envigo (Indianapolis, IN, USA). Animals were maintained on a 12 h light–dark
cycle (07:00–19:00 h) in a climate-controlled room, and allowed access to food and water ad
libitum. In vivo procedures were performed on young, male rats weighing between 300 and 350
g. Cultured neurons were isolated from taken from embryonic day 18 (E18) fetal rat pups.
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Middle Cerebral Artery Occlusion
The middle cerebral artery occlusion (MCAO) method was used to induce permanent focal
cerebral ischemia as previously described (Ajmo, Vernon et al. 2006). Briefly, the external carotid
artery was exposed, ligated, and cut prior to introducing a 40 mm monofilament. The
monofilament was fed through the cut external carotid artery and advanced through the internal
carotid artery until the end of the filament blocked the origin of the middle cerebral artery.
Subsequent reduction in cerebral blood flow was confirmed using Laser Doppler (Moore Lab
Instruments, Farmington, CT). Only animals with a ≥ 60% reduction in cerebral perfusion were
included in the study. Animals subjected to the sham MCAO procedure only underwent exposure
of the common carotid artery without cutting the external carotid or occluding the MCA.
Drug administration
Recombinant human LIF (ProSpec, Ness Ziona, Israel) (125 μg/kg) or PBS (pH 7.4) were
injected intravenously at 6, 24, and 48 h post-MCAO as previously described. Rats were
euthanized at 72 h post-MCAO via intraperitoneal injection of ketamine/xylazine (75 mg/kg and
7.5 mg/kg) as previously described (Seifert, Hall et al. 2012). Animals used for
immunohistochemical

analysis

were

perfused

with

normal

saline

followed

by

4%

paraformaldehyde in phosphate buffer. Animals used for biochemical analysis were only
perfused with saline.
Tissue Homogenization
To obtain whole cell extracts, frozen tissue was homogenized in whole cell lysis buffer
containing the following: 50 mM Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% IGEPAL, 1 mM PMSF,
and a Complete Mini protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). . Briefly,
tissue was disrupted using a handheld electric homogenizer and allowed to incubate on ice for
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20 min. Tissue lysates were vortexed and pipetted to break up nuclei. Protein concentrations
were estimated using a Bradford Protein Assay (Bio-Rad, Hercules, CA).
Primary Neuronal Culture
Primary cortical neurons were isolated and cultured as described previously (Katnik,
Guerrero et al. 2006). Briefly, brains were removed from E18 fetal rat pups, cortices were
separated from the midbrain and hindbrain, and meninges were removed. Cortices were
dissociated by a combination of mechanical disruption and incubation in trypsin/EDTA solution
at 37 °C. Cells were suspended in DMEM complete medium, washed 2x, counted, and plated
onto glass coverslips pre-coated with poly-L-lysine. At 24 h following isolation, DMEM complete
was removed and cells were incubated in Neurobasal medium containing L-glutamine and B-27
serum-free supplement. Cells were treated with 2 µM cytosine-β-D-arabinofuranoside at 5 days
post-isolation to suppress proliferation of glial cells.
Oxygen Glucose Deprivation
In vitro ischemia was achieved via oxygen-glucose deprivation (OGD) as previously
described (Hall, Guyer et al. 2009). Media was aspirated, and 1 ml DMEM without D-glucose or
sodium pyruvate was added to each well. Cells were treated with 200 ng/ml or sterile filtered
PBS as a vehicle control. Neurons were placed in a humidified airtight chamber that was flushed
with 94% N2, 5% CO2, and 1% O2 (Airgas, Tampa, FL) for 15 min. After 15 min, the chamber
was sealed. Once cells were removed from the chamber, supernatants were collected for
assessment of cytotoxity. Cells were washed twice with PBS and either fixed for 10 min in 4%
paraformaldehyde in phosphate buffer or pelleted via centrifugation and snap-frozen. Fixed cells
were used for immunocytochemical staining and cell pellets were stored at -80°C.
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Lactate Dehydrogenase Assay
Measurement of LDH in the cellular supernatant was performed as previously described
using a colorimetric assay (Takara Biosciences, Madison, WI). Supernatant samples from cells
subjected to OGD were diluted 1:4 in fresh cellular medium prior to assay to avoid saturation.
Absorbance readings were measured using a µQuant microplate spectrophotometer (BioTek,
Winooski, VT) at 490 nm. LDH readings from separate experiments were normalized to a control
group (OGD + PBS) to account for differences in the baseline response between batches of
cells.
Promoter Analysis
Identification of transcription factor (TF) binding sites was performed as previously
described using Genomatix Software (Munich, Germany). The sequences for the rat (Rattus
norvegicus) SOD3 gene was used in the search query and a table was generated for all TF sites.
Consensus sites for the TFs in the table were aligned with the rat SOD3 promoter sequence to
identify their locations.
siRNA-mediated Gene Silencing
Primary cortical neurons were isolated and transfected as previously described with
siRNA using the Nucleofector™ 2b Device and the Amaxa™ Basic Nucleofector™ Kit for primary
mammalian neurons (Lonza, Allendale, NJ). Scrambled (Control-A) and siRNA sequences
(MZF-1 and Sp1) were purchased from Santa Cruz Biotechnology. Transfection with 300-400
nM siRNA was achieved using the Nucleofector™ protocol G-013. Following transfection,
neurons were seeded into 12 well plates containing poly-L-lysine coated coverslips and preequilibrated DMEM complete medium. Downregulation of target genes was confirmed using
quantitative PCR (qRT- PCR).
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Isolation of Total RNA
Total RNA was isolated from cortical neurons as previously described using the Qiagen
RNeasy Mini Kit protocol (Velencia, CA). RNA samples were immediately converted to cDNA or
stored at -80°C.
2-step qRT-PCR
Two-step quantitative real-time PCR (qRT- PCR) was performed as previously described
(Davis, Collier et al. 2016) (Rowe, Leonardo et al. 2010). AffinityScript® Master Mix components
for cDNA synthesis and qPCR reactions were purchased from Agilent Technologies (Santa
Clara, CA). The reverse-transcriptase reaction was performed according to the kit protocol using
a Mastercycler Gradient thermal cycler (Eppendorf, Hauppauge, NY). Reaction components
were incubated at 25˚C for 5 min to allow for primer annealing, 42˚C for 30 min to allow for cDNA
synthesis, and finally 95˚C for 5 min to stop the reaction. A Nanodrop ND-1000
spectrophotometer (Thermo-Fisher Scientific, Waltham, MA) was used to assess the quality and
measure the concentration of cDNA samples. All primers (MZF-1, SOD3, GAPDH, 18s rRNA)
were obtained from Qiagen. The qPCR reaction was performed according to kit protocol using
Opticon™ 3.1 Software attached to a Chromo4 DNA ENGINE thermal cycler (Bio-Rad). The
reaction was carried out at the following steps: 15 min at 95˚C to heat reaction components and
activate Taq polymerase, 30 s at 95 ˚C for denaturation, 30 s at 55˚C for annealing, and 30 s at
72˚C for elongating strands. After 40 cycles of denaturation-annealing-elongation, a melt
temperature curve was measured. Cycle threshold values from the gene of interest and
housekeeping genes (GAPDH, 18s rRNA) were used to calculate the relative change in gene
expression.
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Immunohistochemical Analysis
Fluorescent immunohistochemistry was performed on brain tissue sections using a
previously described protocol (Hall, Guyer et al. 2009). The following antibodies were used:
rabbit α-Sp1 (1:1000; Novus Biologicals, Littleton, CO), rabbit α-MZF-1 (1:500; Abcam, San
Francisco, CA), and mouse-α-neuronal nuclear antigen (NeuN) (1:500; EMD Millipore, Billerica,
MA) antibodies. AlexaFluor® 488 and 594 secondary antibodies (1:1000; Life Technologies,
Carlsbad, CA) were used for visualizing antigens. Coverslips were mounted onto slides using
VECTASHIELD® medium containing 4', 6-diamidino-2-phenylindole (DAPI) (Vector Labs,
Burlingame, CA). Images were captured using a Zeiss AxioCam color camera attached to a
Zeiss AxioSkop2 microscope (Thornwood, NY) interfaced with ZEN 2 Imaging Software.
Western Blot Analysis
Western blotting was used for semi-quantitative measurement of protein expression
using a previously described protocol. Briefly, whole cell or nuclear lysates from brain tissue were
run on 10% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were
blocked in 5% milk dissolved in TBST) and probed with the following antibodies: rabbit α-MZF-1
(1:250; Abcam) and rabbit α-Sp1 (1:1000; Novus Biologicals). Membranes were incubated in
AlexaFluor® 488 goat α-rabbit IgG (1:250; Life Technologies) for visualization of protein bands.
Membranes were imaged using a Typhoon 9410 Imager (GE Healthcare Life Sciences,
Marlborough, MA). To normalize for loading, membranes containing whole cell extracts were reprobed with mouse α-β-actin (1:5000; Novus Biologicals) and AlexaFluor® 488 goat α-mouse
IgG1 (1:250; Life Technologies).
Data analysis
Images were minimally processed in a uniform matter across treatment groups and were
analyzed using ImageJ software (NIH, Bethesda, MD). Statistical analysis was for experiments
containing two groups was performed using an independent student’s t-test and a one-way
84

ANOVA was used for those containing three or more groups. Outliers were detected using the
interquartile method as previously described (Rousseeuw and Hubert 2011) and omitted.
Fisher’s Protected Least Significant Difference post hoc test was used to detect prior to statistical
analyses individual differences between groups. A p value of 0.05 or less was considered
significant. All p values reported are one-tailed.
Results
MZF-1 and Sp1 Sites were identified in the Rat SOD3 Promoter
Within the SOD3 promoter, four MZF-1 sites and two Sp1 sites were identified. All MZF1 sites contained ten nucleotides with a core sequence of four consecutive guanines (GGGG).
The Sp1 sites contained 14 nucleotides with a core sequence of three guanines followed by
another nucleotide (GGGX). Interestingly, the third MZF-1 site and the first Sp-1 sites covered
nucleotides 73-80, indicating that these sites overlap with each other. Sequences for all MZF-1
and Sp1 sites may be found in Table 1, while approximate locations in the SOD3 promoter may
be found in Fig. 3.1.
LIF Upregulates MZF-1 in Cortical Neurons
Western blotting was used to determine the protein expression of MZF-1 in the brains of
rats that were euthanized 72 h after MCAO. At this time point, MCAO and LIF administration
resulted in an overall difference in MZF-1 expression (p = 0.0434; F4,14 = 3.266). The ipsilateral
tissue of PBS-treated rats had significantly higher levels of MZF-1 compared to the contralateral
tissue (p = 0.0201) but not compared to tissue from sham rats (p = 0.2042). There clear trend
towards increased expression of MZF-1 in the ipsilateral tissue from the MCAO + LIF rats
compared to sham-operated rats (p = 0.0848) and the contralateral tissue of the same group (p
= 0.0557). (Fig. 3.2a). To examine the neuron-specific change in MZF-1 expression after LIF
treatment, primary cortical neurons were treated with either PBS or 200 ng/ml LIF prior to 24 h
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of OGD. After incubation, neurons were fixed and stained with MZF-1 antibodies. The percentage
of cells that stained positive for MZF-1 was calculated by dividing by the total number of cells
imaged. Neurons that were treated with LIF prior to OGD showed a significant increase in MZF1-postive cells compared to the cells that were treated with PBS (p = 0.002; t = 5.056, df = 5;
Fig. 3.2b).
Neurons that Upregulate MZF-1 also Upregulate SOD3
Previous studies from this lab show that LIF treatment prior to OGD increases SOD3
gene expression in neurons. In addition, Moeenrazakhanlou et al. demonstrated that PI3K/Akt
signaling, which is increased after LIF treatment, controls MZF-1 activity through increased
protein expression (Moeenrezakhanlou, Shephard et al. 2008, Rowe, Collier et al. 2014). To
determine whether MZF-1 upregulation in neurons coincided with increased SOD3 expression,
total RNA was isolated from neurons that were treated with LIF or PBS prior to OGD. Total RNA
was converted to cDNA, which was used to perform qRT-PCR. The PCR results confirmed the
upregulation of MZF-1 after LIF treatment that was observed in the immunohistochemical
analysis (p = 0.0195; t = 3.024, df = 4; Fig. 3.3a). These same samples also showed increased
expression of SOD3 after LIF treatment, indicating that higher levels of MZF-1 are observed in
neurons with increased SOD3 expression (p =0.0302; t = 2.595, df = 4; Fig. 3.3b).
Sp1 Expression is not significantly altered by LIF Treatment
To determine whether LIF controls Sp1 in a protein expression-dependent manner,
western blots were performed using samples from rats euthanized 72 h after MCAO or sham
injury. The protein expression patterns of Sp1 mirrored those of MZF-1; there was an overall
change in Sp1 expression due to the MCAO and LIF treatment that approached significance (p
= 0.0505; F4,13 = 3.167). Although there was a trend towards an increase in Sp1 levels between
sham and PBS ipsilateral (p = 0.2809) as well as between sham and LIF ipsilateral tissue (p =
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0.0962), these increases were not statistically significant (Fig. 3.4a). Among primary cortical
neurons subjected to OGD for 24 h, there was no significant change in Sp1 expression between
neurons treated with PBS and neurons treated with LIF (p = 0.3810; t = 0.3243; df = 4; Fig. 3.4b).
High Sp1 Levels Correlate with Increased MZF-1 after LIF treatment
Considering the high degree of similarity between the expression patterns of Sp1 and
MZF-1 after LIF treatment, Pearson’s r correlation analysis followed by linear regression was
performed to determine whether increased MZF-1 levels in brain tissue were associated with
higher Sp1 expression after sham surgery, MCAO + PBS treatment, and MCAO + LIF treatment.
Among sham samples (p = 0.7931, r = -0.2069) and PBS samples (p = 0.4706, r = 0.2998), there
was no significant correlation between MZF-1 and Sp1 expression (Figs. 3.5a, 3.5b). However,
there was a significant positive correlation between MZF-1 levels and Sp1 levels in the brains of
LIF-treated rats (p = 0.0068, r = 0.8550), demonstrating that higher MZF-1 levels after LIF
treatment correspond to higher Sp1 levels (Fig. 3.5c).
Sp1 and MZF-1 Accumulate in Neuronal Nuclei in vivo
To visualize the expression and localization of Sp1 and MZF-1 in brain tissue after MCAO
+ LIF treatment, brain tissue sections from rats euthanized at the 72 h time point were doublelabeled with antibodies against Sp1/MZF-1 (red), and NeuN (green). At 72 h after MCAO, Sp1 is
expressed at high levels in neurons of the cerebral cortex as well as hippocampal neurons of the
gray matter. Sp1 immunoreactivity was concentrated in the nuclear region of neurons in both
regions of the brain, and staining was also detected independently of neuronal somata in the
white matter regions (Fig. 3.6). Tissue sections labeled with MZF-1 and NeuN antibodies showed
MZF-1 localized in neurons of the cortex and hippocampus. While Sp1 appeared to be localized
to mainly the nucleus of neuronal somata, MZF-1 showed strong immunoreactivity in the nuclear
and cytoplasmic regions. However, while Sp1 showed strong nuclear localization within and
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outside of the hippocampal gray matter, MZF-1 immunoreactivity was strongest in the gray
matter of the hippocampus. By contrast, little MZF-1 staining was observed in the white matter
of the hippocampus (Fig 3.7).
SOD3 co-localizes with MZF-1 and Sp1 after LIF treatment
Double labeling brain sections with NeuN and MZF-1/Sp1 antibodies showed that these TFs
accumulate in neuronal nuclei after LIF treatment. Furthermore, LIF treatment led to a positive
correlation between Sp1 and MZF-1, but this relationship was not observed in samples from
PBS-treated or sham rats. It has not yet been determined whether SOD3 expression is
associated with high levels of MZF-1 and Sp1/ MZF-1 after LIF treatment. Considering the high
levels of Sp1 and MZF-1 in neuronal nuclei of the cortex, which lies within the ischemic core,
these cells could upregulate SOD3 as a defense mechanism against ischemic damage. To
determine whether neurons showing high levels of MZF-1 and Sp1 also express SOD3 in vivo,
representative brain sections from LIF-treated rats euthanized 72 h after MCAO. At this time
point, SOD3 (green) was expressed by several cells in the cerebral cortex. MZF-1 and Sp1 (red)
were expressed by cells of the cortex at this time point. The merged images revealed colocalization of SOD3 with MZF-1 as well as Sp1 after LIF treatment (Fig 3.8).
Sp1 and MZF-1 siRNA counteract in vitro neuroprotection by LIF
To determine whether silencing Sp1 or MZF-1 decreased the neuroprotective effects of
LIF in vitro, siRNA was used to knock down expression of these transcription factors immediately
following isolation. Once transfected neurons were mature, they were treated with PBS or LIF
and subjected to 24 h of OGD. LDH release in the supernatant was used to measure in vitro
cytoxicity. LIF treatment and siRNA-mediated silencing of Sp1 and MZF-1 expression
significantly altered LDH release among treatment groups (p = 0.0017, F5,19 = 5.993). In
accordance with previous findings from this lab, LIF reduced LDH release among scrambled
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siRNA-transfected neurons compared to those treated with PBS prior to OGD. Neurons
transfected with MZF-1 or Sp1 siRNA and treated with PBS were not significantly different from
their scrambled-transfected counterparts. However, neurons transfected with MZF-1 siRNA and
treated with LIF released significantly more LDH compared to the scrambled + LIF group (p =
0.0004), the MZF-1 siRNA + PBS (p = 0.0004), and the scrambled + PBS groups (p = 0.0228).
Cells transfected with Sp1 siRNA and treated with LIF prior to OGD did not differ significantly in
their LDH release compared to scrambled + PBS neurons, but the siRNA counteracted the
protective effect of the LIF seen in the scrambled + LIF neurons (p = 0.0061) and increased LDH
release compared to the Sp1 siRNA + PBS group (p = 0.0206). However, the LDH release from
the Sp1 siRNA + LIF group was still significantly lower than that of the MZF-1 siRNA + LIF group
(p = 0.012; Fig. 3.9).
Discussion
Rowe et al. identified several TFs that regulate the expression of HUCB cell-inducible
genes in cultured OLs. Prdx4, which is induced by HUCBs and LIF in an Akt-dependent manner,
contains binding sites for MZF-1 and Sp1 in its promoter region (Rowe, Leonardo et al. 2010,
Rowe, Leonardo et al. 2012, Rowe, Collier et al. 2014). In addition to its oligoprotective
properties, this laboratory showed that LIF exerts pro-survival effect on neurons via the Aktdependent upregulation of SOD3 (Davis, Collier et al. 2016). Other groups have examined the
ability of Sp1 and MZF-1 to regulate expression of SOD3 in vitro and in vivo (Zelko and Folz
2003, Zelko and Folz 2004, Zelko, Mueller et al. 2008. The fact that in vitro LIF protection is
counteracted by Sp1 and MZF-1 knockdown suggests that both TFs may play a role in the
upregulation of several antioxidant enzymes. Furthermore, cells in the cerebral cortex that
expressed high levels of MZF-1 and Sp1 also had high levels of SOD3 after LIF treatment.
Previously, this lab showed that LIF induces SOD3 in the ipsilateral cerebral cortex at 72 h postMCAO. Among these cortical cells that upregulate SOD3 were neurons {Davis, 2016 #363).
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Therefore, the high levels of MZF-1 and Sp1 in cortical tissue facilitate the increase in SOD3
expression after MCAO and LIF treatment.
Previous research shows that MZF-1 activity is regulated by PI3K/Akt signaling at the
level of protein expression, and the increased MZF-1 mRNA and immunoreactivity in primary
cortical neurons confirms earlier findings. Although MZF-1 upregulation approached, but did not
reach, significance in brain tissue after LIF treatment, these could be due to several factors.
While in vitro cultures contain almost exclusively neurons, tissue samples include neurons, glia,
endothelial cells, as well as other cell types. The double-staining with NeuN and MZF-1 further
demonstrated that MZF-1 upregulation and nuclear translocation is more prominent in neurons
compared to other neural cell types. The majority of hippocampal neurons in the dentate gyrus
showed co-localization of NeuN and MZF-1, but little MZF-1 was found outside of neuronal
tissue. The upregulation of MZF-1 in neurons after LIF treatment may be responsible for the
trend towards increased MZF-1 expression in brain tissue. Immunohistochemical staining and
qRT-PCR data from purified neuronal cultures showed that LIF induces the expression of MZF1 under ischemic conditions. Furthermore, transfection with MZF-1 siRNA prior to LIF treatment
significantly increased in vitro cytotoxicity compared to the scrambled siRNA + LIF group. These
results from in vitro experiments demonstrate that MZF-1 is responsible for the neuroprotective
actions of LIF, and its activation is dependent upon increased gene expression.
Although transfection with Sp1 siRNA counteracted LIF-mediated neuroprotection in
vitro, Sp1 was not significantly upregulated by LIF in brain tissue. Quantitative PCR analysis of
primary cortical neurons showed no change in Sp1 mRNA transcript between PBS and LIFtreated neurons. These results indicate that LIF controls the activity of Sp1 independently of its
expression. In addition, experiments using siRNA-mediated knockdown demonstrated that
among primary cortical neurons, those transfected with MZF-1 siRNA prior to LIF treatment had
significantly higher LDH levels than those transfected with Sp1 siRNA prior to LIF treatment.
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Both sets of neurons that were transfected with siRNA prior to LIF treatment had higher
LDH release than their PBS-treated counterparts, indicating that LIF may be detrimental to
neurons under OGD when lacking one or more TFs. Studies from this laboratory show that the
protective actions that LIF exerts on neurons/glial cells are dependent upon the Akt-dependent
upregulation of protective genes. Without the necessary TFs, in this case Sp1 and MZF-1, it is
possible that the pro-survival effect of Akt-dependent gene expression may be overshadowed
by other signaling pathways. For instance, p38 MAP kinase is activated by LIF signaling, and
Ghatan et al. demonstrated that p38 initiates apoptosis by facilitating the translocation of Bax to
the mitochondria (Ghatan, Larner et al. 2000, Kato, Sano et al. 2000). Since knockdown of either
Sp1 or MZF-1 is sufficient to counteract the in vitro neuroprotection provided by LIF, this data
suggests that the presence of both TFs is necessary for induction of protective genes in neurons.
According to several independent groups, the activity of Sp1 is regulated by multiple
post-translational

modifications.

Suzuki

et

al.

demonstrated

that

p300,

a

histone

acetyltransferase, enhances the DNA-binding of Sp1 via protein-protein interaction and
increasing its acetylation (Suzuki, Kimura et al. 2000). Histone deacetylase inhibitors also
enhance the activity of Sp1 (Huang, Zhao et al. 2005, Marinova, Ren et al. 2009). The HDAC
inhibitor valproic acid enhances neuroprotection following transient MCAO by increasing the
acetylation of Sp1 and the expression of the chaperone Hsp70 (Ren, Leng et al. 2004).
Moreover, Zelko et al. demonstrated that trichostatin A, another histone deacetylase inhibitor,
upregulates SOD3 expression in an Sp1-dependent manner (Zelko and Folz 2004). This lab
demonstrated that inhibition of Akt activity counteracts the protective effects of LIF on cultured o
p300 via phosphorylation of Ser1834, and inhibition of PI3K/Akt signaling via treatment with
LY294002 triggers proteolysis of p300. Therefore, it is possible that enhanced Akt activity
following LIF treatment regulates Sp1 transcriptional activity in a p300-dependent manner (Chen,
Halappanavar et al. 2004, Huang and Chen 2005).
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In addition to acetylation, Sp1 activity is regulated via direct phosphorylation. Multiple
studies indicate that transcriptional activity of Sp1 is increased by Akt-dependent
phosphorylation. According to Reisinger et al., hepatocyte growth factor increases serine
phosphorylation of Sp1 and expression of vascular endothelial growth factor (VEGF). This study
implicated several kinases, including PI3K, MEK1/2, and PKC-ζ, in the activation of
Sp1(Reisinger, Kaufmann et al. 2003). Pore et al. demonstrated that the upregulation of VEGF
is dependent upon Sp1, which is regulated by Akt in a phosphorylation-dependent manner (Pore,
Liu et al. 2004). Sp1 controls expression of other genes downstream of PI3K/Akt signaling.
Phosphorylation of Sp1 by Akt and MAPK signaling increases expression of the cancer
biomarker CD147 (Zhao, Ye et al. 2015). Another study showed that caveolin-1, the main
component of caveolae, is upregulated following increased phosphorylation of Sp1 by Akt (Roy,
Upal et al. 2013). However, phosphorylation and acetylation are only two of the many posttranslational modifications that may alter the activity of Sp1. According to these data, LIF protects
neurons against ischemia via Sp1 but does not significantly increase its expression in vivo.
Consequently, LIF may activate Sp1 by influencing one or more of its post-translational
modifications (Chu 2012).
Although LIF does not directly increase expression of Sp1 in neurons during ischemia,
the significant correlation between MZF-1 and Sp1 protein levels among brain samples from LIF
treated rats indicates a possible relationships between the two TFs. According to previous
studies, the Sp1 promoter region contains binding sites for MZF-1. Higher MZF-1 levels after LIF
treatment may increase transcription of the Sp1 gene, which may explain the trend towards
higher Sp1 expression after LIF treatment in brain tissue (Thakur 2007). The correlation between
MZF-1 and Sp1 levels after LIF treatment may be due to reduced degradation of Sp1. During
ischemia, there is a reduction in the levels of O-glycosylated Sp1 due to low glucose levels in
the infarct. Consequently, hypo-glycosylated Sp1 is more susceptible to degradation by the
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proteasome (Han and Kudlow 1997). PI3K/Akt signaling, a pathway activated by LIF in neural
cells, has been shown to suppress ubiquitin/proteasome-mediated degradation (Wang, Hu et al.
2006, Rowe, Collier et al. 2014, Davis, Collier et al. 2016). Therefore, the higher levels of Sp1
in the brain and its correlation with MZF-1 may be an artifact of its reduced degradation after LIF
treatment rather than increased gene expression.
Another possible explanation for this relationship may be that Sp1 is upregulated by
neurons in response to ischemia, but LIF treatment does not contribute to further upregulation.
As a result, Sp1 levels might be highest in tissue with the most severe ischemic damage.
Previous studies from our lab showed that the induction of Prdx4 and SOD3 after LIF treatment
are not observed under normoxia. The upregulation of MZF-1 in neurons after LIF treatment
appears to follow a similar pattern, where the difference between MZF-1 expression in ipsilateral
and contralateral brain tissue approaches significance (P=0.055). The MCAO+LIF rats are the
only treatment group subjected to ischemia and LIF treatment, and they are the only group with
a significant relationship between levels of MZF-1 and Sp1.
According to the results of the Genomatix analysis, there is an overlapping region
between the consensus sequences for MZF-1 and Sp1. In the promoters of other genes, MZF-1
and Sp1 act as regulators of transcription for similar genes. CD11b and CD14 expression are
regulated by MZF-1/Sp1 and the binding sites for both TFs overlap with each other in both
promoter sequences (Moeenrezakhanlou, Shephard et al. 2008). Shiraga et al. demonstrated
that the promoter for the MUC1 mucin gene also contains overlapping binding sites for MZF-1
and Sp1. Furthermore, supershift analysis confirmed direct interaction between the two TFs at
the MUC1 promoter. Direct protein-protein interaction between the MZF-1 and Sp1 shows that
that they may function as co-activators of transcription for many genes.
Immunohistochemical analysis of brain sections from LIF-treated rats revealed colocalization of Sp1 as well as MZF-1 with neuronal nuclei in the cerebral cortex and the
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hippocampus. The intraluminal model of permanent MCAO utilized by this study produces a
large volume of damage within the cerebral cortex as well as the striatum. This lab previously
showed that SOD3 expression was induced specifically in the ipsilateral cortical tissue of LIFtreated rats. The MZF-1 and Sp1 expression and nuclear localization observed in the ipsilateral
cortex after LIF treatment agreed with this previous findings. While hippocampal damage is not
as severe in this MCAO model compared to cortical damage, this laboratory previously showed
that neuronal degeneration in the hippocampus occurs between 12 h and 7 days after MCAO
(Butler, Kassed et al. 2002). Popp et al. conducted a study showing ischemic damage in regions
of the brain following transient and permanent MCAO. According to the findings, the ipsilateral
hippocampus is within the posterior penumbra, most likely due to manipulation of the internal
carotid artery during the MCAO procedure (Popp, Jaenisch et al. 2009). As with the cortical
neurons, hippocampal neurons showed MZF-1 and Sp1 in the nuclear region, thus indicating
that LIF exerts neuroprotection in the outer penumbra as well.
. Although transfection with either MZF-1 or Sp1 siRNA was sufficient to counteract LIFmediated neuroprotection, one would expect simultaneous silencing to be even more effective
at abrogating the protective effects of LIF. While simultaneous knockdown of genes in primary
cortical neurons is difficult to accomplish, the efficacy of single-gene knockdown demonstrates
that both MZF-1 and Sp1 are important for the neuroprotective properties of LIF in vivo. In
addition, this study is the first to identify a distinct neuroprotective role for MZF-1, which had not
yet been implicated in neural cell signaling. Prdx4 and SOD3, which are both induced by LIF,
contain regulatory sequences for MZF-1 and Sp1 in their promoter regions (Rowe, Leonardo et
al. 2010, Rowe, Collier et al. 2014, Davis, Collier et al. 2016). The pleiotropic effects of LIF
suggest that it may upregulate other protective genes that are controlled by MZF-1 and Sp1.
PI3K/Akt signaling, which is responsible for the protective effects of LIF in neural cells, controls
survival signaling by activating transcription factors. Therefore, other TFs located downstream of
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Akt might mediate the protective effects of LIF. Further studies may help identify other
mechanisms through which LIF controls protective gene expression during focal cerebral
ischemia.
References

Ajmo, C. T., D. O. L. Vernon, et al. (2006). "Sigma receptor activation reduces infarct size at 24
hours after permanent middle cerebral artery occlusion in rats." Current Neurovascular
Research 3(2): 89-98.
Belayev, L., L. Khoutorova, et al. (2003). "Neuroprotective Effect of SolCD39, a Novel Platelet
Aggregation Inhibitor, on Transient Middle Cerebral Artery Occlusion in Rats." Stroke
34(3): 758-763.
Brennan, A. M., S. Won Suh, et al. (2009). "NADPH oxidase is the primary source of
superoxide induced by NMDA receptor activation." Nat Neurosci 12(7): 857-863.
Butler, T. L., C. A. Kassed, et al. (2002). "Neurodegeneration in the rat hippocampus and
striatum after middle cerebral artery occlusion." Brain Research 929(2): 252-260.
Chen, J., S. S. Halappanavar, et al. (2004). "Role of Akt/protein kinase B in the activity of
transcriptional coactivator p300." Cell Mol Life Sci 61(13): 1675-1683.
Chu, S. (2012). "Transcriptional regulation by post-transcriptional modification—Role of
phosphorylation in Sp1 transcriptional activity." Gene 508(1): 1-8.
Davalos, D., J. Grutzendler, et al. (2005). "ATP mediates rapid microglial response to local
brain injury in vivo." Nat Neurosci 8(6): 752-758.
Davis, S. M., L. A. Collier, et al. (2016). "Leukemia Inhibitory Factor Protects Neurons from
Ischemic Damage via Upregulation of Superoxide Dismutase 3." Molecular
Neurobiology: 1-15.
Dawson, V. L., T. M. Dawson, et al. (1991). "Nitric oxide mediates glutamate neurotoxicity in
primary cortical cultures." Proceedings of the National Academy of Sciences 88(14):
6368-6371.
Dirnagl, U., C. Iadecola, et al. (1999). "Pathobiology of ischaemic stroke: an integrated view.
[Review]." Trends in neurosciences 22(9): 391-397.
Eltzschig, H. K., D. Köhler, et al. (2009). "Central role of Sp1-regulated CD39 in
hypoxia/ischemia protection." Blood 113(1): 224-232.
95

Faraco, G., S. Fossati, et al. (2007). "High mobility group box 1 protein is released by neural
cells upon different stresses and worsens ischemic neurodegeneration in vitro and in
vivo." Journal of neurochemistry 103(2): 590-603.
Gasche, Y., J.-C. Copin, et al. (2001). "Matrix metalloproteinase inhibition prevents oxidative
stress-associated blood–brain barrier disruption after transient focal cerebral ischemia."
Journal of Cerebral Blood Flow & Metabolism 21(12): 1393-1400.
Ghatan, S., S. Larner, et al. (2000). "p38 Map Kinase Mediates Bax Translocation in Nitric
Oxide–Induced Apoptosis in Neurons." The Journal of Cell Biology 150(2): 335-348.
Hacke, W., M. Kaste, et al. (2008). "Thrombolysis with alteplase 3 to 4.5 hours after acute
ischemic stroke." New England Journal of Medicine 359(13): 1317-1329.
Hall, A. A., A. G. Guyer, et al. (2009). "Human umbilical cord blood cells directly suppress
ischemic oligodendrocyte cell death." Journal of Neuroscience Research 87(2): 333341.
Han, I. and J. E. Kudlow (1997). "Reduced O glycosylation of Sp1 is associated with increased
proteasome susceptibility." Molecular and Cellular Biology 17(5): 2550-2558.
Hart, M. L., I. C. Gorzolla, et al. (2010). "SP1-dependent induction of CD39 facilitates hepatic
ischemic preconditioning." The Journal of Immunology 184(7): 4017-4024.
Hromas, R., S. Collins, et al. (1991). "A retinoic acid-responsive human zinc finger gene, MZF1, preferentially expressed in myeloid cells." Journal of Biological Chemistry 266(22):
14183-14187.
Hromas, R., B. Davis, et al. (1996). Hematopoietic transcriptional regulation by the myeloid zinc
finger gene, MZF-1. Molecular Aspects of Myeloid Stem Cell Development, Springer:
159-164.
Huang, W.-C. and C.-C. Chen (2005). "Akt Phosphorylation of p300 at Ser-1834 Is Essential
for Its Histone Acetyltransferase and Transcriptional Activity." Molecular and Cellular
Biology 25(15): 6592-6602.
Huang, W., S. Zhao, et al. (2005). "Trichostatin A Induces Transforming Growth Factor β Type
II Receptor Promoter Activity and Acetylation of Sp1 by Recruitment of PCAF/p300 to a
Sp1·NF-Y Complex." Journal of Biological Chemistry 280(11): 10047-10054.
Hui, P., X. Guo, et al. (1995). "Isolation and functional characterization of the human gene
encoding the myeloid zinc finger protein MZF-1." Biochemistry 34(50): 16493-16502.
Katnik, C., W. R. Guerrero, et al. (2006). "Sigma-1 Receptor Activation Prevents Intracellular
Calcium Dysregulation in Cortical Neurons during in Vitro Ischemia." Journal of
Pharmacology and Experimental Therapeutics 319(3): 1355-1365.
96

Kato, T., M. Sano, et al. (2000). "Calmodulin Kinases II and IV and Calcineurin Are Involved in
Leukemia Inhibitory Factor–Induced Cardiac Hypertrophy in Rats." Circulation
Research 87(10): 937-945.
Kim, J.-H., P. N. Bogner, et al. (2008). "Up-regulation of peroxiredoxin 1 in lung cancer and its
implication as a prognostic and therapeutic target." Clinical Cancer Research 14(8):
2326-2333.
Leonardo, C. C., A. A. Hall, et al. (2010). "Human umbilical cord blood cell therapy blocks the
morphological change and recruitment of CD11b‐expressing, isolectin‐binding
proinflammatory cells after middle cerebral artery occlusion." Journal of Neuroscience
Research 88(6): 1213-1222.
Luo, X., X. Zhang, et al. (2009). "Crucial roles of MZF‐1 in the transcriptional regulation of
apomorphine‐induced modulation of FGF‐2 expression in astrocytic cultures." Journal
of neurochemistry 108(4): 952-961.
Marinova, Z., M. Ren, et al. (2009). "Valproic acid induces functional heat‐shock protein 70 via
class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1
acetylation." Journal of neurochemistry 111(4): 976-987.
McColl, B. W., N. J. Rothwell, et al. (2008). "Systemic inflammation alters the kinetics of
cerebrovascular tight junction disruption after experimental stroke in mice." J Neurosci
28(38): 9451-9462.
Mizusawa, H., T. Ishii, et al. (2000). "Peroxiredoxin I (macrophage 23 kDa stress protein) is
highly and widely expressed in the rat nervous system." Neuroscience letters 283(1):
57-60.
Moeenrezakhanlou, A., L. Shephard, et al. (2008). "Myeloid cell differentiation in response to
calcitriol for expression CD11b and CD14 is regulated by myeloid zinc finger-1 protein
downstream of phosphatidylinositol 3-kinase." Journal of Leukocyte Biology 84(2): 519528.
Morris, J., B. Davis, et al. (1995). "The myeloid zinc finger gene, MZF-1, regulates the CD34
promoter in vitro." Blood 86(10): 3640-3647.
Offner, H., S. Subramanian, et al. (2006). "Experimental stroke induces massive, rapid
activation of the peripheral immune system." Journal of Cerebral Blood Flow &
Metabolism 26(5): 654-665.
Popp, A., N. Jaenisch, et al. (2009). "Identification of Ischemic Regions in a Rat Model of
Stroke." PLoS ONE 4(3): e4764.

97

Pore, N., S. Liu, et al. (2004). "Sp1 Is Involved in Akt-mediated Induction of VEGF Expression
through an HIF-alpha-independent Mechanism." Molecular Biology of the Cell 15(11):
4841-4853.
Reisinger, K., R. Kaufmann, et al. (2003). "Increased Sp1 phosphorylation as a mechanism of
hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor
(VEGF/VPF) transcription." Journal of Cell Science 116(2): 225-238.
Ren, M., Y. Leng, et al. (2004). "Valproic acid reduces brain damage induced by transient focal
cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat
shock protein induction." Journal of neurochemistry 89(6): 1358-1367.
Rousseeuw, P. J. and M. Hubert (2011). "Robust statistics for outlier detection." Wiley
Interdisciplinary Reviews: Data Mining and Knowledge Discovery 1(1): 73-79.
Rowe, D. D., L. A. Collier, et al. (2014). "Leukemia inhibitor factor promotes functional recovery
and oligodendrocyte survival in rat models of focal ischemia." European Journal of
Neuroscience 40(7): 3111-3119.
Rowe, D. D., C. C. Leonardo, et al. (2010). "Cord blood administration induces oligodendrocyte
survival through alterations in gene expression." Brain research 1366: 172-188.
Rowe, D. D., C. C. Leonardo, et al. (2012). "Human umbilical cord blood cells protect
oligodendrocytes from brain ischemia through Akt signal transduction." Journal of
Biological Chemistry 287(6): 4177-4187.
Roy, B., K. Upal, et al. (2013). "Caveolin‐1 is a novel regulator of K‐RAS‐dependent migration
in colon carcinogenesis." International Journal of Cancer 133(1): 43-57.
Ryu, H., J. Lee, et al. (2003). "Sp1 and Sp3 are oxidative stress-inducible, antideath
transcription factors in cortical neurons." The Journal of neuroscience 23(9): 35973606.
Schabitz, W.-R., C. Kruger, et al. (2007). "A neuroprotective function for the hematopoietic
protein granulocyte-macrophage colony stimulating factor (GM-CSF)." J Cereb Blood
Flow Metab 28(1): 29-43.
Seifert, H. A., A. A. Hall, et al. (2012). "A transient decrease in spleen size following stroke
corresponds to splenocyte release into systemic circulation." Journal of Neuroimmune
Pharmacology 7(4): 1017-1024.
Suzuki, T., A. Kimura, et al. (2000). "Regulation of interaction of the acetyltransferase region of
p300 and the DNA-binding domain of Sp1 on and through DNA binding." Genes to
Cells 5(1): 29-41.

98

Takahashi, K., N. Hayashi, et al. (2006). "Molecular mechanisms for transcriptional regulation
of human high-affinity IgE receptor β-chain gene induced by GM-CSF." The Journal of
Immunology 177(7): 4605-4611.
Talwalkar, A., S. Uddin, et al. (2015). Trends in Emergency Department Visits for Ischemic
Stroke and Transient Ischemic Attack: United States, 201-2011, US Department of
Health and Human Services, Centers for Disease Control and Prevention, National
Center for Health Statistics.
Taylor, R. A. and L. H. Sansing (2013). "Microglial responses after ischemic stroke and
intracerebral hemorrhage." Clinical and Developmental Immunology 2013.
Thakur, V. S. (2007). Regulation of Sp1 Promoter in Lung Epithelial Cells, ProQuest.
Tsai, S.-J., J.-M. Hwang, et al. (2012). "Overexpression of myeloid zinc finger 1 suppresses
matrix metalloproteinase-2 expression and reduces invasiveness of SiHa human
cervical cancer cells." Biochemical and biophysical research communications 425(2):
462-467.
Wang, X., Z. Hu, et al. (2006). "Insulin resistance accelerates muscle protein degradation:
activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling."
Endocrinology 147(9): 4160-4168.
Yeh, S. H., W. B. Yang, et al. (2011). "Translational and transcriptional control of Sp1 against
ischaemia through a hydrogen peroxide-activated internal ribosomal entry site
pathway." Nucleic acids research: gkr161.
Zelko, I. and R. Folz (2003). "Myeloid zinc finger (MZF)-like, Kruppel-like and Ets families of
transcription factors determine the cell-specific expression of mouse extracellular
superoxide dismutase." Biochem. J 369: 375-386.
Zelko, I. N. and R. J. Folz (2004). "Sp1 and Sp3 transcription factors mediate trichostatin Ainduced and basal expression of extracellular superoxide dismutase." Free Radical
Biology and Medicine 37(8): 1256-1271.
Zelko, I. N., M. R. Mueller, et al. (2008). "Transcription factors sp1 and sp3 regulate expression
of human extracellular superoxide dismutase in lung fibroblasts." American journal of
respiratory cell and molecular biology 39(2): 243-251.
Zhao, J., W. Ye, et al. (2015). "Sp1-CD147 positive feedback loop promotes the invasion ability
of ovarian cancer." Oncology reports 34(1): 67-76.

99

Table 1. MZF-1 and Sp1 have Binding Sites in the SOD3 Promoter. Genomatix was used to
identify binding sites for MZF-1 and Specificity Protein-1, another protective transcription factor
activated by Akt signaling, in the promoter for the superoxide dismutase 3 (SOD3) rat gene. Four
MZF-1 sites were identified in the promoter. All identified MZF-1 sites were 11 nucleotides long
and contained four consecutive guanine residues (GGGG) in the anchor position. Two Sp1
binding sites containing 14 nucleotides each and a core sequence of three guanines followed by
another residue (GGGX) were found as well. As noted by the start and ending positions of each
binding site, the first Sp1 site and the third MZF-1 site contain overlapping resides at positions
73-80.

Transcription

Start

End

Strand

Factor

Position

Position

(+/-)

MZF-1

13

23

+

aaGGGGaacta

MZF-1

46

56

+

gtGGGGacaat

Sp1

64

80

+

agcggGGGAggggggaa

MZF-1

73

83

+

ggGGGGaaagg

Sp1

178

194

+

aggagGGGCagggaaag

MZF-1

368

378

+

ggGGGGaggag

100

Sequence

Figure 3.1. Locations of MZF-1 and Sp1 binding sites in the rat SOD3 promoter. Of the four
MZF-1 sites that were identified by Genomatix, three were clustered within the first 100
nucleotides of the promoter sequence while the fourth MZF-1 site was located downstream near
the middle of the sequence. The first Sp1 site was preceded by the second and overlapped with
the third MZF-1 binding site, suggesting that the two TFs interact with each other. The second
Sp1 site was located approximately mid-way between the third and fourth MZF-1 site. All of the
binding sequences for MZF-1 and Sp1 were located on the positive strand.
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Figure 3.2. MZF-1 is upregulated by cultured neurons but not brain tissue after LIF
treatment. (a) Western blotting analysis showed that there was a trend towards increased
expression of MZF-1 in the ipsilateral tissue of PBS-treated rats after MCAO compared to that of
sham-operated rats. In addition, the increase between MZF-1 levels in the ipsilateral tissue of
LIF-treated rats and that of sham/PBS-treated rats approached, but did not quite reach
significance. n = 4 per group. (b) To determine the neuron-specific expression of MZF-1 after LIF
treatment, immunohistochemistry was performed on fixed primary neurons that were treated with
either PBS or 200 ng/ml LIF prior to 24 h OGD. Compared to the PBS-treated cells, there was
significantly higher levels of MZF-1 immunoreactivity in the cells treated with LIF prior to OGD
(*p<0.01). n = 5 per group.
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Figure 3.3. Cells with elevated MZF-1 after LIF treatment upregulate SOD3 mRNA. (a)
Although immunohistochemical staining revealed higher levels of MZF-1 after LIF treatment,
quantitative real-time PCR was used to determine whether neurons that express high levels of
MZF-1 also upregulate SOD3 after LIF treatment. As expected, MZF-1 mRNA was significantly
upregulated after LIF treatment (*p<0.05). (b) SOD3 mRNA levels were measured in the same
neuronal samples to determine whether SOD3 upregulation coincided with MZF-1 upregulation
after LIF treatment. Neurons treated with LIF prior to OGD had significantly higher levels of SOD3
mRNA compared to LIF treatment. n = 3 per group
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Figure 3.4. Sp1 is not upregulated in brain tissue or primary neurons after LIF treatment.
(a) Western blotting was performed to determine protein expression in brain tissue after MCAO
and LIF treatment. There was an increase in Sp1 expression in the ipsilateral tissue of LIFtreated rats compared to that of PBS-treated or sham rats, but this increase did not quite reach
significance. n = 4 per group (b) Real time PCR analysis showed that Sp1 expression was not
significantly different between neurons that were treated with either PBS or LIF prior to OGD. n
= 3 per group.
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Figure 3.5. MZF-1 Upregulation Correlates with Higher Sp1 Levels in LIF-treated Rats.
Linear regression analysis was performed on the normalized western blot band densities for
MZF-1 and Sp1 in brain tissue samples to determine whether higher Sp1 levels were associated
with greater MZF-1 expression. (a) There was no significant correlation between MZF-1 and Sp1
levels in brain tissue samples from sham operated rats. (b) Samples from PBS-treated rats also
showed no correlation between MZF-1 and Sp1 levels. (c) There was a significant correlation
and a positive relationship between MZF-1 and Sp1 protein expression in tissue samples from
LIF-treated rats (p<0.01). n ≥4 samples per group.
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Figure 3.6. Sp1 accumulates in neuronal nuclei after LIF treatment. Brain tissue sections
from rats that were treated with LIF and euthanized 72 h after MCAO were labeled with antibodies
against Sp1 and neuronal nuclear antigen (NeuN) to determine whether LIF causes translocation
of Sp1 to the nucleus. Cortical staining revealed strong co-localization of Sp1 (red) and NeuN
(green). In the dentate gyrus of the hippocampus, Sp1 was localized to neuronal nuclei. In
addition, Sp1 immunoreactivity was detected in the nuclei of non-neuronal tissue of the
hippocampus. Sp1 was observed in neuronal nuclei in the cortical and striatal tissue adjacent to
the external capsule, but levels within the external capsule were very low. Arrows identify
representative cells. Scale bars = 100 µm.

106

Figure 3.7. MZF-1 is expressed in the nuclei of cortical and hippocampal neurons.
Antibodies against MZF-1 (red) and NeuN (green) were used to label brain sections from rats
treated with LIF and euthanized 72 h after MCAO. In the cerebral cortex, neurons staining
positive for NeuN also expressed MZF-1. In addition, the MZF-1 expressed by cortical neurons
appeared to be localized to the nuclei. In the hippocampus, MZF-1 immunoreactivity was very
strong in neuronal nuclei. By contrast, little MZF-1 immunoreactivity was observed in nonneuronal tissue of the hippocampus. MZF-1 also co-localized with NeuN in neurons adjacent to
the external capsule. While MZF-1 immunoreactivity was visible within the external capsule, it
less noticeable than MZF-1 staining in neuronal tissue. Arrows identify representative cells. Scale
bars = 100 µm.
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Figure 3.8. SOD3 co-localizes with MZF-1 and Sp1. Cortical tissue from 72 h LIF-treated rats
was double labeled with antibodies against SOD3 (green), MZF-1 or Sp1 (red). At this time point,
there was a high degree of co-localization between SOD3 and MZF-1 as well as SOD3 and Sp1.
Arrows identify representative cells. Scale bars = 100 µm.
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Figure 3.9. MZF-1 and Sp1 siRNA counteract LIF-mediated neuroprotection in vitro.
Neurons were transfected with either scrambled, MZF-1, or Sp1 siRNA immediately following
isolation. Once neurons were mature, they were treated with PBS or 200 ng/ml LIF and subjected
to OGD for 24 h. Lactate dehydrogenase (LDH) activity was measured using a colorimetric
assay. To account for variations between batches of neurons, absorbance values were
normalized to the mean absorbance for the Scr + PBS group prior to analysis. Although LDH
release was significantly decreased in the Scr + LIF group compared to the Scr + PBS group
(*p<0.05), this neuroprotective effect was counteracted by previous transfection with MZF-1
siRNA prior to LIF treatment (#p<0.001). Transfection with Sp1 siRNA prior to LIF treatment
also significantly increased LDH release compared to the Scr + LIF group (^p<0.05). n ≥ 4 per
group.
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CHAPTER 4:
LIFR IS UPREGULATED IN A TIME-DEPENDENT MANNER IN THE SPLEEN AND IN THE
BRAIN AFTER LIF TREATMENT
Note to Reader
Stephanie Davis is the main author of this chapter. However, assistance in
experimentation as well as editing of this section was provided by Lisa A. Collier, Jawad A.
Fazal, Dr. Christopher C. Leonardo, and Dr. Craig T. Ajmo Jr. All experimentation in this
chapter was overseen by Dr. Keith R. Pennypacker.
Abstract
Leukemia inhibitory factor (LIF) has previously been shown to activate protective
PI3K/Akt signaling through binding to its heterodimeric receptor (LIFR/gp130). The goal of this
study was to determine whether LIFR expression is increased after permanent middle cerebral
artery occlusion (MCAO) the brain and the spleen. Permanent stroke was induced via middle
cerebral artery occlusion and animals were administered PBS or 125 µg/kg LIF at 6, 24, and 48
h after MCAO. Western blotting was used to measure protein expression of LIFR in the spleen
and the brain. Genomatix software was used to identify binding sites for LIF-dependent TFs in
the LIFR promoter. Cortical neurons were treated with several concentrations (2, 5, 10, 25, or 50
nM) of a JAK1-specific inhibitor and subjected to OGD or normoxia for 24 h. Lactate
dehydrogenase (LDH) was measured to assess in vitro cytotoxicity. LIFR expression was
significantly increased in the brain at 72 h post-MCAO among LIF-treated rats compared to sham
and PBS-treated rats. Genomatix identified two binding sites for Sp1 in the LIFR promoter.
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Although LIFR expression in the spleen decreased after MCAO, it significantly increased from
24 to 72 h post-MCAO among all stroked rats, with 17% higher levels in LIF-treated rats
compared to PBS-treated rats at 72 h. LIF significantly increased the spleen weight compared to
PBS treatment 72 h after MCAO, but did not completely prevent splenic contraction. There were
significant correlations between LIFR expression in the brain and the spleen and the severity of
post-stroke neuroinflammation. Finally, JAK1 inhibition using GLPG0634 (5, 10, 25, and 50 nM)
significantly reduced LDH release under OGD, but the concentration that yielded the largest
decrease (5 nM) had no effect under normoxia. These results indicate that LIFR upregulation
may be important for sensitizing neural cells and splenocytes to LIF signaling after stroke, and
that JAK1 inhibition may be a neuroprotective strategy against ischemic damage.
Introduction:
Recently, this laboratory demonstrated that administration of leukemia inhibitory factor
(LIF) after ischemic stroke promotes the survival of oligodendrocytes and neurons through the
increased expression of antioxidant genes (Rowe, Collier et al. 2014, Davis, Collier et al. 2016).
Due to its pleiotropic effects on pro-survival signaling and immunomodulation, LIF has emerged
as a promising therapeutic for inflammatory diseases of the CNS. For instance, LIF promotes
white matter survival in animal models of multiple sclerosis (MS) by activating anti-apoptotic
signaling, countering the effects of interferon gamma (IFNγ), and most recently, by increasing
populations of regulatory T lymphocytes (Tregs) that limit autoimmune-mediated damage
(Vartanian, Li et al. 1995, Slaets, Dumont et al. 2008, Janssens, Van den Haute et al. 2015).
One possible reason behind the efficacy of LIF in treating neuroinflammation is its role as an
endogenous immunomodulatory cytokine. Certain populations of T lymphocytes, which
contribute to white matter damage in MS lesions, may limit further damage by secreting LIF
(Vanderlocht, Hellings et al. 2006). Several leukocyte populations as well as oligodendrocytes
also upregulate the low-affinity, LIF-specific subunit of the LIF receptor (LIFR) in animal models
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of MS (Butzkueven, Zhang et al. 2002, Janssens, Van den Haute et al. 2015). Previously, this
laboratory showed that cortical neurons express the LIFR subunit in vitro and in vivo (Davis,
Collier et al. 2016). Although LIFR and the high-affinity converter subunit, glycoprotein 130
(gp130), mediate the downstream effects of LIF, gp130 participates in the downstream signaling
of IL-6. IL-6 is a pro-inflammatory cytokine that is implicated in the development of CD4+ IL-17+
helper T (Th17) lymphocytes. Therefore, the presence of LIFR may mediate the antiinflammatory effects of LIF and similar neurotropic cytokines.
Although LIFR is expressed by several populations of immune cells, the role of
LIFR/gp130 signaling in the post-stroke splenic response to stroke has not yet been explored.
Previous studies from this lab showed that human umbilical cord blood (HUCB) cells ,which exert
effects on gene expression and white matter survival that are comparable to LIF, counteract the
decrease in spleen size and reduce the number of CD3+CD8+ splenocytes after stroke
(Vendrame, Gemma et al. 2006). LIF is among the protective factors expressed by HUCB cells,
but no studies have determined whether LIF is involved with these effect. A report by Gao et al.
shows that splenocytes are capable of participating in LIF signaling. In this study, splenocytes
were isolated from mice that received a heart transplant followed by CD4/CD8 blockade to induce
tolerance. Upon stimulation, these splenocytes released higher levels of LIF and lower levels of
IL-6 compared to the group that did not have induced tolerance (Gao, Thompson et al. 2009).
Since LIF is administered systemically after stroke, it is possible that LIF may exert
immunomodulatory effects on splenocytes.
Upon LIF binding, LIFR and gp130 participate in the activation of three main signaling
pathways: Ras/MAPK, PI3K/Akt, and JAK/STAT (Boulton, Stahl et al. 1994, Stahl, Boulton et al.
1994, Oh, Fujio et al. 1998). Although this laboratory determined that Akt activity is essential for
mediating the neuroprotective and oligoprotective effects of LIF against in vitro ischemia, the
protective signaling mechanisms lying upstream of PI3K/Akt and downstream of LIFR/gp130
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have not yet been heavily explored. Stahl et al. identified the association of Janus Kinases 1 and
2 (JAK1/2) associate with both LIF receptor subunits (Stahl, Boulton et al. 1994). The binding of
LIF to its receptor facilitates the dimerization of LIFR/gp130, as well as the recruitment of
JAK1/JAK2. The JAKs undergo auto-phosphorylation, and phosphorylate both LIFR subunits as
well (Cheng, Chen et al. 2001). While JAKs are known for controlling the activity of STAT
proteins, they are involved with regulating the other two signaling pathways, including PI3K/Akt.
Although both JAK1 and JAK2 are activated by LIF signaling, studies suggest that JAK1
is a more integral component of downstream LIF signaling. Rodig et al. showed that Jak -/- mice
show deficiencies in LIF and IL-6 signaling (Rodig, Meraz et al. 1998). T293 cells lacking
functional JAK1 are unable to respond to LIF. While cell that lack JAK2 show deficiencies in LIF
signaling, they only demonstrate a 31% decrease in responsiveness. (Nicholson, Willson et al.
1999) In fact, Oh et al. demonstrated that the association between p85, the regulatory subunit of
PI3K, and JAK1 is required for the phosphorylation of PI3K and activation of downstream Akt
signaling in cardiomyocytes (Oh, Fujio et al. 1998). Other reports show that JAK1 activates PI3K
via a complex of proteins that also includes SHP-2, Gab-1, and STAT3 downstream of IL-6
signaling (Hsu, Shi et al. 2004). JAK1 is implicated in facilitating the neuroprotective effects of
other IL-6 family cytokines. For instance, oncostatin M confers protection for primary cortical
neurons against 3-nitroproprionic acid, a drug that inhibits complex II of the mitochondrial
electron transport chain, by upregulating the anti-apoptotic protein myeloid cell leukemia-1.
However, inhibition of JAK1 reversed these protective effects. (Chang, Hwang et al. 2015).
While previous studies from this lab have focused on the downstream effects of LIF on
gene expression in neural cells, the goal of this study is to identify upstream signaling
mechanisms of LIF in the brain and spleen. The hypotheses to be tested for this study are that
systemic LIF administration further sensitizes neural cells and splenocytes by upregulation of
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LIFR after stroke, and that JAK1 activity is necessary for conferring LIF-mediated
neuroprotection.
Materials and Methods
Animal Care
Animal procedures were pre-approved by the Institutional Animal Care and Use
Committee at the University of South Florida and performed according to the NIH Guide for the
Care and Use of Laboratory Animals. Power analysis was used to determine the appropriate
number of animals for each experiment. Sprague–Dawley rats were purchased from Envigo
(Indianapolis, IN, USA). Animals were maintained on a 12 h light–dark cycle (07:00–19:00 h) in
a climate-controlled room, and allowed access to food and water ad libitum. In vivo procedures
were performed on young, male rats weighing between 300 and 350 g. Cultured neurons were
isolated from taken from embryonic day 18 (E18) fetal rat pups.
Middle Cerebral Artery Occlusion
Permanent focal cerebral ischemia was induced using the intraluminal middle cerebral
artery occlusion (MCAO) model as previously described (Ajmo, Vernon et al. 2006). A 40 mm
monofilament was introduced through the ligated external carotid artery and advanced through
the internal carotid artery. The filament was advanced until it reached the origin of the middle
cerebral artery. Reduction in cerebral blood flow was confirmed using Laser Doppler (Moore Lab
Instruments, Farmington, CT). Only animals experiencing ≥ 60% reduction in cerebral perfusion
were included in the study. Animals subjected to the sham MCAO procedure were anesthetized
and underwent exposure of the common carotid artery without subsequent occlusion of the
middle cerebral artery.
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Drug Treatment
Recombinant human LIF (ProSpec, Ness Ziona, Israel) (125 μg/kg) or PBS (pH 7.4) was
administered intravenously at 6, 24, and 48 h post-MCAO as previously described (Rowe, Collier
et al. 2014, Davis, Collier et al. 2016). Rats were euthanized at 24, 48 and 72 h post-MCAO via
intraperitoneal injection of ketamine/xylazine solution (75 mg/kg and 7.5 mg/kg) (Seifert, Hall et
al. 2012). Animals used for immunohistochemical analysis were perfused transcardially with
normal saline followed by 4% paraformaldehyde in phosphate buffer. Animals used for
biochemical analysis were perfused with saline but not paraformaldehyde prior to obtaining
tissue. Fresh tissue was snap frozen and stored at -80°C until further processing.
Tissue Homogenization
To obtain whole cell extracts, frozen tissue was homogenized in whole cell lysis buffer
containing the following: 50 mM Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% IGEPAL, 1 mM PMSF,
and a Complete Mini protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). .. An
electric homogenizer was used to disrupt tissue and lysates were incubated on ice for 20 min.
Tissue lysates were vortexed and pipetted to break up nuclei. Protein concentrations were
determined by performing a Bradford Assay according to the manufacturer’s protocol (Bio-Rad,
Hercules, CA). Briefly, Bradford reagent containing Coomassie blue was added to diluted protein
samples and absorbance was read at 595 nm using a SmartSpec 3000 spectrophotometer (BioRad). Concentrations were determined by comparing the absorbance readings against a
standard curve.
Primary Neuronal Culture
Primary cortical neurons were isolated and cultured as described previously(Katnik,
Guerrero et al. 2006). Briefly, brains were removed from E18 fetal rat pups, cortices were
separated from the midbrain and hindbrain, and meninges were removed. Cortices were
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dissociated by a combination of mechanical disruption and incubation in trypsin/EDTA solution
at 37 °C. Cells were re-suspended in DMEM complete, washed 2x, counted, and plated onto
glass coverslips pre-coated with poly-L-lysine. At 24 h following isolation, DMEM complete was
removed and cells were incubated in Neurobasal medium containing L-glutamine and B-27
serum-free supplement. Cells were treated with 2 µM cytosine-β-D-arabinofuranoside at 5 days
post-isolation to suppress proliferation of glial cells.
Oxygen Glucose Deprivation
In vitro ischemia was achieved via oxygen-glucose deprivation (OGD) as previously
described (Hall, Guyer et al. 2009). DMEM without D-glucose or sodium pyruvate was added to
each well. Cells were treated with the following concentrations of the JAK1-specific inhibitor
GLPG0634 (Medchem Express, Monmouth Junction, NJ): 2.5, 5, 10, 25, and 50 nM. DMSO
(0.5%) was used as a vehicle control. Cells were placed in a 37°C humidified airtight chamber
that was flushed with 94% N2, 5% CO2, and 1% O2 (Airgas, Tampa, FL) for 15 min. After 15 min,
the chamber was sealed. To control for the effects of in vitro ischemia, cells were incubated in
fresh Neurobasal Complete medium, treated with either GLPG0634 or DMSO, and incubated for
24 h in a 37°C humidified incubator containing 75% N2, 20% O2 and 5% CO2. Once cells were
removed from the chamber, supernatants were collected for assessment of cytotoxicity. Cells
were washed twice with PBS and either fixed for 10 min in 4% paraformaldehyde in phosphate
buffer or pelleted via centrifugation and snap-frozen. Cell pellets were stored at -80°C until further
processing.
Lactate Dehydrogenase Assay
Measurement of lactate dehydrogenase (LDH) in the cellular supernatant was performed
as previously described using a colorimetric assay (Takara Biosciences, Madison, WI) (Davis,
Collier et al. 2016). Supernatant samples from cells subjected to OGD were diluted 1:4 in fresh
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cellular medium prior to assay. A µQuant microplate spectrophotometer (BioTek, Winooski, VT)
was used to read absorbance at 490 nm. LDH readings from separate experiments were
normalized to a control group (OGD + PBS) to account for differences in the baseline response
between batches of cells.
Promoter Analysis
Identification of transcription factor binding sites was performed as previously described
using Genomatix Software (Munich, Germany)(Rowe, Leonardo et al. 2010). The sequences for
the rat (Rattus norvegicus) LIFR gene was used in the search query and a table was generated
for all TFs that had consensus sequences in the LIFR promoter.
Western Blot Analysis
Western blotting was used for semi-quantitative measurement of protein expression.
Briefly, whole cell from brain or spleen tissue were run on 10% SDS-PAGE gels and transferred
to nitrocellulose membranes. Membranes were blocked in 5% milk dissolved in TBST) and
probed with rabbit α-LIFR antibodies (1:100; Santa Cruz). Membranes were incubated in
AlexaFluor® 488 goat α-rabbit IgG (1:250; Life Technologies) for visualization of protein bands.
Membranes were imaged using a Typhoon 9410 Imager (GE Healthcare Life Sciences,
Marlborough, MA). To normalize for loading, membranes containing whole cell extracts were reprobed with mouse α-β-actin (1:5000; Novus Biologicals) and AlexaFluor® 488 goat α-mouse
IgG1 (1:250; Life Technologies).
Data analysis
All images were analyzed using ImageJ software (NIH, Bethesda, MD) and all statistical
tests were performed using GraphPad Prism 5.0 Software (La Jolla, CA). Statistical analysis was
for experiments containing two groups was performed using an independent student’s t-test. One
or two-way ANOVAs were used to analyze data sets containing three or more groups. Outliers
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were identified using the interquartile method or median absolute deviation as previously
described and omitted prior to analyses (Rousseeuw and Hubert 2011, Leys, Ley et al. 2013).
Fisher’s Protected Least Significant Difference post hoc test was used to detect individual
differences between groups. A p value of 0.05 or less was considered significant. All p values
reported are one-tailed, except for the p values obtained from of Pearson correlation analyses.
Results
LIF Increases LIFR in the Brain at 72 h post-MCAO
Western blotting was used to determine levels of LIFR expression in the brain at 72 h
post-MCAO. At this time point, there was a significant overall change in the levels of LIFR in
brain tissue after MCAO and LIF treatment (p = 0.0097; F4,12 = 5.46). LIFR levels were 124%
higher in the ipsilateral tissue from PBS-treated rats compared to sham tissue, but this increase
was not statistically significant. However, there was a significant increase in LIFR protein
expression in the ipsilateral tissue from LIF-treated rats compared to levels in the ipsilateral
tissue from PBS-treated rats (p = 0.0184) and sham rats (p = 0.0005). There was no significant
change in LIFR protein expression between tissue from sham rats and contralateral tissue from
either treatment group (Fig. 4.1).
Specificity Protein 1 Binding Sites were identified in the LIFR Promoter
Genomatix software was used as previously described in Chapter 3 to locate transcription
factor binding sites within the LIFR promoter sequence. Data reported in the previous chapter
showed that the transcription factors (TFs) myeloid zinc finger-1 (MZF-1) and specificity protein
1 (Sp1) were responsible for in vitro LIF-mediated neuroprotection. Although no MZF-1 sites
were found, two Sp1 sites were located in close proximity to each other. The first site spanned
from nucleotides 414 to 430 on the negative strand and had the following sequence:
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caaatGGGCtgggccgt. The second site was located from nucleotides 427 to 443 and had the
sequence tttgtGGGCggtgcca (Fig. 4.2).
LIF Increases Spleen Weight after MCAO but not Splenic LIFR Expression
Western blotting was used to determine whether MCAO and LIF treatment altered levels
of LIFR in the brain at 72 h post-MCAO. At 72 h post-MCAO, there was a significant change in
splenic LIFR expression among sham, PBS, and LIF-treated rats (p = 0.0472; F2,21 = 3.554).
LIFR levels were lower in PBS treated rats (p = 0.0176) and LIF-treated rats (p = 0.0389)
compared to sham rats. There was a trend towards increased LIFR expression in the spleens of
LIF-treated rats compared to PBS-treated rats at this time point, but the increase was not
statistically significant (Fig. 4.3a).
Compared to spleens from sham-operated rats, MCAO and LIF treatment caused a
significant overall change in the average spleen weight (p < 0.0001, F2,7 0= 10.79). There was a
significant decrease in spleen weight among rats treated with PBS after MCAO compared to the
sham-operated rats (p < 0.0001). Rats treated with LIF after MCAO had significantly smaller
spleen weights compared to sham-operated rats (p = 0.0049). Rats treated with LIF had
significantly larger spleens compared to rats treated with PBS at 72 h post-MCAO (p = 0.0372).
(Fig. 4.3b).
Brain and Splenic LIFR Expression Correlates with Spleen Weight
Previous studies determined that reduction in spleen weight after stroke contributes to
the severity of neuroinflammation (Seifert, Hall et al. 2012). To determine the relationship
between LIFR expression and the severity of the post-stroke immune response, Pearson r
correlation analyses were performed to determine the relationship between LIFR expression and
the reduction in spleen weight. There was a significant negative correlation between protein
expression of LIFR in the brain and spleen weight at 72 h after MCAO (p = 0.0177; r = -0.6676;
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Fig. 4.4a). On the other hand, there was a significant positive correlation between splenic LIFR
expression and spleen weight among rats euthanized at 72 h after MCAO (p = 0.0074, r = 0.5325,
Fig. 4.4b).
JAK1 Inhibition is Neuroprotective under OGD
In order to determine the optimum concentration of the JAK1 inhibitor (GLPG0634)
necessary to counteract the neuroprotective mechanisms of LIF, a concentration-response
assay was performed using five concentrations of GLPG0634 (2.5, 5, 10, 25, and 50 nM) in
addition to a vehicle control (DMSO). Cells were subjected to OGD for 24 h and LDH release
was measured to detect approximate levels of cell death. Treatment with GLPG034 and 24 h
OGD yielded a significant difference in LDH release among treatment groups (p < 0.0001; F7,53
= 9.966). The lowest concentration (2.5 nM) yielded a decrease in LDH release compared to
DMSO that was very close to significance (p = 0.0507), while the 5 nM concentration yielded the
greatest drop in LDH release compared to DMSO (p < 0.0001). The other treatments, including
10 nM (p = 0.0098), 25 nM (p = 0.0019), and 50 nM (p = 0.0182), also significantly reduced LDH
release after 24 h OGD. Neurons were also incubated for 24 h under normoxic conditions
following treatment with DMSO or 5 nM GLPG0634. Both treatment groups had significantly
lower LDH release compared to the OGD + DMSO treatment group (p < 0.0001). However, there
was only a trend towards reduced LDH release in the neurons treated with 5 nM GLPG0634
compared to the DMSO + Normoxia group (Fig. 4.5).
Discussion
Previously, this lab showed that LIF controls the expression of protective
antioxidant genes in the brain (Rowe, Collier et al. 2014, Davis, Collier et al. 2016). By
maintaining high levels of LIFR, LIF increases expression of these enzymes among vulnerable
cells. When LIF binds to its receptor, its tail is phosphorylated by ERK1/2, thus triggering its
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degradation (Blanchard, Duplomb et al. 2000). However, increasing protein expression of LIFR
counteracts the degradation that occurs after prolonged LIFR/gp130 stimulation. LIFR
upregulation has previously been shown to protect oligodendrocytes against injury in a mouse
model of MS (Butzkueven, Zhang et al. 2002). The in vivo upregulation of LIFR after LIF
treatment demonstrates that exogenous LIF treatment may help prolong its neuroprotective
effects via expression of its receptor.
LIFR levels in the brain are higher among rats with lower spleen weights, which indicate
that LIFR is induced to counteract damage from invading immune cells. A smaller spleen
indicates the release of splenocytes into the peripheral circulation and infiltration of the brain
(Seifert, Hall et al. 2012). The infiltration of peripheral leukocytes after stroke contributes towards
this increase in brain LIFR levels, since many of these cell populations express LIFR (Janssens,
Slaets et al. 2015). In addition, neural cells may upregulate LIFR in response to injury or
neuroinflammation (Butzkueven, Zhang et al. 2002). Therefore, cells in the brain may increase
LIFR expression to amplify the antioxidant effects of LIF.
The previous chapter of this dissertation showed that Sp1 is one of the TFs that is
required for conferring its protective effects in neurons. According to Genomatix, Sp1 has two
binding sites in the LIFR promoter. Although data from the previous chapter implicates Sp1 in
LIF-mediated neuroprotection against OGD, Sp1 may contribute to neuroprotection against
ischemic oxidative damage in the absence of LIF (Yeh, Yang et al. 2011). By controlling levels
of LIFR, Sp1 would not only sensitize cells to signaling from LIF, but other IL-6 cytokines that
utilize the LIFR subunit (i.e. ciliary neurotrophic factor, oncostatin M, cardiotrophin-1).
Splenic LIFR protein expression was significantly lower in both MCAO groups at 72 h
compared to the sham-operated group. Furthermore, a positive relationship was observed
between spleen weight and splenic LIFR expression. The migration of LIFR+ leukocytes from
the spleen to the brain after stroke may contribute to this drop in LIFR expression compared to
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sham levels Janssens et al. demonstrated that macrophages/microglia and T lymphocytes in the
lesions of MS patients expressed high levels of LIFR {Janssens, 2015 #145}. By upregulating
LIFR, leukocytes increase their sensitivity to LIF, which is also found at high levels in active MS
lesions (Vanderlocht, Hellings et al. 2006). Although there was a significant increase in spleen
weight after LIF treatment, LIFR levels in the spleen was not significantly higher after LIF
treatment compared to the PBS-treated rats. The small difference in LIFR levels between LIF
and PBS-treated rats could be explained by populations of splenocytes that increase LIFR after
CNS injury. For instance, Cao et al. showed that lymphocyte populations of the spleen upregulate
LIFR after induction of experimental autoimmune encephalomyelitis. Increased LIFR expression
on splenocytes decreases CNS damage by reducing numbers of pro-inflammatory
lymphocytes(Cao, Yang et al. 2011). It is possible that remaining splenocytes that did not enter
the peripheral circulation may upregulate LIFR as a general protective mechanism after stroke.
At 72 h after MCAO, LIF-treated rats had significantly larger spleens than PBS-treated
rats. However, the spleen weight among LIF-treated rats was still significantly lower than sham
rats, which shows that LIF lessened but did not block the decrease in spleen weight. The drug
treatment regimen utilized in these animal studies involves intravenous LIF administration rather
than direct intracranial or intraventricular administration. While systemic administration allows
LIF to reach the spleen, this treatment failed to attenuate the decrease in spleen size. In a study
published by Vendrame et al., HUCB cell therapy, which confers similar pro-survival effects to
LIF treatment, counteracted the release of splenocytes into the circulation (Vendrame, Gemma
et al. 2006). This phenomenon is explained by the release of chemokines from the HUCB cells
that promote chemotaxis of the splenocytes back to the spleen (Newman, Willing et al. 2006).
However, the ability to prevent or reverse the splenic response is not necessarily enough to
reduce brain damage. According to Ajmo et al., systemic injection of the α1-adrenoreceptor
antagonist prazosin attenuated the decrease in spleen size, but did not significantly reduce
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infarct size (Ajmo Jr, Collier et al. 2009). Therefore, LIF may modulate the immune response via
a mechanism independent of the splenic response.
Although the hypothesis for this study indicated that JAK1 activity contributed to
neuroprotection during ischemia by facilitating LIF signaling, the concentration-response
experiments under normoxia and OGD demonstrated that JAK1 inhibition is neuroprotective
under OGD but has no effect on cell death under normoxia. Although JAK1 has been implicated
in LIF-mediated activation of PI3K/Akt signaling, JAK1 activity has also been shown to contribute
to neurodegeneration. For instance, JAK1 activation contributes to neuronal death after spinal
cord injury as well as ischemic stroke through tyrosine phosphorylation of STAT1 (Takagi,
Harada et al. 2002, Osuka, Watanabe et al. 2011). Therefore, GLPG0634 treatment prior to
OGD may have a neuroprotective effect through inhibition of STAT1. Several of the in vitro
studies that implicate JAK1 in neuroprotection involve its role in STAT3 activation. Studies in the
literature indicate that STAT3 activation serves as a figurative double-edged sword during
cerebral ischemia. Among neurons, activated STAT3 may upregulate genes that protect against
ischemia(Jung, Kim et al. 2009). However, STAT3 activation plays a detrimental role during
stroke by contributing to IL-6 and IL-23-induced development of Th17 cells. According to Yang
et al., STAT3 upregulates the retinoic acid receptor-related orphan receptor γ-T, a marker for
Th17 lymphocytes while suppressing expression of Forkhead box transcription factor P3
(FoxP3), a Treg-specific transcription factor (Yang, Panopoulos et al. 2007).
In this study, JAK1 inhibition was only effective at reducing neuronal death under in vitro
ischemia, and not under normoxia. This finding demonstrates that JAK1 activity increases under
ischemia, and it favors the activation of signaling pathways that are detrimental to neurons over
neuroprotective signaling. GLPG0634, an inhibitor that favors JAK1 over other Janus Kinase
members JAK2/3 and Tyk2, is currently undergoing Phase II clinical trials for use in rheumatoid
arthritis patients. According to a preclinical study by Van Rompaey et al., GLPG0634 reduces
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production of interferon gamma (IFNγ), IL-13, and IL-17, which are involved in the development
of mature CD4+CCR5+ (Th1), CD4+CCR3+ (Th2), and Th17 lymphocytes (Van Rompaey,
Galien et al. 2013). Considering the detrimental role of Th1 and Th17 cells in the post-stroke
inflammatory response, GLPG0634 may have potential as stroke therapeutic that could target
neuroprotection as well as the inflammatory response.
This laboratory has published several studies examining the pro-survival effects
of LIF signaling. However, the regulation of LIFR expression and activity during stroke is less
understood. LIF treatment did not significantly counteract the splenic contraction after stroke over
time or compared to PBS treatment. However, this study showed that brain LIFR expression
increases after LIF treatment, and LIFR expression in splenocytes increases in a time-dependent
manner after stroke. Since LIFR is responsible for mediating the neuroprotective effects of
multiple IL-6 family cytokines, targeting its expression in future studies may sensitize neural cells
to the protective properties of exogenous and endogenous LIF signaling.
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Figure 4.1. LIF upregulates LIFR in the Brain 72 h after MCAO. Western blotting was used to
determine levels of LIFR protein expression in brain tissue 72 h after MCAO. Ipsilateral tissue
from LIF treated rats had significantly higher levels of LIFR compared to sham tissue (*p<0.01)
and ipsilateral tissue from PBS-treated rats (#p<0.05). n =4 per treatment group.
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Figure 4.2. The LIFR Promoter contains two Sp1 binding sites. Genomatix was used to
identify binding sites for MZF-1 and Sp1, which are responsible for LIF-mediated
neuroprotection, in the LIFR promoter sequence. Although no MZF-1 sites were identified, two
Sp1 sites were identified on each strand at approximately the same location.
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Figure 4.3. LIF Significantly Increases Spleen Weight but not Splenic LIFR Expression. (a)
At 72 h, there was a change in splenic LIFR expression between Sham, PBS, and LIF-treated
rats that reached statistical significance. At this time point, both PBS and LIF-treated rats had
significantly lower LIFR expression in the spleen compared to sham rats (*p<0.05). There was a
small trend towards higher LIFR expression in the spleens of LIF-treated rats compared to PBStreated rats, but this increase was not significant. n = 8 animals per group. (b) Compared to
Sham rats, LIF (*p<0.01) and PBS-treated (**p<0.0001) rats had significantly smaller spleens.
However, at this time point the LIF-treated rats had significantly larger spleens than PBS-treated
rats (#p<0.05). n ≥ 23 animals per group.
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Figure 4.4. LIFR Expression in Brain and Spleen Correlates with Spleen Weight after
MCAO. (a) There was a significant negative correlation between LIFR and spleen weight
(*p<0.05), and higher LIFR expression was associated with a smaller spleen at 72 h post-MCAO.
n = 4 per treatment group. (b) Splenic LIFR protein levels positively correlated with spleen size
at 72 h post-MCAO (*p<0.01). n = 8 per treatment group
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Figure 4.5. JAK1 inhibition reduces neuronal death under OGD. Neurons were treated with
GLPG034 or DMSO prior to incubation for 24 h under OGD or normoxia. 2.5 nM GLPG034 led
to a decrease in LDH release that approached significance. However, 5 nM (***p<0.0001), 10
nM, 25 nM (**p<0.01), and 50 nM (*p<0.05) GLPG0634 yielded significant decreases in LDH
release compared to DMSO. Cells treated with DMSO and incubated under normoxia showed
significantly lower LDH release compared to their OGD-subjected counterparts (***p<0.0001).
Under normoxia, treatment with 5 nM GLPG0634 did not significantly change LDH release
compared to the DMSO-treated cells incubated under normoxia. n ≥ 7 per treatment group.
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CHAPTER 5:
DISCUSSION
Overview
As the fifth leading cause of death and a major cause of disability in the United States,
stroke creates a massive burden on the healthcare system. Although 5-10% of all stroke patients
benefit from thrombolytic therapy, the overwhelming majority of patients are faced with a stunning
lack of therapeutic options. While tissue plasminogen activator (tPA) restores perfusion to the
infarct if administered within 3-4.5 hours, the majority of stroke patients are unable to receive
treatment within this time window. In addition, the use of tPA in stroke patients also carries
serious risk for hemorrhage, since tPA often weakens the blood-brain barrier. Several research
groups, including this group have turned their attention away from thrombolytic agents and have
chosen to focus on drugs that will improve cellular survival and target both phases of
pathophysiology.
During the initial phase of stroke injury, increased calcium signaling activates enzymes
that produce reactive oxygen species (ROS), such as neuronal nitric oxide (NO) synthase and
NADPH oxidase. These ROS damage lipid membranes, oxidize proteins, and trigger apoptosis
via mitochondrial dysfunction. Although ROS contribute to the initial phase of ischemic
cytotoxicity, oxidative damage to neural cells continues into the delayed phase of
neuroinflammation.

Respiratory

bursts

from

activated

microglia,

peripheral

monocytes/macrophages, and neutrophils weaken surviving cells in the penumbra. Considering
the integral role that oxidative stress plays during both phases of stroke pathophysiology,
researchers expected free-radical scavenging drugs such as NXY-059 to perform well in clinical
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trials. Unfortunately direct administration of antioxidants has not yielded any viable therapeutic
options for stroke patients.
Although the failure of exogenous antioxidant drugs is discouraging, these unsuccessful
trials do not mean that antioxidant enzymes cannot protect neural cells against stroke. While the
early success of NXY-059 was ultimately undone by its short half -life (2-4 h) and inability to
cross the blood-brain barrier (BBB) without difficulty, antioxidant enzymes avoid these pitfalls
(Strid, Borga et al. 2002). As mentioned in Chapter 1 of this dissertation, neurons and glia are
equipped with basal levels of endogenous antioxidants including glutathione peroxidase,
catalase, and the superoxide dismutase (SOD) enzymes. Since these enzymes are expressed
by the brain prior to stroke, the question of whether they can cross the BBB is not an issue.
Antioxidant enzymes eventually undergo degradation, but degraded enzymes are replenished
by newly synthesized protein. Finally, the brain’s antioxidant enzymes include some of the most
efficient enzymes known in nature. At its maximum rate, catalase may break down approximately
40 million molecules of hydrogen peroxide per second (Ho, Xiong et al. 2004). Considering these
advantages, this laboratory has focused on identifying novel treatments with a broad therapeutic
window and the ability to enhance the brain’s antioxidant capacity.
Human umbilical cord blood (HUCB) cell therapy showed extremely promising results in
a rat model of permanent focal cerebral ischemia by enhancing the expression of protective
genes. Two of these genes, peroxiredoxin IV (Prdx4) and metallothionein III (Mt3), protect white
matter by scavenging ROS. In vitro studies using cultured oligodendrocytes (OLs) showed that
HUCB cells exerted oligoprotection against ischemia via PI3K/Akt signaling during oxygen
glucose deprivation (OGD). HUCB treatment also increased Prdx4 mRNA compared to cells
subjected to OGD alone. Blocking the activity of Prdx4 during in vitro ischemia counteracted the
protective effect of the cells, demonstrating the integral role of Prdx4 in HUCB-mediated
antioxidant protection(Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). HUCB therapy
exerted potent antioxidant and pro-survival effects on white matter, but there was a high degree
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of variability between batches of cells. This laboratory chose leukemia inhibitory factor (LIF), a
neurokine expressed by HUCB cells, to confer the protective effects of HUCB cell therapy without
the variability of cellular treatment.
The Pleiotropic Effects of LIF in the Brain
So far, this laboratory has focused mainly on the pro-survival and antioxidant-inducing
properties of LIF in neurons and OLs. Data from other groups shows that the in vivo effects of
LIF extend beyond pro-survival signaling and enhanced expression of antioxidant genes. By
acting through multiple cell types, LIF treatment provides synergistic protection for neural cells
during ischemia (Figure 5.1).
LIF Differentially Regulates Antioxidants in Neurons and OLs
Rowe et al. demonstrated that intravenous treatment with LIF at 6, 24, and 48 h after
MCAO reduced infarct size, improved sensimotor skills, and lessened white matter damage.
Similar to the HUCB cells, LIF protected cultured OLs were dependent upon Akt signaling and
the full activity of Prdx4, since treating OLs with Akt Inhibitor IV or anti-Prdx4 antibodies negated
the decrease in lactate dehydrogenase (LDH) release seen after LIF treatment. (Rowe, Leonardo
et al. 2010, Rowe, Leonardo et al. 2012). Mt3 expression was also induced by LIF treatment,
although this upregulation was not dependent upon Akt activity. Although LIF treatment
significantly upregulated Prdx4 mRNA among OLs subjected to OGD, total SOD activity was
significantly decreased compared after LIF treatment. Blocking Prdx4 not only increased LDH
release, but it returned SOD activity to levels similar to the cells treated with PBS prior to OGD.
The decrease in SOD activity coincides with increased antioxidant protection from Prdx4, but
inhibiting Prdx4 did not significantly increase SOD activity compared to the OGD alone treatment
group. While OLs increase SOD activity in response to oxidative stress, they aren’t able to
increase activity to compensate for decreased Prdx4. By contrast, neurons treated with LIF had
significantly higher levels of SOD3 siRNA compared to neurons treated with PBS. Cells
transfected with SOD3 siRNA and treated with LIF showed no significant decrease in cell death
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compared to neurons transfected with scrambled siRNA and treated with PBS. Therefore, LIF
upregulates different antioxidant genes depending upon the cell type. Increased Prdx4 and Mt3
expression are a hallmark of LIF-mediated oligoprotection, while SOD3 upregulation is a neuronspecific mechanism of protection (Rowe 2011 , Rowe, Collier et al. 2014, Davis, Collier et al.
2016).
Although LIF confers unique neuroprotective properties among neurons, studies from this
laboratory demonstrate that while LIF significantly decreases neuronal death during ischemia,
the reduction is not as great compared to oligodendrocyte cultures. OLs are especially vulnerable
to ROS-mediated damage due to their high lipid content. Currently, there are no studies
indicating that OLs endogenously produce LIF during injury. By contrast, astrocytes and neurons
are able to increase LIF expression during ischemia (Suzuki, Tanaka et al. 2000). This difference
between neurons and LIF might explain why the reduction in cell death was greater in OLs
compared to neurons. Astrocytic contamination in neuronal cultures might also protect neurons
from OGD-mediated damage. To prevent this confounding effect, neurons were treated with
cytosine-β-D-arabinofuranoside to prevent the proliferation of astrocytes. Nevertheless, a small
number of astrocytes in neuronal cultures may produce enough LIF to provide neuroprotection
under PBS treatment alone (Banner, Moayeri et al. 1997).
In Chapter 2, this laboratory showed that rats receiving LIF treatment show significantly
higher levels of SOD activity in the ipsilateral hemisphere 72 h after MCAO. Although the brain
homogenates used in these experiments contained lysates from neurons as well as glial cells,
there are several pieces of evidence indicating that neurons are primarily contributing to the
increased SOD activity seen after LIF treatment. Several studies in the literature demonstrate
that SOD3 has low basal expression in the brain, but neurons increase SOD3 mRNA after LIF
treatment in vitro. Countering this upregulation with SOD3 siRNA treatment reverses the
protective effect of LIF administration, demonstrating a positive relationship between SOD3
expression/activity and neuronal survival. In vivo studies confirmed this positive relationship,
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since rats treated with LIF after MCAO showed smaller infarct volumes, significantly higher SOD
activity, and increased SOD3 protein expression. Among OLs, there was an inverse relationship
between cell survival and SOD activity. OLs treated with LIF prior to OGD showed significant
decreases in SOD activity and LDH release, while administration of the Prdx4 antibody reversed
these effects.
Among brain sections from LIF treated rats, SOD3 immunoreactivity increased in the
cortical tissue of the ischemic core/penumbra, but little SOD3 immunoreactivity was observed in
the external capsule (unpublished results). SOD3+ cells possessed the triangular morphology of
pyramidal neurons, which are the primary type of neurons in the cortex. Double-labeling cortical
tissue with MAP2 and SOD3 antibodies confirmed that cortical neurons express SOD3 after LIF
treatment. While it is possible that astrocytes and vascular cells of the gray matter also
upregulated SOD3, these data suggests that SOD3 induction is primarily a neuronal
phenomenon.
One common characteristic of antioxidant enzymes induced by LIF treatment, is the
ability to be secreted into the extracellular environment. SOD3, unlike SOD1 or SOD2, contains
a signaling peptide that allows for its secretion into the extracellular environment. (Zelko, Mariani
et al. 2002). Of the Prdx family enzymes, Prdx4 is the only isoform that is localized to the
endoplasmic reticulum and contains a signaling peptide. Therefore, Prdx4 may also be secreted
into the extracellular space from OLs. Mt3 does not contain a signal peptide, but El Ghazi et al.
discovered that astrocytes secrete Mt3 via a multi-protein complex (El Ghazi, Martin et al. 2010).
Prdx enzymes catalyze the breakdown of hydrogen peroxide to water and oxygen, but cannot
break down superoxide. Even with increased Prdx4 expression, OLs are still vulnerable to
superoxide-mediated damage during cerebral ischemia.

Likewise, SOD3 breaks down

superoxide but is unable to process hydrogen peroxide. Mt3 also reacts with superoxide anions
in addition to hydroxyl radicals (Thornalley and Vašák 1985). By increasing the expression of
secreted antioxidant enzymes, LIF is able to protect neural cells against multiple species of ROS.
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SOD3 Activity Enhances the Protective Effects of NO
Since superoxide reacts with free NO to form ONOO-, SOD3 indirectly increases NO
bioavailability in the cerebral vasculature. NO promotes tissue repair via several mechanisms.
NO production activates protein kinase G (PKG) by increasing cGMP synthesis by guanylate
cyclase.

PKG increases cerebral blood flow in the ischemic hemisphere by promoting

vasodilation of large cerebral vessels. In the cerebral microvasculature, endothelial NO synthase
(eNOS) activity increases synthesis of vascular endothelial growth factor, which promotes
angiogenesis. The synthesis of new blood vessels improves perfusion of the infarct by diverting
blood flow around the occluded vessel. In addition to its effects on vascular tone and
angiogenesis, NO also promotes synthesis of brain-derived neurotrophic factor (BDNF), a
protective growth factor. In a study by Chen et al., eNOS knockout mice had larger infarct
volumes at 24 h post-MCAO, decreased neurogenesis in the subventricular zone, and impaired
angiogenesis compared to their wild-type counterparts (Chen, Zacharek et al. 2005).
LIF promotes the self-renewal of several pluripotent stem cell populations, including neural stem
cells (NSCs). According to Bauer et al., LIF decreases neurogenesis in the SVZ and the olfactory
bulb while promoting NPC proliferation. By maintaining a high population of NSCs, LIF treatment
ensures that these cells will be available to repair damaged brain tissue and replace dying cells.
After MCAO, NSCs utilize blood vessels to migrate toward the infarct, BDNF synthesis, which is
regulated by NO production, increases the rate of neurogenesis.
Akt Activity Protects Microvascular Integrity
During stroke, breakdown of the BBB renders neural cells vulnerable to the peripheral
immune system and vasogenic edema. Tight junction (TJ) components, which include the
claudins (Cldns), occludin, and zona occludens, are responsible for maintaining barrier integrity
in the cerebral microvessels. Downregulation of TJ proteins during cerebral ischemia contributes
to overall brain damage. Strecker et al. showed that monocyte chemoattractant protein-1 (MCP1), which recruits immune cells to the brain during stroke, decreases expression of the TJ protein
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Cldn5. MCP-1 knockout mice expressed higher levels of claudin-5 in the cerebral vasculature
compared to wild-type mice, and they also exhibited smaller infarcts and less protein
extravasation into the parenchyma (Strecker, Minnerup et al. 2013).
Factors that increase PI3K/Akt activation can increase expression of several Cldns
expressed at the BBB. For instance, granulocyte colony stimulating factor, an Akt-activating
cytokine that protects OLs during OGD, prevents the downregulation of Cldn5 and Cldn3 during
neonatal hypoxic-ischemic injury and reduced vasogenic edema as measured by Evans blue
extravasation (Li, Klebe et al. 2015). Akt protects against this downregulation of Cldn5 via
inactivation of Forkhead Box Transcription Factor O1 (FoxO1) (Beard, Haines et al. 2014).
PI3K/Akt signaling induced by Pigment Epithelium-Derived Factor Peptide rescues expression
of zona occludens 1 and occludin in the blood-retinal barrier of Ins2 (Akita) diabetic mice (Liu,
Leo et al. 2012). LIF is transported through the cerebral vasculature via active transport, and the
rate of transport has been shown to increase during central nervous system (CNS) injury.
Endothelial cells of the CNS express LIFR and gp130, and LIFR protein expression increases in
addition to LIF transport (Pan, Cain et al. 2006). Therefore, LIF could induce PI3K/Akt signaling
within endothelial cells in addition to crossing the BBB. By activating this signaling pathway, LIF
could rescue TJ protein expression and protect neural cells from vascular leakage.
LIF Enhances Proliferation of NSCs
According to Laterza et al., induced neural stem cells (NSCs) secrete LIF in response to
stimulation with interferon gamma (IFNγ) (Laterza, Merlini et al. 2013). Published work from this
laboratory demonstrated that IFNγ mediates the post-stroke inflammatory response and the
infiltration of peripheral immune cells in the brain. Although IFNγ does not directly damage
neurons, it indirectly contributes to neuronal death via activation of pro-inflammatory
macrophages/microglia (Seifert, Leonardo et al. 2012, Seifert, Collier et al. 2014). Therefore,
the release of LIF from NSC populations acts as a protective mechanism against neural cells,
which are susceptible to immune-mediated damage. Since LIF increases the population of
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NSCs, this mechanism would perpetuate the protective effects of exogenous LIF administration
by enhancing endogenous LIF production. Since NSCs secrete multiple pro-survival factors,
they have been examined by several groups as a therapeutic option for ischemic stroke.
Systemic LIF administration maintains NSC populations and increases the brain’s capacity of
neural regeneration while avoiding some of the pitfalls associated with cellular therapies.
The Neuroprotective Signaling of LIF
As demonstrated by these findings, several mechanisms of LIF in neurons overlap with
its pro-survival signaling in OLs. Some of these common effects of LIF treatment include the
reduction in cytotoxicity, increased Akt signaling, and upregulation of antioxidant expression at
the level of transcription. However, several new mechanisms of LIF-mediated neuroprotection
have been identified from these experiments. These mechanisms, which are displayed in Figure
5.2, will be discussed below.
LIF Administration Sensitizes Neural Cells to LIFR signaling
At 72 h after MCAO, LIF receptor (LIFR) expression is increased significantly in the brains
of LIF-treated rats compared to the PBS-treated and sham groups. Although qPCR or
immunohistochemical staining will be needed to confirm whether this effect is specific to neurons,
this laboratory demonstrated previously that LIFR is localized in neuronal tissue (Davis, Collier
et al. 2016). However, OLs upregulate LIFR in response to injury, so this further studies are
necessary to demonstrate whether LIFR is induced in multiple neural cell types after LIF
treatment. Furthermore, the LIFR promoter contained two Sp1 binding sites. Sp1 contains
binding sites in genes that are induced in OLs (Prdx4, Mt3) and neurons (SOD3), so it is possible
that upregulation is occurring in white and gray matter. Since LIFR expression in the brain
negatively correlates with spleen weight, it is possible that neural cells induce LIFR to protect
against immune-mediated damage. However, the increase in brain LIFR levels between sham
rats and PBS rats was not significant. Therefore, LIF treatment is primarily responsible for this
increase in LIFR treatment.
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Although LIFR is a component of the LIF-specific receptor, increasing the expression of
LIFR would sensitize neurons to IL-6 family cytokines that also signal through receptors that
contain LIFR. Ciliary neurotrophic factor (CNTF), which exerts similar Akt-dependent pro-survival
effects on neurons, signals through a gp130/CNTFR/LIFR tripartite receptor(Alonzi, Middleton et
al. 2001). Since CNTF does not have a signal sequence, it cannot undergo ER/Golgi-dependent
exocytosis in the same manner as LIF. Previous groups claimed that CNTF could only be
released by dying astrocytes. Lee et al. showed that intact astrocytes can upregulate and release
CNTF in response to CNS injury(Lee, Deller et al. 1997). Increased LIFR in the brain would not
only sensitize the brain to exogenous LIF, but also IL-6 family neurokines that are released from
astrocytes. According to Pan et al., LIFR is involved with elevated LIF transport across the BBB
during CNS injury. Therefore, higher levels of LIFR which would increase the bioavailability of
exogenous LIF to neural cells during stroke(Pan, Cain et al. 2006).
Akt, but not JAK1 activity protects neurons during OGD
Previously, this lab demonstrated that LIF-mediated neuroprotection and oligoprotection
depends upon Akt signaling by showing how Akt inhibitor IV treatment counteracts the reduction
in LDH release observed after LIF treatment (Rowe, Collier et al. 2014, Davis, Collier et al. 2016).
Since LIF exerts its protective signaling via control of gene expression, inhibition of Akt signaling
would prevent the activation of necessary transcription factors (TFs) and upregulation of Aktdependent genes. Specificity protein 1 (Sp1) and myeloid zinc finger-1 (MZF-1), the TFs that are
responsible for LIF-mediated neuroprotection, have previously shown to be controlled by Akt
signaling. However, the role of PI3K in LIF-mediated neuroprotection during stroke has not been
examined. Previously, this laboratory showed that inhibition of PI3K counteracted the protective
effects of HUCB cells, which also regulate antioxidant genes through Akt signaling(Rowe,
Leonardo et al. 2012). As a result, PI3K almost certainly plays a role in the neuroprotective and
oligoprotective effects of LIF signaling, but further experiments will be needed to test this
hypothesis.
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In Chapter 2 of this dissertation, SOD3 knockdown increased apoptosis among PBS- and
LIF-treated neurons compared to their scrambled siRNA-transfected counterparts. Laatikeinen
et al. demonstrated that SOD3 increases cell survival in a rat model of hindlimb ischemia by
increasing phosphorylation of Akt. This increased Akt activity increased phosphorylation and
subsequent inactivation of FoxO3, a transcription factor that upregulates genes involved with
apoptosis (Laatikainen, Incoronato et al. 2011). Furthermore, this lab previously showed that at
72 h after middle cerebral artery occlusion (MCAO), neurons expressing high levels of SOD3
also showed high levels of Akt phosphorylation in vivo (Davis, Collier et al. 2016). By maintaining
Akt activity, SOD3 upregulation helps prolong anti-apoptotic signaling after LIF has been
degraded.
The initial hypothesis in Aim 3 stated that JAK1 inhibition would counteract the protective
effects of LIF. However, JAK1 inhibition alone was shown to be neuroprotective under OGD.
While it is still possible that JAK1 activation links LIF-LIFR binding with downstream PI3K/Akt
signaling, these data suggests that JAK1 activity is primarily detrimental during OGD. Further
studies showing the change in JAK1 phosphorylation between PBS and LIF-treated neurons will
be needed to determine the exact role of JAK1 in LIF signaling. Previous studies show that JAK1
activity contributes to the protective actions of LIF, but JAK1 may also play a role in the
termination of LIF signal transduction (Oh, Fujio et al. 1998). Phosphorylation of LIFR by ERK1/2
leads to endocytosis and proteasome-mediated degradation of LIFR (Blanchard, Duplomb et al.
2000). According to Quintás-Cardama et al., treatment with the JAK1/2 inhibitor INCB018424
decreases phosphorylation of ERK1/2 in a dose-dependent manner. Since JAK1 lies upstream
of several signaling pathways, it is possible that it plays a dual role in regards to LIF signaling
(Quintás-Cardama, Vaddi et al. 2010). In the absence of LIF treatment, the neuroprotective
properties of GLPG0634 are likely due to the inhibition of STAT1 signaling. During focal cerebral
ischemia, STAT1 phosphorylation contributes to increased caspase proteolysis and apoptotic

142

cell death (Takagi, Harada et al. 2002). Since JAK1 directly phosphorylates STAT1, its inhibition
could reduce apoptotic death during in vitro ischemia.
Since the JAK1 inhibition alone significantly reduces LDH release under OGD, it is likely
that JAK1 inhibition will add to the protective effects of LIF rather than counteract it. Since JAK1
lies upstream of multiple signaling pathways, it is possible that pharmacological inhibition alone
is not sufficient to determine whether JAK1 plays a role in LIF-mediated neuroprotection. Future
studies may require the measurement of active (phosphorylated) JAK1 among cells treated with
LIF vs cells treated with PBS using immunohistochemistry as well as western blotting to
determine its involvement in LIF signaling.
MZF-1 and Sp1 Regulate Genes Induced by LIF
Several TFs that regulate the expression of Akt-inducible genes were identified by this
laboratory. Among those TFs were MZF-1 and Sp1, which had binding sites in eight and seven
out of eight genes total. Analysis of promoter regions using Genomatix software indicated that
Sp1 and MZF-1 binding sites were present in the promoters of Prdx4 and Mt3. In addition, both
TFs have binding sites in the promoter sequence of peroxiredoxin V (Prdx5), a mitochondrial
Prdx isoform that is also induced by Akt signaling (Shahaduzzaman, Mehta et al. 2015). Several
groups demonstrated that Sp1 and MZF-1 regulated transcription of SOD3, and the SOD3
promoter sequence contained multiple binding sites for both TFs. Although MZF-1 has been
shown to regulate gene expression of SOD3, these studies focused on lung tissue and other
non-neuronal cell types. Luo et al. demonstrated that MZF-1 plays a protective role in astrocytes
by mediating the upregulation of fibroblast growth factor-2 after apomorphine treatment.(Luo,
Zhang et al. 2009). In addition, Ahlemeyer et al. demonstrated that retinoic acid, which increases
expression of MZF-1, protects cells against oxidative damage by maintaining SOD enzyme levels
(Ahlemeyer, Bauerbach et al. 2001).

However, this laboratory is the first group to implicate
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MZF-1 as a transcription factor that is not only expressed by neurons, but acts in a
neuroprotective manner.
Currently, very little data exists regarding the regulation of MZF-1 activity in vivo and in
vitro. Moeenrezakhanlou et al. showed that PI3K/Akt signaling controls MZF-1 activity at the level
of protein expression. This finding was confirmed to be true in neurons via the qPCR and
immunohistochemical staining in Chapter 3. MZF-1 upregulation after LIF treatment was not
quite significant in vivo, but the presence of non-neuronal cells in brain tissue could mask the in
vivo neuronal upregulation of MZF-1. Double-labeling brain sections with antibodies against
neuronal nuclear antigen (NeuN) and MZF-1 showed a strong degree of co-localization in the
cortex, but the adjacent white matter in the external capsule showed much lower levels of MZF1 expression. MZF-1 upregulation, like SOD3 upregulation, could be exclusive to neurons after
LIF treatment. Transfecting neurons with MZF-1 siRNA counteracted the neuroprotective effect
of LIF treatment, showing that the upregulation of MZF-1 is necessary for LIF-mediated
neuroprotection.
Sp1 is known as a ubiquitously expressed transcription factor, and its levels were not
significantly altered by LIF treatment in vivo and in vitro. However, the trend towards increased
expression in the brains of LIF-treated animals indicates that LIF helps maintain Sp1 against
proteasome-mediated degradation(Han and Kudlow 1997, Wang, Hu et al. 2006). Moreover, Sp1
is controlled by multiple post-translational modifications that are regulated by Akt, including
acetylation and phosphorylation (Suzuki, Kimura et al. 2000, Chen, Halappanavar et al. 2004,
Bae, Park et al. 2006) Inhibiting Akt counteracted the reduction in cell death observed after LIF
treatment in both neurons and OLs. Similarly, transfecting cells with Sp1 siRNA counteracted
the protective effects of LIF in neurons. Unlike MZF-1, Sp1 is not upregulated by LIF at the level
of transcription, but LIF treatment is ineffective with reduced Sp1 expression. These data show
that Sp1 is regulated by LIF in a manner independently of gene expression. According to
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correlation analysis, there is a positive relationship between Sp1 and MZF-1 protein expression
after LIF treatment, but not PBS treatment or sham injury. High levels of both TFs are beneficial
since they are both necessary for the protective effects of LIF. In addition, immunohistochemical
staining demonstrated that cells in the cerebral cortex express high levels of Sp1/MZF-1 and
SOD3 after LIF treatment. Further investigation will indicate whether Sp1 and MZF-1 act as coregulators of SOD3 transcription.
Through these studies, this laboratory identified several neuroprotective mechanisms of
LIF treatment, namely the upregulation of SOD3 and MZF-1 and the activation of Sp1. LIF exerts
its protection through common signaling mechanisms in neurons and OLs, most notably through
Akt. Prdx4, which is regulated by Akt, contains binding sites for Sp1 and MZF-1 in its promoter.
Further studies will determine whether these TFs play a role in oligoprotection, or whether LIF
activates additional TFs in neurons and glia. The neuroprotective pathways utilized by LIF are
visualized in Figure 1.
SOD3 Upregulation is Responsible for Higher SOD Activity
A previous publication from this lab demonstrated that LIF reduces overall tissue damage
and white matter degradation after stroke. However, the antioxidant-inducing effects of LIF had
only been identified through in vitro studies(Rowe, Collier et al. 2014). By determining that LIF
increases total superoxide dismutase activity, this lab showed distinct in vivo antioxidant
protection conferred by LIF administration after MCAO. Superoxide anions exert profound
damage to cellular components through direct oxidation and by reacting with NO to form
peroxynitrite (Bonfoco, Krainc et al. 1995). SOD enzymes, in conjunction with endogenous
peroxidases, catalyzes the breakdown of superoxide anions to peroxide and ultimately, water
and molecular oxygen. Therefore, increasing SOD activity in the brain has profound effects on
reducing cellular damage and increasing survival during ischemia.
Through increased Prdx4 expression, LIF treatment confers protection against the
oxidation of white matter components. However, in vitro studies using cultured OLs
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demonstrated that these cells have a limited ability to upregulate SOD activity under ischemia,
and that LIF treatment reduced SOD activity in OLs. This discrepancy between cultured
oligodendrocyte studies and in vivo SOD activity demonstrated that systemic LIF treatment
induces SOD activity in other cell types (Rowe, Collier et al. 2014, Davis, Collier et al. 2016).
It is possible that LIF increases SOD activity through post-translational modification, but
microarray and qPCR data from previous studies involving LIF and other Akt-inducing therapies
shows that protective genes are controlled at the level of transcription. Western blotting and
immunohistochemical analysis on samples used in the SOD inhibition assay confirmed that
higher levels of SOD3 expression are present when SOD activity is upregulated. According to
the western blotting analysis, SOD1 was only significantly upregulated in the contralateral tissue
of LIF-treated rats. An explanation for this phenomenon was discussed in Chapter 2; although
LIF may induce SOD1, ischemic conditions cause SOD1 to aggregate(Chen, Guan et al. 2012).
If these SOD1 aggregates precipitate out of the homogenized brain tissue, they may not be
detected via western blotting. SOD2 was not altered significantly among treatment groups, but it
was lower in the ipsilateral tissue of LIF-treated rats compared to the tissue from Sham and PBStreated rats. The decreased SOD2 expression might be a consequence of decreased oxidative
damage in the tissue from the LIF rats as well as upregulated Akt activity. Akt inactivates FoxO3
via phosphorylation, and decreases transcription of the SOD2 gene(Li, Chiu et al. 2006).
Nonetheless, the upregulation in SOD3 appears sufficient to counteract any minor decreases in
SOD2 expression, since SOD activity is significantly higher in the brains of LIF-treated rats.
Using qPCR analysis, this lab demonstrated that neurons increased SOD3 mRNA after
LIF treatment. Therefore, the in vivo upregulation of SOD3 protein expression is due to LIF
signaling in neurons. To confirm that SOD3 was responsible for LIF-mediated protection against
ischemic damage in neurons, SOD3 siRNA was used to silence expression. Using the
Nucleofector electroporation device and a transfection protocol optimized for primary mammalian
neurons, an approximately 30% decrease in SOD3 expression was achieved. Although
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neutralizing antibodies were used in the oligodendrocyte studies, silencing SOD3 expression at
the level of transcription is a more efficient manner of counteracting the effects of LIF in neurons,
since the SOD3 siRNA transfection prevented the LIF-mediated increase in SOD3 mRNA.
According to Laatikainen et al., SOD3 enhances pro-survival signaling by maintaining Akt
phosphorylation. Since LIF protects neurons and OLs by activating Akt, SOD3 helps prolong the
pro-survival actions of LIF (Laatikainen, Incoronato et al. 2011). Suppressing the upregulation of
SOD3 prevents LIF from protecting neurons against apoptotic and necrotic cell death.
Indirect Mechanisms of Neuroprotection by LIF
Although these experiments focused mainly on the neuroprotective and antioxidant
effects of LIF, there is strong evidence to suggest that LIF could act as an immunomodulatory
agent during stroke. As an anti-inflammatory cytokine, LIF alters the phenotypes of several
immune cells in vivo. Since pro-inflammatory microglia/peripheral leukocytes exert the majority
of damage to cells in the penumbra after stroke, LIF could potentially promote survival in this
region by shifting the immune balance from pro- to anti-inflammatory. The proposed mechanisms
of LIF-mediated immunomodulation during stroke are detailed in Figure 4.3.
Splenic LIFR increases after MCAO
At 72 h after MCAO, there was a significant decrease in splenic LIFR expression
compared to the levels of sham rats. This drop in LIFR expression is explained by the migration
of immune cells from the spleen to the ischemic hemisphere. LIF treatment slightly increased
splenic LIFR levels compared to PBS treatment at 72 h post-MCAO, although this increase was
not statistically significant. The drop in LIFR expression from sham to MCAO rats suggests that
splenocytes expressing LIFR are migrating into the periphery. The increase in LIFR expression
after LIF treatment could be explained by a decrease in the number of splenocytes leaving the
spleen. This phenomenon is reflected in the higher spleen weights observed among LIF-treated
rats. In addition, the higher level of LIFR in the spleen might also be due to upregulation of LIFR
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on splenocytes.
expression

after

Future studies will identify whether LIF significantly alters splenic gene
MCAO,

and whether

these

changes promote neuroprotection

or

neurodegeneration. It should be noted that western blotting could only be used to measure LIFR
expression of splenocytes that were not released into the peripheral circulation. Flow cytometry
will be necessary to confirm LIFR expression on immune cells in the peripheral blood and the
brain. Although LIF treatment does not significantly change splenic LIFR expression, the
increase in spleen weight after LIF treatment suggests that systemic LIF acts at the spleen during
stroke.
Previously, this laboratory demonstrated that spleen size decreases after MCAO as
splenocytes migrate to the ischemic brain. Although the spleens of LIF-treated rats were still
significantly smaller than those of sham rats, there was a significant increase in spleen size from
PBS to LIF-treated rats at 72 h after MCAO. Therefore, while LIF treatment may decrease the
migration of splenocytes, it does not completely counteract the decrease in spleen size.
However, it is likely that LIF exerts more potent immunomodulatory signaling on splenocytes
within the peripheral circulation and the brain.
LIF controls Treg/Th17 Development
Several groups demonstrate that LIF inhibits the development of CD4+IL-17+ Th17 cells
while favoring the maturation of CD4+CD25+FoxP3+ Tregs. There are conflicting reports as to
whether or not increased Treg populations are detrimental or beneficial after permanent stroke.
While Tregs quell the post-stroke immune response by releasing anti-inflammatory cytokines
such as LIF, IL-10, and TGF-β (Gao, Thompson et al. 2009, Iadecola and Anrather 2011, Tran
2011), other studies suggest that higher Treg populations increase the risk of infection by
contributing to post-stroke immunodepression (Offner, Vandenbark et al. 2009). In spite of the
controversy Tregs, LIF also counteracts IL-6 signaling during T lymphocyte maturation. IL-6
contributes to the development of CD4+IL-17+ helper T (Th17) lymphocytes via activation of
JAK1/STAT3 signaling (Dienz and Rincon 2009, Gao, Thompson et al. 2009, Metcalfe 2011).
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The increase in the number of Th17 cells, which are implicated in several autoimmune diseases,
play a largely detrimental role during stroke (Hu, Zheng et al. 2014). Luo et al. demonstrated
that administration of IL-33 reduced brain damage after stroke by suppressing Th17-mediated
inflammation (Luo, Zhou et al. 2015). Gelderblom et al. demonstrated that IL-17, which is
produced by Th17 cells, stimulates the release of the chemokine CXCL1 during cerebral
ischemia, which increases the extravasation of neutrophils into the parenchyma. Neutralizing IL17 using antibodies decreased the infarct volume and reduced deficiencies in sensimotor
function (Gelderblom, Weymar et al. 2012). Therefore, the increase in Tregs that occurs after
LIF treatment may be beneficial by preventing the development of Th17 lymphocytes and the
subsequent release of IL-17.
LIF induces Anti-Inflammatory Phenotype in Macrophages/Microglia
Although LIF influences the development of naïve T lymphocytes, it also favors the
differentiation of monocytes into anti-inflammatory macrophages/microglia. While proinflammatory macrophages worsen tissue damage during stroke via the release of proinflammatory mediators (TNF-α, IL-12, IL-6, IL-1β, NO, etc.) anti-inflammatory cells are primarily
phagocytic and release anti-inflammatory mediators. In addition, these macrophages/microglia
recruit other anti-inflammatory cells such as CD4+CCR4+ helper T (Th2) lymphocytes and Tregs
to the site of injury. Duluc et al. demonstrated that LIF and IL-6, in conjunction with macrophage
colony stimulating factor (M-CSF), cause monocytes to differentiate into tumor-associated
macrophages, a specialized class of anti-inflammatory leukocytes that protect cancerous
growths from natural killer cells (Duluc, Delneste et al. 2007). Although pro-inflammatory
macrophages/microglia further damage neural cells after stroke by perpetuating inflammation
and producing reactive oxygen species, macrophages/microglia with an anti-inflammatory
phenotype contribute to the repair process during ischemia (Merrill, Ignarro et al. 1993, Patel,
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Ritzel et al. 2013). Therefore, LIF may indirectly reduce the neuroinflammation-associated
damage during stroke by increasing the population of anti-inflammatory macrophages/microglia.
Neutrophil Infiltration is reduced by LIF
Neutrophils are another population of splenic immune cells that are influenced by the
anti-inflammatory properties of LIF. Although LIF does not reduce neutrophilic ROS production,
it does inhibit their migration (Klempner and Rocklin 1983). Banner et al. demonstrated that
neutrophil infiltration of the injured area is significantly reduced in LIF knockout mice after
intraplanar injection of complete Freud’s adjuvant (CFA). In addition, local LIF administration
reduced synthesis of IL-1β, which is involved with neutrophil recruitment. (Banner, Patterson et
al. 1998, Oliveira, Canetti et al. 2008). This laboratory previously demonstrated that splenectomy
two weeks prior to MCAO reduced myeloperoxidase immunoreactivity in the infarct, indicating a
reduction in neutrophil-mediated brain damage (Ajmo, Vernon et al. 2008). However, LIF may
have a dual role in the regulation of neutrophil function. According to a report by Waring et al.,
low expression of LIF is associated with chronic inflammatory conditions such as rheumatoid
arthritis. However, acute inflammatory conditions such as sepsis were associated with high levels
of LIF. These data suggest that LIF might contribute to the neutrophil-mediated inflammatory
response, which is characteristic of acute inflammation. On the other hand, LIF is primarily antiinflammatory in regards to monocytes/macrophages and lymphocytes, which are present at sites
of chronic inflammation (Waring, Wycherley et al. 1992). Flow cytometry may be used in future
investigations to determine whether LIF treatment alters the populations of neutrophils,
alternatively-activated monocytes/macrophages and Th17/Tregs.
Conclusion
Through these experiments, this laboratory has identified several new mechanisms of
neuroprotection by LIF. By upregulating neuronal SOD3, LIF increases neuronal survival during
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in vitro ischemia and increases total SOD activity in vivo. MZF-1 and Sp1, which bind to the
promoter of the SOD3 gene, are essential for LIF-mediated neuroprotection in vitro. Furthermore,
LIF increases MZF-1 transcriptional activity by increasing its gene expression during ischemia.
LIFR was upregulated in the brain tissue of LIF-treated rats, and splenic LIFR increased in a
time-dependent manner following MCAO. While it is clear that the protective effects of LIF
extends to neurons in addition to OLs, further studies will be necessary before testing LIF as a
stroke treatment in humans. Even though full SOD3 expression is required for the full
neuroprotective effects of LIF, it is possible that it upregulates other Akt-inducible antioxidant
genes in neurons, such as Prdx5. In addition, the presence of MZF-1 and Sp1 in the promoters
of all LIF-inducible antioxidants suggests that other genes may be involved.
Although LIFR did not counteract the splenic response during stroke, the time-dependent
increase in splenic LIFR expression suggests that LIF is altering gene expression in splenocytes.
Flow cytometry may be used to determine whether LIFR expression increased on splenocytes
in the brain or peripheral circulation. In addition, flow cytometry may be used to measure the
changes in immune cell populations after LIF treatment. A previous study by Butzkueven et al.
showed that LIF administration during EAE increased oligodendrocyte survival but did not
increase or decrease CD3+CD4+ T lymphocyte populations(Butzkueven, Zhang et al. 2002).
This study does not taken into account the differences in markers between T lymphocyte
subtypes. For instance, antibodies against CD4 as well as FoxP3 would be required to detect
changes in Treg populations after LIF treatment. Even if LIF does not alter the total number of
CD4+ T lymphocytes, it could increase the ratio of Tregs/Th17 cells.
Finally, all studies performed in this laboratory have utilized young, male Sprague-Dawley
rats for in vivo experiments. Considering that young, male humans do not match the
demographics of the typical ischemic stroke patient, LIF will need to be tested on aged rats of
both sexes. Young, female rats have not been used in these studies due to the neuroprotective
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effect of estrogen. Once female rats cease to have an estrous cycle, they are more vulnerable
to stroke-related damage. Furthermore, pharmacokinetic changes that occur with age will need
to be taken into account, and dosing will need to be adjusted as needed. Nevertheless, the
synergistic effects of LIF on the expression of antioxidant genes in addition to its
immunomodulatory properties make it a promising candidate for future investigation.
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Figure 5.1: LIF Exerts Pleiotropic Effects on Cell Populations in the Brain. Research from
this lab demonstrates that LIF signaling in neurons upregulates levels of SOD3, which dismutates
superoxide to hydrogen peroxide. Mt3, which is upregulated in oligodendrocytes, also breaks
down excess superoxide. Prdx4 levels increase in oligodendrocytes after LIF treatment, which
increases its breakdown into water and molecular oxygen. By decreasing superoxide, SOD3 also
prevents the reaction of NO with superoxide to form peroxynitrite, which reduces NO
bioavailability and increases cell damage. NO aids in tissue repair by increasing vasodilation and
cerebral blood flow within the infarct. In addition, NO release contributes to angiogenesis and
the growth of new collateral vessels, which also increases tissue repair. LIF also increases the
proliferation of NSCs in the subventricular zone. During injury, NSCs migrate to the infarct and
increase neurogenesis/gliogenesis, which aids in the formation of new neural tissue during
stroke.
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Figure 5.2: The proposed mechanisms of LIF-mediated neuroprotection during ishcemia.
By binding to its heterodimeric receptor, LIF increases Akt activation. Akt signaling increases
transcriptional activity of MZF-1 via increased gene expression and Sp1, possibly through
increased post-translational modification. MZF-1 and Sp1 bind to the SOD3 promoter, and
induce its transcription. In addition, Sp1 possibly binds to the LIFR promoter and increases LIFR
gene expression. Higher SOD3 expression maintains levels of phosphorylated Akt and increases
total SOD activity. SOD activity increases the antioxidant capacity of the brain, and reduces
caspase-3-dependent apoptosis. JAK1, which has been shown to associate with several
cytokine receptors, opposes neuroprotective signaling via the STAT1/caspase-3 pathway. By
reducing apoptosis in neurons, LIF promotes neuronal survival during ischemia.
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Figure 5.3: Proposed Mechanisms of Indirect Neuroprotection by LIF during Stroke.
Although LIF does not completely block the splenic response after stroke, it significantly
increases spleen weight and splenic LIFR levels compared to PBS treatment after stroke. Since
LIF is administered systemically, there is the possibility that IT may exert other effects on the
spleen, but these effects have not yet been determined. After stroke, the spleen releases immune
cells into the systemic circulation. These cells include monocytes/macrophages, lymphocytes,
and neutrophils. LIF has been shown to alter the phenotypes of T lymphocytes and
macrophages/microglia from pro-inflammatory to anti-inflammatory in vivo. LIF treatment also
has been shown to reduce the infiltration of neutrophils to areas of injury by inhibiting their
mobility.
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APPENDIX A: PERMISSION TO USE PREVIOUSLY PUBLISHED
MATERIAL IN CHAPTER 2

160

161

162

163

164

ABOUT THE AUTHOR
Stephanie M. Davis graduated summa cum laude with a Bachelor of Science from the
Honors College at Florida Southern College in the Spring of 2012, where she majored in
Biochemistry and Molecular Biology and minored in Economics. She was accepted into the Fall
2012 class of the Ph.D. program in Biomedical Sciences at the University of South Florida
College of Medicine. Upon starting the program, Ms. Davis received the Presidential Doctoral
Fellowship from the USF Office of Graduate Studies.
While in the Ph.D. program, Ms. Davis majored in Molecular Pharmacology and
Physiology. In 2014, she joined the lab of Dr. Keith Pennypacker and focused her efforts on
investigating the neuroprotective signaling of novel stroke therapeutics. In addition to authoring
and co-authoring papers in the field of neuroinflammation and stroke, Ms. Davis was accepted
to present at the International Stroke Conference for two consecutive years through a rigorous
peer-review process. In addition to her research, Ms. Davis served the graduate student body at
the USF College of Medicine by acting as Department Representative and President of the
Association of Medical Science Graduate Students.

